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1 Microbial biofilms and cysticfibrosis
Graphical abstract showing the role of the genetic defect and pulmonary infections in
the lung failure observed in cystic fibrosis patients. Mucus plugging as a result of the
mutation leads to the increased vulnerability to lung infections. The infections become
chronic and evoke an immune response which results in tissue damage and a declining
lung function.
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1.1 Microbial biofilms: the predominant mode of
growth of bacteria
1.1.1 Definition of a biofilm
Thinking of bacteria, an image of free swimming, single bacteria automati-
cally comes to mind. This is called the planktonic mode of growth and was
for decades considered the predominant style of living of bacteria. However,
researchers began to realize that this was not the only bacterial lifestyle around
the 1920’s - 1930’s. In that period, marine microbiologists were among the first
to use the term ”film” to describe the formation of a slimy, bacterial coating
on submerged surfaces. [1, 2] These adhered bacterial cells were named ses-
sile cells and were found to easily outnumber the planktonic bacteria by 3
to 4 orders of magnitude in many natural environments. [1, 3] Closer obser-
vations revealed that the sessile bacteria form communities that are enclosed
by a slimy, gel-like matrix consisting of polymers and other components ex-
creted by the bacteria. [4] By the 1970’s the term ”biofilm” was introduced to
describe this bacterial lifestyle. [5] Confocal microscopy studies allowed de-
tailed imaging of the biofilm structure and revealed that the bacteria are not
randomly trapped inside the matrix, but that they can be structurally orga-
nized in elaborate ways. [6–10] Furthermore, it was observed that the gene
expression pattern of biofilm cells differs profoundly from their planktonic
counterparts, confirming that the planktonic and biofilm mode of growth are
two distinct lifestyles. [11] All of these discoveries have led to a refined defi-
nition of a microbial biofilm: a structured community of bacteria enclosed in
an at least partially self-produced extracellular matrix which is adherent to an
inert or living substratum. [12, 13]
1.1.2 Biofilm formation and structure
The formation of a biofilm is usually described as a three-stage process involv-
ing cell attachment, biofilm maturation and cell dispersal. (Figure 1.1). In the
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first stage, bacteria adhere to a surface and form microcolonies. Free floating
biofilm fragments can lodge into cavities in a surface and planktonic bacteria
were observed to avidly attach to almost any kind of surface. [13] On all water
submerged surfaces, a thin film of absorbed organic molecules is immediately
formed. This conditioning film changes the surface properties of the substra-
tum and can have an influence on the strength of the interaction between the
bacteria and the substratum. [14, 15] Initially, the attachment of planktonic
bacteria is of a reversible nature since the interaction with the surface is weak
and is mainly governed by electrostatic, hydrophobic and van der Waals inter-
actions. [14, 16] Many bacteria leave the surface again during this stage. Next,
the bacteria become irreversibly attached to the surface by producing extra-
cellular polymeric substances (EPS) that will bind to the surface or by ligands
located on the pili or fimbriae. [16] For Pseudomonas putida, it was for instance
described that type IV pili are involved in this irreversible attachment. [17]
Furthermore, the type IV pili were found to be important in the formation of
microcolonies by twitching motility. [18] The irreversible attachment subse-
quently initiates the steady production of EPS, which will form the biofilm
matrix. [12]
Figure 1.1: Schematic representation of biofilm formation and dispersal. [19]
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Figure 1.2: A: Transmission image, B: Widefield fluorescence image, C: Confocal im-
age. All images display the same cluster in a Burkholderia multivorans biofilms and were
taken 20 µm above the substratum.
In the next stage, the microcolonies mature and form a structured and dif-
ferentiated biofilm. Our understanding about the structural organization of
biofilms was revolutionized by the introduction of confocal microscopy into
this research field. Since confocal microscopy eliminates out of focus light, it
allowed the imaging of thick, light scattering biofilms with relative ease. (Fig-
ure 1.2) While the transmission and wide field fluorescence images are often
blurred by light scattering, out of focus features and out of focus fluorescence,
the confocal image still allows the observation of the individual cells and the
3D shape of the biofilm. Major advantages over electron microscopy are the
possibility to image living, fully hydrated biofilms without disturbing the 3D
structure and the ability to follow dynamic processes in function of time. The
use of confocal microscopy for biofilm imaging was pioneered by the Caldwell
group who found that the biofilm architecture can be species specific. [6] Pseu-
domonas aeruginosa and Pseudomonas fluorescens biofilms formed a layer with
maximum cell density close to the substratum. The upper layer was more
diffuse and contained less cells. A Vibrio paraheamolyticus biofilm showed the
reverse situation, namely a higher density of bacterial cells in the upper lay-
ers. Another important observation was the presence of channels and pores
inside the biofilm. This heterogeneous structure consisting of dense bacterial
clusters which are separated from each other by channels or voids that contain
6
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only very low amounts of biofilm material can be found in many different en-
vironmental settings. [10, 20] Therefore, conceptual drawings of biofilms often
show this kind of tower and mushroom like structures as can be seen in Figure
1.1. This 3D organization allows increased liquid flow through the channels
in the biofilm. Both diffusion and convection attribute to mass transfer in the
channels while in the bacterial clusters, only diffusion takes place. As a con-
sequence, oxygen and nutrients can be transported faster into the biofilm and
waste products are removed more efficiently when the channels are present.
Proof for the concept that the channels can provide increased access to nutri-
ents and oxygen to the biofilm was given by a study that showed high oxygen
concentrations in these channels. [21–23] Other evidence for liquid flow in the
channels was given by following the transport of dyes and particles as they
flowed through the channels of biofilms grown in a flow cell. [22, 24, 25]
Figure 1.3: A schematic representation of 3 often observed biofilm structures.
Although the so-called mushroom-water channel biofilm structure is often
described, this is not the only 3D structure which is formed by fully grown
biofilms. At least two other 3D structures are quite common. The mosaic
structure is an extreme form of the mushroom-water channel structure as the
clusters are so far apart that the space dividing them can hardly be named
a water channel any more. The other is the flat, slab-like biofilm structure,
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which is a (dense) layer of bacteria without any voids or channels. [26] A
schematic representation of these three biofilm structures can be found in Fig-
ure 1.3. It was observed that the same species of bacteria can grow biofilms
with different 3D structures when subjected to different nutrient conditions.
For instance, Pseudomonas aeruginosa PAO1 was seen to produce a flat biofilm
or mushroom-water channel structure depending on the growth medium. [27,
28] The shear stress biofilms are subjected to can also influence their 3D struc-
ture. Thinner, denser biofilm structures are formed when the shear stress is
high. [29, 30] The clusters can also elongate under shear stress, forming fil-
amentous streamers that trail off the clusters and oscillate in the current, or
the biofilm can show a ripple pattern. [30] (Figure 1.4) This nicely illustrates
the visco-elasticity of the EPS matrix. Therefore, it is clear that the final 3D
structure of a biofilm depends on a number of external factors as well.
The matrix thus provides structural integrity to the biofilm. Furthermore,
it plays a key role in the micro environment of the bacteria since the porosity,
water content, charge, sorption properties and hydrophobicity of the biofilm
depend largely on the physicochemical properties of the matrix materials. [31]
When analyzing the composition of the matrix, it was found to consist of ex-
tracellular polysaccharides, proteins, glycoproteins, glycolipids and extracel-
lular DNA (eDNA). This eDNA was found to be a true structural component
and not just a remnant of lysed cells. [32–34] The matrix has other roles be-
sides maintaining the structural integrity of the biofilm. It keeps the biofilm
hydrated, offers protection to the cells and can provide them with nutrients
by adsorbing substances from the surroundings or by serving as a nutrient
source itself. Furthermore, it can promote horizontal gene transfer by facili-
tating close contact between cells. [31] A list displaying the various functions
of the biofilm matrix is summarized in Table 1.1.
From the mature biofilm, matrix material and cells are almost constantly
being shed. This dispersion, the third stage, allows the bacteria to colonize
new surfaces and escape starvation. In P. aeruginosa and P. fluorescens biofilms,
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Table 1.1: Recognized functions of the biofilm matrix. [4]
Function Relevance for biofilms Matrix components involved
Adhesion Bridging between cells, immobilization of biofilm,
allowing high cell-cell densities
Polysaccharides, proteins,
DNA, amphiphilic molecules
Aggregation of
bacterial cells
Bridging between cells, immobilization of biofilm,
allowing high cell densities and cell-cell recogni-
tion
Polysaccharides, proteins,
DNA
Cohesion of bio-
films
Hydrated polymer network, mechanical stability
and determinates biofilm architecture plus allow-
ing cell-cell communication
Polysaccharides, proteins,
DNA
Retention of water Maintains a highly hydrated microenvironment,
leading to tolerance to dessication
Hydrophilic polysaccharides
and possibly proteins
Protective barrier Confers resistance to nonspecific and specific host
defenses during infection, tolerance to various an-
timicrobial agents plus protecting cyanobacterial
nitrogenase from the harmful effects of oxygen
and protecting against grazing protoza
Polysaccharides and proteins
Sorption of orga-
nic compounds
Accumulation of nutrients from the environment
and the sorption of xenobiotics
Polysaccharides and proteins
Sorption of inor-
ganic ions
Promotes polysaccharide gel formation, ion ex-
change, mineral formation and accumulation of
metal ions
Charged polysaccharides
and proteins, inorganic sub-
stituents such as phosphate &
sulphate
Enzymatic activ-
ity
Digestion of exogenous macromolecules for nutri-
ent acquisition, degradation of structural EPS, al-
lowing the release of cells from biofilms
Proteins
Nutrient source Source of carbon-, nitrogen- and phosphorus-
containing compounds for utilization by the
biofilm
Potentially all matrix compo-
nents
Exchange of ge-
netic information
Facilitates horizontal gene transfer between cells DNA
Electron donor or
acceptor
Permits redox activity in the biofilm matrix Proteins and, possibly, humic
substance
Export of cell
components
Releases cellular material via membrane vesicles
as a result of metabolic turnover
Nucleic acids, enzymes,
lipopolysaccharides and
phospholipids
Sink for excess en-
ergy
Stores excess carbon under unbalanced carbon to
nitrogen ratios
Polysaccharides
Binding of en-
zymes
Results in the accumulation, retention and stabi-
lization of enzymes through their interaction with
polysaccharides
Polysaccharides and enzymes
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Figure 1.4: Biofilm structures such as mushrooms are found in low shear environments
(A, B, C) while ripples (D, E) and streamers (F, G, H, I) can be seen in biofilms growing
under high shear conditions. [30]
dispersal of planktonic cells via enzymatic degradation of the matrix has been
described. [35, 36] Planktonic cells were formed in the interior of the biofilm
clusters and subsequently released into the environment, leaving mound-like
hollow structures behind. [11, 37] This type of dispersal is named swarming
or seeding dispersal. Pieces of the biofilm can also be shed or break off under
shear stress, referred to as clumping dispersal. [38] A last dispersal mecha-
nism is surface dispersal in which the biofilm itself moves across a surface. In
that way, it differs from the previous two dispersal strategies. An example of
this is the rippling motion of biofilms under shear stress. [39]
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It should be noted that although single-species biofilms are often cultured
for research purposes, multi-species biofilms dominate in natural environ-
ments. Furthermore, biofilms are not only formed by bacteria as fungi and
algae are known to form biofilms as well. [40, 41] Multispecies biofilms con-
sisting of bacteria, algae and/or fungi can be abundantly found in nature.
[42, 43]
1.1.3 Communication within biofilms
It is clear that the multicellular behavior of biofilms requires a degree of coor-
dination between the bacterial cells. A cell-to-cell communication mechanism
which allows the bacteria to coordinate their gene expression in function of
the bacterial population density has indeed been described. This process is
termed quorum sensing and depends on the production of signal molecules,
also called autoinducers, by the bacterial cells. Although the presence of au-
toinducers was already discovered around 1970, the term ”quorum sensing”
was not adopted until 1994. [44] Early observations that pointed towards a
coordinated behavior of bacteria mediated by signal molecules included au-
toinduction of luminescence in Vibrio harveyj, which only occurred in the late
exponential and early stationary phase. When adding cell free extracts from
the growth medium of a stationary phase culture to a culture in the early log
phase, luminescence could be induced which proved that the autoinducer was
only produced in cultures with a high cell density. [45, 46]
One of the best described quorum sensing systems is the N-acylhomose-
rine lactone (AHL) dependent quorum sensing, which is used by many Gram-
negative bacteria. [44, 47–56] This example can be used to illustrate the process
of quorum sensing. A population of bacteria steadily produces the AHL sig-
nal molecules via AHL synthase, a member of the LuxI protein family. AHL
molecules will accumulate in the environment surrounding the bacteria. The
higher the cell density, the higher the concentration of AHL molecules will
be. The AHL molecules can diffuse into the bacterial cells and when a critical
intracellular concentration is reached, AHL binds to LuxR, a transcriptional
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regulator protein. This activated complex can activate or repress the tran-
scription of various genes and therefore cause a change in collective bacterial
behavior. [50] Examples of processes under the control of quorum sensing are
virulence, mobility, swarming, biofilm formation and the collective adaptation
of bacteria to environmental stress. [50]
As said, quorum sensing has a role in biofilm formation. It was observed
to regulate biofilm matrix synthesis in the early or late stages of biofilm de-
velopment in some species. [28, 57, 58] Quorum sensing can trigger biofilm
dispersal as well as regulate the biofilm architecture. [59] For example, bio-
surfactant molecules called rhamnolipids are produced by P. aeruginosa under
quorum sensing control. These molecules keep the channels inside the biofilm
open and prevent the colonization of the channels by other bacterial species.
[60] Furthermore, quorum sensing is likely involved in the production and or-
ganization of eDNA as well. In P. aeruginosa biofilms, the distribution of eDNA
was found to depend on the various stages of biofilm formation. [61] Likely,
quorum sensing plays other roles as well during biofilm formation and dis-
persal, but the full extent of the processes and functions it influences remains
to be explored.
1.2 From acute to chronic infection
1.2.1 The role of biofilms in chronic infections
Biofilm formation can occur when bacteria colonize or infect the human body
as well. It is now estimated that over 60 % of the bacterial infections involve
the formation of biofilms. [62] Table 1.2 provides a partial list with known
(device related) biofilm infections or diseases to illustrate the extent of the
problem.
Acute infections involve planktonic bacteria and can be treated effectively
by administering antibiotics. However, antibiotic treatment was not always
found to clear every infection. Chronic infections that show low-grade or in-
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Table 1.2: Partial list of infections and diseases linked to biofilms [62]
Infection or disease Bacterial species usually involved
Dental caries Acidogenic Gram-positive cocci
Peridontitis Gram-negative anaerobic oral bacteria
Otitis media Haemophilus influenzae
Chronic tonsillitis Various species
Cystic fibrosis pneumonia P. aeruginosa , Burkholderia cepacia complex
Endocarditis Viridans group Streptococci, Staphylococci
Necrotizing fasciitis Streptococci
Musculoskeletal infections Gram-positive cocci
Osteomyelitis Various species
Biliary tract infection Enteric bacteria
Infectious kidney stones Gram-negative rods
Bacterial prostatitis Escherichia coli, other Gram-negative bacteria
Infections associated with foreign body
materials
Bacterial species usually involved
Contact lens P. aeruginosa , Gram-positive cocci
Sutures Staphyloccci
Ventilation-associated pneumonia Gram-negative rods
Mechanical heart valves Staphylococci
Vascular grafts Gram-positive cocci
Arteriovenous shunts Staphylococci
Endovascular catheter infections Staphylococci
Cerebral spinal fluid shunts Staphylococci
Peritoneal dialysis peritonitis Various species
Urinary catheter infections E. coli, Gram-negative rods
Intrauterine devices Actinomyces israelii and others
Penile prosthesis Staphylococci
Orthopedic prosthesis Staphyoccci
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termittent symptoms do occur, even in otherwise uncompromised individu-
als. By examining chronically infected tissue or the surface from a medical
device involved in a chronic infection, the presence of matrix enclosed bacte-
ria was observed. [12, 63–65] There are two categories of biofilm infections:
the ones that involve infection of a soft or hard tissue and device related in-
fections. Soft or hard tissues can become infected after a trauma or are more
sensitive to infection through predisposition of the host, as for example is seen
in diabetic ulcers or chronic pulmonary infections in cystic fibrosis patients.
[63, 66] In case of device related infections, the device itself serves as a sub-
strate for the adhesion of the bacteria. [67] The recurring symptoms seen in
chronic infections are often caused by planktonic cells shed from the biofilm.
Antibiotic therapy can temporarily relieve the symptoms but may not fully
eradicate the biofilm. In that case, the symptoms will return once the therapy
is discontinued. [68] Confirming the presence of biofilms in a chronic infec-
tion is not straight forward. Sometimes, it is even difficult to determine which
species is involved in the infection since the biofilm bacteria can switch to a vi-
able but non-culturable phenotype under the control of stress response genes.
[69] Parsek & Singh have proposed a set of criteria to help define the charac-
teristics of a biofilm infection based on these observations. Firstly, the bacteria
must be surface associated. Secondly, the bacteria must be present in clusters
or microcolonies embedded in an extracellular matrix. Thirdly, the infection
should be confined to a particular location and finally, the infection cannot be
eradicated using classic antibiotic therapy. [70]
1.2.2 Causes of biofilm persistence
Biofilms show an increased tolerance towards the immune defenses of the
host. The biofilm matrix protects the biofilm from the immune system as it
blocks antibodies from reaching the bacteria and prevents the removal of the
biofilm by phagocytosis. [71–74] This way, the infection can persist, even in an
immunocompetent host. The inability of the immune system to clear the infec-
tion leads to frustrated phagocytosis which causes tissue damage and possibly
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spreading of the infection. [12, 71] This process is illustrated by Figure 1.5
Figure 1.5: Scheme showing the inability of the immune system and antibiotics to clear
a biofilm infection. A: Planktonic bacteria are easily cleared by the immune system
and antibiotic treatment. B: Once a biofilm is formed, eradication via the immune
system and antibiotic treatment is not achieved. C and D: Since the immune system
can detect the presence of the bacteria but is unable to eradicate the biofilm, frustrated
phagocytosis takes place which damages the surrounding tissue. [71]
Biofilms are also more tolerant to antimicrobial therapy compared to their
planktonic counterparts. In some cases, biofilms were shown to resist an-
tibiotics at concentrations hundreds of times higher than needed to kill their
planktonic counterparts. [75] Three mechanisms are believed to be involved.
Firstly, the biofilm matrix can act as a barrier for antimicrobial agents. The
matrix itself can retard the diffusion of antibiotics, mainly by electrostatic in-
teractions between the matrix polymers and the antibiotic. The binding of
positively charged aminoglycosides to the negatively charged alginate matrix
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of P. aeruginosa biofilms is an example hereof. [76] A decrease of the effective
concentration and slower diffusion of antimicrobial agents by matrix binding
allows the bacteria to increase their resistance before a lethal dose is reached.
Furthermore, degradation of the antibiotic can take place in the biofilm matrix.
Known examples are the degradation of β-lactam antibiotics in the matrix of P.
aeruginosa biofilms by secreted β-lactamases and the inactivation of H2O2 by
secreted catalase. [77, 78] These enzymes can inactivate the antimicrobials in
the outer layers of the biofilms since the inactivation occurs faster than the dif-
fusion of the antimicrobials into the biofilm. The bacteria inside dense biofilm
structures are therefore protected.
Secondly, subpopulations of biofilm cells are found to be in a slow growing
or starved state, making them less susceptible to antimicrobial agents. In a
mature biofilm, heterogeneity occurs since micro environments with different
osmolarities, oxygen levels, cell densities and nutrient supply can be found.
[62] Inside dense biofilm structures, oxygen and nutrient depletion lead to
increasing numbers of bacteria with low metabolic activity. Since antibiotics
usually require metabolically active cells in order to be effective, cells residing
in these niches are less susceptible. [76, 79, 80]
Low metabolic activity is not the only way in which a subpopulation of
cells can cause the increased antimicrobial tolerance observed for biofilms.
When the dose dependent ofloxacin killing of P. aeruginosa was tested, the
number of live cells first decreased rapidly with increasing ofloxacin concen-
trations. However, after a certain dose, increasing the concentration did not
lead to increased killing and complete eradication of P. aeruginosa could not
be achieved. Although slow growth and dormancy could be observed in this
surviving cell population, it does not completely explain this phenotype as an-
tibiotics that also kill slow or non-growing bacteria such as fluoroquinolones
are equally unable to eradicate these cells. [81] These observations suggest
that other mechanisms besides slow growth caused the increased persistence.
The surviving cells were named persister cells and represent a third and likely
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the most important mechanism of increased antimicrobial tolerance. As most
biofilm bacteria show increased tolerance but not increased resistance to an-
timicrobial agents, most biofilm cells can eventually be killed by antimicrobial
therapy. However, the matrix protects the remaining persister cells from clear-
ance by the immune system. Once the antimicrobial therapy is discontinued,
the persister cells cause regrowth of the biofilm. [82] This explains the inter-
mittent symptoms associated with chronic biofilm infections.
The persister cells represent approximately less than 1 % of the total cell
poluation in a biofilm. [82, 83] A trademark of these cells is that they do not
grow nor die in the presence of high amounts of antimicrobial agents. They are
not mutants displaying increased antimicrobial resistance since the number of
persister cells does not increase when a new culture is grown starting from
persister cells only. [81] Persister cells thus show a different phenotype rather
than a different genotype. The mechanisms these persisters use to survive are
only just beginning to be unraveled. One of the survival mechanisms was
recently shown to be the reduction in oxidative stress. [83, 84]
1.2.3 Treatment of biofilm infections
Biofilm infections are inherently connected to the use of medical devices. As
a consequence of the frequent use of these devices, device related infections
induce a substantial economic burden. For example, catheter related sepsis
is reported to augment treatment costs by $ 28,000 per case. Nosocomial uri-
nary tract infections, which are a subset of these catheter related infections,
account for approximately 900,000 admissions annually in the US. [85] This
underscores the vast extent of the problem. Therefore, strategies against de-
vice related biofilm infections are aimed at the prevention of device coloniza-
tion and the killing of adhered bacterial cells. [86] The prevention of device
contamination is achieved by sterilization of the device combined with proper
hygienic measures during device insertion. Systemic prophylaxis can also be
considered in some cases. [87] Pretreatment of the device with antimicrobial
agents can prevent colonization by bacteria as well. [86] To clear an existing
17
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biofilm from catheters, antimicrobial lock therapy has proven to be a success-
ful approach. [88] Unfortunately, in many cases the only method for effec-
tively clearing the infection is removal of the device.
Since classical antimicrobial therapy is often unsuccessful in clearing bio-
film infections and new antimicrobial compounds are not readily available,
new concepts are being tested to eradicate biofilms. Quorum sensing inhibi-
tors are being investigated to prevent biofilm formation and adaptation of the
bacteria to their environment. [89, 90] Also, photodynamic therapy is being
explored, where a photosensitizer that produces reactive oxygen species upon
light irradiation is applied to the infection site which leads to damage to the
bacteria. [91–94] Another approach is the use of ultrasound in combination
with antibiotics. Their synergistic effect can lead to a higher degree of killing
of the biofilm bacteria, possibly by increased penetration of the antibiotic into
the biofilm. [95–97] Yet another approach is the interference with the biofilm
integrity, e.g. by substances that degrade the biofilm matrix. For instance,
DNase and alginate lyase have been shown to provide a synergistic effect with
antimicrobial agents. [98, 99] Phage therapy has also proven to be promising
in the prevention and eradication of biofilms. [100, 101] Another approach
is to optimize the drug delivery process to the biofilm to ensure a maximal
delivery of antimicrobial agents to the bacterial cells. This can be done e.g. by
using lipid and polymer nanoparticles, as is reviewed extensively in the next
chapter.
1.3 Cystic fibrosis
1.3.1 Molecular biology
Cystic fibrosis (CF) is the most common genetically inherited disease in the
Caucasian population and has an incidence of about 1 in 2500 births. [102–
104] The gene which is affected in CF was determined to be located on the long
arm of chromosome 7 and was for the first time cloned and sequenced in 1989.
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[105–107] CF only manifests when both copies of the gene are affected by the
mutation. Therefore, CF is described as an autosomal recessive disease caused
by mutations in the cystic fibrosis transmembrane conductance regulator gene
(CFTR) .
The CFTR gene is approximately 250 kB long and codes for the CFTR pro-
tein, which consists of 1480 amino acids. The CFTR protein shows an ATP-
binding cassette (ABC) transporter structure. It contains two repeated motifs,
each one consisting of six membrane spanning α-helices and a hydrophilic
region which corresponds with a nucleotide binding domain (NBD) . Further-
more, it contains a highly charged regulatory (R) domain which can be phos-
phorylated by protein kinase A and protein kinase C. [108] The membrane
spanning helices form a chloride channel that is regulated by phosphoryla-
tion of the R-domain and by binding of ATP to the NBDs. [109–111]
Figure 1.6: The CFTR structure and its integration in the cell membrane. [112, 113]
The CFTR channel is primarily located on the apical membrane of epithe-
lial cells that line mucus membranes where it plays a role in ion and fluid
homeostasis. [111, 114] Although its function as a chloride channel has been
well established, evidence points towards involvement of the CFTR channel
function, or dysfunction for that matter, in the reabsorption of sodium by the
19
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epithelial sodium channel (ENaC). The CFTR was found to be a downregula-
tor of the ENaC, limiting the sodium reabsorption. [115–117] Some researchers
suggest CFTR might play a role in the bicarbonate secretion and the regula-
tion of the outwardly rectified chloride channel and the renal ATP-sensitive
potassium channel ROMK2 as well. [118–121] It is clear that the full extent
of the CFTR function and the other processes and channels it may influence
remains to be elucidated.
Nowadays, more than 1600 different mutations have been shown to re-
sult in CF. [103, 122] The most common one is the deletion of the codon for
phenylalanine at position 508 (phe508del or ∆F508). This mutation accounts
for almost 70 % of CF cases and is followed by G542X (2.6 %), N1303K (1.6 %),
G551D (1.5 %) and W1282 (1.0 %). [107] It must be noted that these percent-
ages are indicative and can vary dependent on the ethnic group studied. The
mutations lead to abnormal cellular processing of the CFTR and/or result in
the lack of functional CFTR at the apical membrane of the cells. Based on the
molecular mechanism behind CFTR dysfunction, the mutations are divided
into six different classes. In class I mutations, no full length CFTR mRNA
and thus no CFTR protein is produced. Class II mutations result in the abnor-
mal folding of the protein, leading to incorrect trafficking and the absence of
CFTR on the cell membrane. The phe508del mutation is an example of this
case. Class III and IV mutations lead to normal trafficking but the CFTR is
dysfunctional due to changes in the open probability of the channel or due to
a lower conductance respectively. Class V mutations lead to reduced produc-
tion of CFTR and class VI results in a CFTR which is functional, but shows a
high turnover at the cell membrane due to instability caused by the mutation.
[107, 123] An overview of these different classes is presented in Figure 1.7.
1.3.2 Physiopathology
Dysfunction of the CFTR affects the function of multiple organs, mainly the
lungs, gastro intestinal tract, pancreas and reproductive system. Since the
pulmonary complications are often the primary cause of mortality and since
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Figure 1.7: An overview of the different classes of mutations that lead to CF. [123]
the focus of this thesis will be pulmonary infections in CF patients, the phys-
iopathology of the CF lung disease is discussed in detail.
There are two main hypotheses that partially explain the initiation of CF
airway disease and the increased vulnerability for pulmonary infections as a
consequence of the CFTR defect. The ‘isotonic low volume hypothesis’ states
that because of the lack of inhibition of the ENaC, increased sodium reab-
sorption occurs which leads to osmotic depletion of the airway surface liquid
(ASL). [124] The hypothesis is based on the observation that the volume of
the ASL can be regulated by active ion transport in order to establish opti-
mal mucociliary clearance. [125, 126] When the periciliary layer, i.e. the layer
of the ASL in which the cilia beat, dehydrates, the overlaying mucus layer
comes into contact with the epithelial cells and adheres to it via interaction
with tethered surface mucins and other surface molecules. [127–129] This
causes impaired mucociliary clearance and thus stasis and accumulation of
mucus as illustrated in Figure 1.8. The process of mucus plugging starts in
the small airways and is progressive towards the larger airways throughout
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the patients’ life. [127, 130] Due to the loss of mucociliary clearance, coloniza-
tion with pathogens can occur, leading to a chronic neutrophilic inflammatory
response. Necrosis of the neutrophiles causes the release of DNA and filamen-
tous actin, which in turn increase the viscosity of the mucus. [128, 131, 132]
The altered viscoelastic properties of the mucus have another consequence as
well. As the thick mucus can glue together the folds in the small airways, they
cannot properly unfold upon inspiration, leading to a reduced airway lumi-
nal diameter. Besides this, small airway remodeling takes place resulting in
thickening of the wall of the airways, thereby reducing their compliance. The
airway remodeling is progressive as well and its exact cause remains largely
unknown. The continuous inflammation and stiffening of the smooth muscles
due to the absence of sufficient stretching by breathing are factors that likely
play a role. [127] The mucus plugging, infection, inflammation and subse-
quent damage to the lung tissue form in fact a vicious cycle which leads to
reduced pulmonary function over time and ultimately death by respiratory
failure. (Figure 1.9)
The other hypothesis is the ’high salt hypothesis’ which states that the
salt concentration of the airway surface liquid is increased in CF, leading to
the inhibition of antimicrobial peptides and therefore increasing the risk for
infections. [133, 134] More compelling evidence exists for the low volume
hypothesis since the measurement of airway surface liquid ion composition
was shown to be the same for uninfected CF patients and healthy subjects.
[135, 136, 136–139] However, the ionic composition of the airway surface liq-
uid could be different in local micro-environments such as the submucosal
glands and the mucus plugs, or could be influenced by processes such as
chronic inflammation and infection. [140, 141] Therefore, it may be that the
high salt hypothesis still contributes to the CF airway pathogenesis.
A final aspect of CF lung disease is the increased inflammatory reaction
in the airways which can be observed even in absence of pathogens. When
colonized, the inflammatory reaction is often more pronounced than can be
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expected by the bacterial stimuli only. [142, 143] How exactly the increased
inflammatory reaction is linked to the CFTR defect still needs to be resolved,
but it is clear that it influences the innate immune function of the respiratory
epithelium, immune cell function and the level of oxidative stress in the air-
ways. [144]
Figure 1.8: Situation in healthy lungs and in CF affected lungs which show ASL deple-
tion and mucus plugging. Adapted from [145].
1.3.3 Pulmonary infections
As said, pulmonary infections play an important role as they tend to speed up
disease progression via increasing the inflammatory response. [147] Several
species of micro organisms are able to colonize the lungs of CF patients. The
most commonly isolated pathogens are Staphylococcus aureus, Pseudomonas ae-
ruginosa , Haemophilus influenzae, Achromobacter xylosoxidans, Stenotrophomonas
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Figure 1.9: Vicious cycle leading to the early death of most CF patients. Adapted from
[146].
maltophilia and pathogens belonging to the Burkholderia cepacia complex. These
pathogens are usually acquired in an age-dependent sequence. [132, 148, 149]
During childhood, H. influenza and S. aureus are rapidly acquired with on aver-
age 20 and 40 % of CF infants of less than one year old being colonized, respec-
tively. [132] H. influenza is a common commensal of the upper airways and S.
aureus frequently colonizes the anterior nares. From there, both pathogens can
spread towards the lungs and cause infection. [149]
P. aeruginosa colonization also has an early onset, on average at the age of
15 months. [150] P. aeruginosa is presumably acquired from the environment,
but patient-to-patient transmission was observed as well in several cases. [149]
The prevalence of P. aeruginosa infections increases with the age of the patients
with most adult CF patients showing intermittent or chronic infection. In-
creased morbidity and mortality is associated with P. aeruginosa colonization,
which increases the risk of death over an 8 year period by 2 to 3 times. [151]
Some time after initial colonization, P. aeruginosa adopts the mucoid pheno-
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type and can form biofilms consisting of bacterial microcolonies surrounded
by an alginate matrix leading to increased antibiotic tolerance and hamper-
ing clearance by the immune system. [27, 152] The expression of β-lactamases
and efflux pumps as well as modification of antibiotic targets further compli-
cate treatment. [153] At this point, the infection becomes chronic and the pro-
longed inflammatory response leads to a gradual decrease of the lung func-
tion.
S. maltophilia and A. xylosoxidans are opportunistic pathogens and are often
isolated from adolescents aged 11 to 17 years and adult patients aged 18-25
years, respectively. [132, 149] Currently, there is no evidence for patient-to-
patient transmission for these pathogens and due to their low virulence, their
impact on the decline in lung function is thought to be minimal. [132] The
same cannot be said for infections with B. cepacia complex (Bcc) bacteria. The
Bcc consists of 18 closely related Burkholderia species of which most are able
to infect CF patients. [154] The prevalence of Bcc infections increases with the
age of the patients but is generally lower than 10 %. Infections with these bac-
teria are feared because of the possible occurrence of the cepacia syndrome,
a rapid and often fatal clinical deterioration associated with high fever, bac-
teremia, necrotizing pneumonia and respiratory failure which occurs in ap-
proximately 20 % of Bcc infected patients. [149, 155, 156] B. multivorans and
B. cenocepacia account for most of the Bcc infections. Patients infected with B.
cenocepacia show an increased mortality compared to patients infected with B.
multivorans or P. aeruginosa due to the increased virulence and risk of cepacia
syndrome associated with this pathogen. [157, 158] B. cenocepacia and some B.
multivorans and B. dolosa strains are mainly associated with patient-to-patient
transmission while the other Bcc infections are thought to be acquired from the
natural environment. [149, 159] By ensuring patient segregation, the preva-
lence of Bcc infections has dropped from 9 to 4 % between 1990 and 2005.
[148] The most problematic feature of Bcc bacteria is their intrinsic multidrug
resistance. Resistance to aminoglycoside and polymixin antibiotics due to al-
terations in the membrane lipopolysaccharides has been described. [160] Also,
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resistance to β-lactam antibiotics via the production of β-lactamases was ob-
served. [161] Furthermore, the presence of antibiotic efflux pumps has been
confirmed, which results in resistance towards most classes of antimicrobial
agents. [162, 163] Athough unproven to date, biofilm formation in the lungs
of CF patients by Bcc bacteria is a likely possibility and could lead to a further
increased tolerance to antimicrobial agents.
The ’low volume’ and the ’hight salt’ hypotheses discussed earlier explain
the increased vulnerability of the lungs for pathogen colonization but do not
explain why the lungs are only colonized by certain pathogens. In the case
of P. aeruginosa , several hypotheses offer an explanation for this observation.
Firstly, increased adherence of P. aeruginosa can be explained by an increase in
the expression of asialoganglioside-1, which increases the adherence of P. aeru-
ginosa to the lung epithelium. The increased expression of asialoganglioside-1
is likely a consequence of the increased inflammation of the airways. [164–
166] Secondly, the CFTR itself can be a receptor for P. aeruginosa. Binding of
P. aeruginosa to the receptor leads to the internalization and clearance of the
bacteria. [167, 168] The absence of CFTR could thus cause a reduced clearance
of P. aeruginosa from the airways. It is thought that this mechanism is more
important in early colonization of the lungs since non-mucoid strains were
shown to bind to CFTR while mucoid strains, whose the presence is indicative
of a chronic infection, did not. [169] However, the relevance of CFTR as a P.
aeruginosa receptor is still under debate.
1.3.4 Symptoms
As said before, CF affects several organ systems leading to various symptoms.
The earliest clinical sign of CF is meconium ileus, a bowel obstruction caused
by abnormally viscous meconium. Meconium ileus is associated with pancre-
atic exocrine insufficiency caused by the CFTR gene mutation. [170] Due to
the CFTR defect, the pancreatic fluid- and bicarbonate secretion are both de-
creased. The pancreatic insufficiency is caused by the build-up of the thick se-
cretions and enzymes inside the pancreas, which causes obstruction and pan-
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creatic lesions due to activation of the digestive enzymes inside the pancreas.
Symptoms pointing towards pancreatic insufficiency besides meconium ileus
are diarrhea, which can present as steatorrhea, malnutrition, growth failure,
deficiencies in fat-soluble vitamins, hemolytic anemia and edema. The pro-
gressive pancreatic damage can also result in diabetes later in life. [122, 171]
In the gastrointestinal tract, the most prominent symptoms are caused by
gastrointestinal dysmotility. This translates into gastroesophageal reflux and
constipation. Furthermore, delayed gastric emptying is observed due to the
pancreatic insufficiency. Symptoms associated with this are poor appetite and
an early satiety feeling. [171]
Also the reproductive system is affected by CF. In up to 98 % of the male
patients, bilateral absence of the vas deferens causes infertility. [172] The vas
deferens is resorbed due to blockage by mucoid secretions, which is a direct
result of the CFTR dysfunction. [122] In female patients, the anatomy of the
reproductive system is normal but reduced fertility is observed. This is caused
by the formation of a tenacious cervical mucus which reduces the accessibil-
ity of the uterus to sperm as it does not undergo midcycle thinning. [122]
Poor nutritional status can be an additional source of reduced fertility in CF
women, as it can cause secondary amenorrhea or anovulatory cycles. [172]
Pulmonary complications are the main cause of morbidity and pulmonary
failure primarily accounts for the mortality associated with CF. The lungs are
initially normal at birth with the only indication of CF being the more frequent
bacterial infections during infancy. [122] About one third of CF children are
diagnosed with respiratory infections within one year after birth. [173] These
children present with cough, tachypnea and wheezing and often show recur-
rent or persistent bronchiolitis. [174] Later in life, cough associated with spu-
tum expectoration becomes the most prominent symptom of respiratory dis-
ease. [132] The volume and the visual appearance of the sputum evolves with
the disease progression. It becomes more green and can start to show streaks
of blood. In late stage disease, hemoptysis can also occur. [132, 173] When
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the pulmonary function decreases, increasing levels of dyspnea and shortness
of breath arise and the patients become oxygen dependent and wheelchair
bound until they succumb to pulmonary failure. [132, 173] The pulmonary
complications limit the average life expectancy to 37 years. [175, 176]
1.3.5 Diagnosis
One of the easiest and cheapest ways of diagnosing CF is the sweat test, which
is regarded the gold standard. [177] In this test, the chloride and sodium con-
centrations are measured since these are typically elevated in CF patients. Pi-
locarpine is first driven into the skin by iontophoresis to stimulate sweating
where after the sweat is collected for analysis. A sweat chloride concentration
above 60 mmol/l is indicative of classic CF, concentrations in the range of 30
to 60 mmol/l are borderline and may point to non-classic CF. Concentrations
lower than 30 mmol/l are normal, but non-classic CF is still a possibility if clin-
ical signs of CF are present. If the sweat tests reveals elevated chloride levels
or a CF phenotype is present in at least one organ system, genetic analysis is
used to confirm the diagnosis. [146, 177] Other tests to assess the sodium and
chloride transport over epithelial cells such as the measurement of the nasal
transepithelial potential difference (NPD) and the intestinal current measure-
ment can be used to refine the diagnosis. [146] A flow chart which can be used
in the diagnostic process is represented in Figure 1.10.
In Belgium, screening of neonates is not yet implemented. However, early
diagnosis allows for early access to specialized care and to counsel parents
with regard to future pregnancies. [103] A study regarding the pros and cons
of neonatal screening in Belgium was published in 2010. [178] These authors
are in favor of screening but only in case of consent of the parents who are
briefed about the screening program, CF and the risk of false positive and neg-
ative test results. In addition, the screening should only be done for mutations
associated with a severe disease course. Lastly, segregation of patients accord-
ing to their microbiological status should be strictly implemented to avoid
early P. aeruginosa colonization. Screening can be performed using the im-
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munoreactive trypsinogen assay, which is a radioimmunoassay. [179] Due to
(partial) pancreatic duct blockage, trypsin and trypsinogen levels in the blood
are elevated. [180] For infants not affected by CF, the trypsin and trypsinogen
levels return to normal within the first weeks after birth while these remain el-
evated in CF affected infants for several months. [146] By re-evaluation some
time after a first positive result, false positives can be identified.
Figure 1.10: Flow chart of CF diagnosis starting from the sweat test. Adapted from
[146]
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1.3.6 Management of CF
Since there currently is no cure for CF, all treatments are directed towards
management of its symptoms and the prevention of disease progression. This
means that CF patients will need medication and supplements as well as phys-
iotherapy on a daily basis for most of their lives. Adherence to the therapy is
of the utmost importance to limit the progression of the disease. Since CF
manifests in several organs and pulmonary complications require the combi-
nation of several medicational and non-medicational approaches, therapy can
take up a significant portion of time every day.
Pancreatic insufficiency can be managed by using enzyme supplements
such as Creon to correct the fat and protein maldigestion. [171] To cope with
the malnutrition, CF patients require a calorie and protein intake which is 120
to 150 % of the normal recommended daily allowance. Additionally, using
supplements with fat soluble vitamins is essential. [181] If diabetes occurs,
normal blood sugar can be achieved with oral hypoglycaemic agents or in-
sulin without compromising the calorie intake of the patient. [181] In case
of constipation, oral laxatives or enemas can be used. A high fiber diet, ade-
quate fluid intake and by establishing regular bowel habits are recommended
to prevent constipation. [122, 171]
When end stage lung disease is reached, lung transplantation is the only
life prolonging treatment that can be offered. To postpone the need for a lung
transplantation and to improve the quality of life, treatment of the pulmonary
complications receives considerable attention. It involves the combination of
physiotherapy, physical exercise and the combination of different classes of
medication. Establishing increased airway clearance is highly recommended
to compensate for the impaired mucociliary clearance. A first way to increase
airway clearance is physiotherapy. The mostly used techniques are postural
drainage, autogenic drainage, active cycle breathing, positive expiratory pres-
sure and oscillating positive expiratory pressure. All these techniques were
found to be equally effective in mobilizing mucus. The choice of technique
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is therefore discussed with the patient. [182, 183] Reducing the tenacity of
the lung mucus using inhaled medication is an additional way of increasing
the airway clearance. It was reported that CF lung mucus contains very lit-
tle intact mucin. [131] The increased viscoelasticity is mainly caused by the
presence of large amounts of DNA and filamentous actin derived from de-
graded neutrophils. Therefore, the only mucolytic with proven efficacy is dor-
nase alpha, an inhalable solution of recombinant human desoxyribonuclease
I. Reduced exacerbation rates of CF patients using dornase alpha have been
reported and the effect likely results from the increased airway clearance. Be-
sides this, a positive effect of dornase alpha on inflammation markers and the
the rate of lung function decline was observed as well. [184, 185] In this light,
it is recommended to include dornase alpha in the therapy early on.
Reducing the viscosity of the lung secretions via increasing the hydration
of the mucus is used as well. Inhaled hypertonic saline and mannitol are of-
ten used for this purpose. Both agents are able to improve mucociliary clear-
ance by osmotically drawing water into the airway lumen and were shown
to increase mucus clearance and improve the lung function. [186–189] The
combination of mannitol with dornase alpha did not show a synergistic effect.
[186]
The most important pillar in lung function preservation is infection con-
trol. Prevention of infection by patient segregation should always be imple-
mented and can be combined with the prophylactic usage of antibiotics. Pa-
tients should especially avoid contact with individuals infected with methi-
cillin resistant S. aureus, transmissible P. aeruginosa stains and Bcc. Antibiotic
prophylaxis is aimed at reducing the prevalence of S. aureus infections and
at preventing secondary bacterial infection in the occasion of a viral respi-
ratory infection. [190] When infection does occur, antimicrobial therapy is
used to prevent the establishment of a chronic infection and the formation of
biofilms. As P. aeruginosa and B. multivorans are used in this thesis, the an-
tibiotic treatment of these two organisms will be elaborated. Since the tran-
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sition of P. aeruginosa from the non-mucoid form to the mucoid form marks
the beginning of chronic infection, eradication needs to be achieved before
the transition takes place. When the presence of P. aeruginosa is confirmed,
the first choice of therapy is the combination of nebulized colistin with oral
ciprofloxacin, which should be used for 3 months. If the patient presents
with a regrowth or shows intolerance for colistin or ciprofloxacin, inhaled to-
bramycin can be used instead. In the case of a chronic P. aeruginosa infection,
a regimen of regular nebulized colistin can be used to control the infection.
Again, in case of intolerance against colistin or if the clinical situation does
not improve, inhaled tobramycin can be used instead. During a pulmonary
exacerbation, the antibiotics are usually administered intravenously. The use
of nebulized gentamycin, tobramycin or colistin in the prevention of P. aeru-
ginosa infection is used by some CF centers, but the benefit of this approach
versus the risk of increasing bacterial resistance and potential toxicity of the
long term treatment is not clear yet. [190] Due to the high intrinsic resistance
of Bcc bacteria, in vitro sensitivity testing is recommended before selecting
the antibiotic treatment regimen. For the same reason, combination therapy
should be used for the treatment of Bcc exacerbations. Co-trimoxazole, doxy-
cycline and trimethoprim can be administered orally. Suitable intravenously
administered antibiotics are meropenem, temocillin, ceftazidime, imipinem,
piperacillin-tazobactam, trimethoprim, doxycycline or co-trimoxazole. Cef-
tazidime and taurolidine are also available for inhalation therapy. It is impor-
tant to note that the relatively high amounts of DNA in the CF mucus causes
a reduction in the efficacy of antibiotics via electrostatic binding. This was for
example being shown for the positively charged aminoglycoside antibiotic to-
bramycin. [191]
Research was also directed towards finding agents that correct the CFTR
function. [192] These agents can be divided into three classes: correctors,
which promote trafficking and membrane insertion of the mutant CFTR, po-
tentiators, which activate mutant CFTR already localized on the apical mem-
brane and agents which suppress premature stop codons. Lumacaftor (Vertex
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Pharmaceuticals Inc., not yet approved) is an example of a CFTR corrector that
can be used for patients with the phe508del mutation. It corrects the misfould-
ing of the protein and therefore prevents its degradation. [193, 194] Ivacaftor,
tradename Kalydeco marketed by Vertex Pharmaceuticals Inc, is a CFTR po-
tentiator which is currently on the market for patients with the G551D class III
mutation. Ivacaftor increases the open probability of the mutant CFTR chan-
nel, increasing the chloride secretion. Furthermore, the sodium and water
hyper-absorption was reduced. [195] Very recently, a study combining both
lumacaftor and ivacaftor has shown promising results in patients who are
phe508del homozygotes. [196] For class I mutations, ataluren (PTC Thera-
peutics, Inc) can be used to attain read-through of premature stop codons.
Variable results have been achieved with CF patients exhibiting this class of
mutations. [195]
Furthermore, ion transport regulators and ENaC inhibitors are being de-
veloped. Denufosol is an example of an ion transport regulator. It decreases
the sodium reabsorption via the ENaC and stimulates the chloride secretion
via the calcium-activated chloride channel, leading to rehydration of the air-
way mucus. [189] Despite promising results in an earlier trial, this beneficial
effect was not confirmed in a second phase 3 clinical trial. [197] The ENaC
inhibitors are still in the early phase of development. Examples are the com-
pounds P552-02 (Parion sciences), GS-9411 (Parion Sciences and Gilead Sci-
ences) and Camostat (Novartis). [189]
Lastly, CF is a good candidate for treatment by gene therapy. In 1989, it
was believed that with the progression in the field of gene therapy, CF could
be cured within 5 years. The lungs are seemingly easily accessible for gene
delivery and it was estimated that of CFTR expression as low as 10 % would
be sufficient to prevent pulmonary symptomes. [198] At the present date,
gene therapy is still not available. The tenacious lung secretions, which pose
a barrier to gene transfection, tight junctions between the cells, the inability to
reach the small airways and the cells of the submucosal glands are some of the
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barriers gene therapy vectors need to overcome. [198, 199] At the moment, a
large double-blind clinical trial using a liposomal vector has just been ended
in the UK. In this trial, a monthly dose of the nebulized liposomes containing
the CFTR gene was administered for one year. The results from this trial will
be announced later this year at the North American CF Conference (October
2014).
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2.1 Abstract
Biofilms are matrix-enclosed communities of bacteria that show increased an-
tibiotic resistance and the capability to evade the immune system. They can
cause recalcitrant infections which cannot be cured with classical antibiotic
therapy. Drug delivery by lipid or polymer nanoparticles is considered a
promising strategy for overcoming biofilm resistance. These particles are able
to improve the delivery of antibiotics to the bacterial cells, thereby increas-
ing the efficacy of the treatment. In this review we give an overview of the
types of polymer and lipid nanoparticles that have been developed for this
purpose. The antimicrobial activity of nanoparticle encapsulated antibiotics
compared to the activity of the free antibiotic is discussed in detail. In ad-
dition, targeting and triggered drug release strategies to further improve the
antimicrobial activity are reviewed. Finally, ample attention is given to ad-
vanced microscopy methods that shed light on the behavior of nanoparticles
inside biofilms, allowing further optimization of the nanoformulations. Lipid
and polymer nanoparticles were found to increase the antimicrobial efficacy
in many cases. Strategies such as the use of fusogenic liposomes, targeting
of the nanoparticles and triggered release of the antimicrobial agent ensured
the delivery of the antimicrobial agent in close proximity of the bacterial cells,
maximizing the exposure of the biofilm to the antimicrobial agent. The major-
ity of the discussed papers still present data on the in vitro anti-biofilm activity
of nanoformulations, indicating that there is an urgent need for more in vivo
studies in this field.
2.2 Why use nanotechnology?
The number of publications involving the use of nanomedicines for the pre-
vention of biofilm formation and the eradication of existing biofilms has been
growing steadily over the past decade, with special attention going to lipid
and polymer nanoparticles. Attractive properties of these particles are their
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biocompatibility, the versatility of materials and surface modifications, the
possibility for targeting and triggered release, their ability to incorporate li-
pophilic as well as hydrophilic drugs and a reduction of unwanted side ef-
fects of the drug. [1, 2] In the context of treating biofilm infections, the use of
nanoparticles to encapsulate antimicrobial agents might have several benefits.
The nanoparticles can protect the antimicrobial agent from binding to matrix
material and enzymatic inactivation. Lipid nanoparticles can fuse with the
bacterial outer membrane, delivering the antimicrobial agent directly to the
bacterial cells. Furthermore, by targeting of the nanoparticles to the biofilm,
a high dose of antimicrobial agents can be delivered in the direct proximity
of the bacterial cells, thereby maximizing therapeutic benefit while reducing
unwanted side effects.
In this section, an overview of lipid and polymer nanoparticles for drug
delivery to bacterial biofilms is provided. First, the delivery of antimicrobial
agents to bacterial biofilms is discussed. A distinction is made between par-
ticles used for non-targeted delivery, particles for targeted delivery and par-
ticles that are designed to release the antimicrobial agent upon application of
an external trigger. Next, methods that allow quantification of transport and
interactions of nanoparticles in bacterial biofilms are discussed as they can
provide essential information to optimize the nanoparticle formulations. Ta-
ble 2.1 lists all the liposomal formulations that were tested in the context of
drug delivery to biofilms and Table 2.2 all the polymer and lipid-polymer hy-
brid nanoparticles. For the abbreviations of the lipids and polymers used we
refer to the legends of Table 2.1 and 2.2 at the end of this chapter.
2.3 Non-targeted delivery to biofilms
2.3.1 Lipid nanoparticles
Due to their versatility and biocompatibility, liposomes are attractive candi-
dates for nanoparticle mediated drug delivery in biofilms. Liposomes are
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spherical vesicles consisting of one or more phospholipid double layers. Li-
pophilic drugs can be incorporated into the phospholipid double layers while
hydrophilic drugs can be encapsulated into the aqueous core. Several authors
have reported that the encapsulation of antibiotics in liposomes resulted in
lower minimal inhibitory concentrations (MIC) for clinically relevant biofilm
forming organisms or in lower minimal biofilm inhibitory concentrations (M-
BIC) compared to the free antibiotic in vitro. Different mechanisms for this in-
creased activity of nanoparticle encapsulated antimicrobial agents have been
proposed. Similarly, micelles, which consist of a single phospholipid layer,
can also be used as drug delivery vehicles. In contrast to liposomes, these
particles can only carry lipophilic drugs.
Fusogenic liposomes
One of the biggest advantages of using liposomes as drug delivery vehicles, is
their potential to fuse with phospholipid membranes and deliver the antibi-
otic directly to the cells. Fusogenic liposomes consist of lipids that make the
lipid bilayer more fluid and can promote destabilization of biological mem-
branes. Liposomes containing a phosphoethanolamine (PE) moiety such as
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) are well-known ex-
amples. [3–5] The fluidity of liposomes can be tuned by the choice of phos-
pholipids. In general, the shorter the acyl chains of the phospholipids, the
lower the phase transition temperature (Tc) of the liposomes will be. The pres-
ence of double bounds or asymmetry in the acyl chains tends to lower the Tc
of the liposomes as well since this induces a disturbance in the packing of the
phospholipid bilayer. [6] Also the addition of cholesterol lowers the Tc. [7]
It was found that the bactericidal activity of liposomal tobramycin primar-
ily depends on the fluidity of the liposomal membrane. DPPC:DMPG lipo-
somes, called Fluidosomes™, with a Tc of approximately 30 °C showed a sig-
nificant decrease in viability of Pseudomonas aeruginosa biofilms compared to
the free antibiotic. P. aeruginosa is known for causing chronic pulmonary in-
fections in cystic fibrosis (CF) patients and patients suffering of non-CF bron-
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chiectasis, but can also cause wound and device related infections. Two very
recent reviews on the use of lipid, polymer and lipid polymer hybrid nanopar-
ticles for the treatment of chronic P. aeruginosa lung infections have been pub-
lished. [8, 9] Using Fluidosomes™, complete eradication of a chronic pul-
monary P. aeruginosa infection was obtained in an in vivo rat model. The
antibiotic was found to remain manly in the lungs after liposomal delivery
compared to the free drug, which likely reduces systemic side effects and tox-
icity. However, no increased antimicrobial effect of DSPC:DMPC liposomes
with a Tc around 44 °C was observed. [10] The antimicrobial activity of the
Fluidosomes™ was further compared to that of free tobramycin in in vitro
biofilms of P. aeruginosa , Stenotrophomonas maltophilia and Burkholderia cepa-
cia, which are CF pathogens, and Escherichia coli and Staphylococcus aureus.
Fluidosomes™ showed an increased antimicrobial effect compared to the free
antibiotic in all biofilms tested, meaning that the advantage of Fluidosomes™
is not restricted to one species of bacteria. [11, 12] Experimental evidence for
membrane fusion of Fluidosomes™ was obtained from flow cytometry and
from lipid mixing studies that both showed mixing of the lipids from the
Fluidosomes™ with the membrane of the bacteria (Figure 2.1 A and B). For
flow cytometry, Fluidosomes™ were labeled with a membrane-inserting flu-
orescent probe. After incubation and removal of non-adsorbed liposomes,
an increase in fluorescence of the bacteria was measured indicating incor-
poration of the lipids from the Fluidosomes™ into the bacterial outer mem-
brane. For the lipid-mixing assay, two membrane inserting fluorescent probes
that show fluorescence resonance energy transfer (FRET) were used to label
the Fluidosomes™. The change in FRET efficiency when the Fluidosomes™
were incubated with the bacteria was indicative of a fusion process. Electron
microscopy on the other hand showed that immunogold labeled antibiotics
could be found internalized in the bacterial cells to a higher degree when de-
livered by Fluidosomes™ as compared to the free antibiotic (Figure 2.1 D and
E). In addition, the electron microscopy images showed close contact between
the liposomes and the outer membrane of the bacteria (Figure 2.1 C). [13]
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Figure 2.1: (A) Flow cytometry histograms of two P. aeruginosa strains (25619 and 429)
show a higher percentage of fluorescent cells when treated with fluorescently labeled
Fluidosomes™ (lip) compared to free fluorescent dye (ctrl). (B) Lipid mixing assay
using rhodamine (Rh) and N-(7-nitro-2-1,3-benzoxadiazol-4-yl) (NBD) as fluorescent
dyes. The relative change in the fluorescence intensities indicate a change in the dis-
tance between both dyes. (C) Thickening of the outer membrane of a P. aeruginosa
cell likely by interaction of Fluidosomes™ (arrow). Magnification: x50561. (D) Im-
munogold staining of tobramycin delivered by Fluidosomes™ or in the free form (E).
Gold nanoparticles (dense black spheres) are indicated with arrows. Magnification (D):
x41126, (E): x36720. Reprinted with permission from [13].
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Surprisingly, when the Fluidosomes™ were loaded with meropenem, high-
er MIC values compared to the free antibiotic were obtained in P. aeruginosa
biofilms. [14] The explanation for this difference with tobramycin is likely an
interaction between meropenem and the liposomal membrane that inhibits
the fusion between bacteria and the liposomes. Fluidosomes™-tobramycin are
currently further developed by Axentis Pharma (Zurich, Switzerland) for the
treatment of B. cepacia infections in CF patients. No further information about
ongoing clinical trials with this formulation is available.
Increased antimicrobial activity of amikacin, gentamicin and tobramycin
containing liposomes either composed of DPPC:Chol or DSPC:Chol was ob-
served in P. aeruginosa or Burkholderia cenocepacia biofilms respectively. Fu-
sion of these liposomes with the bacteria was also proven by a combination
of flow cytometry, lipid mixing, TEM and immunochemistry techniques as
mentioned above. [15, 16] Of interest is a comparative study between free
vancomycin and two types of liposomal formulations. Contradictory to the
previously mentioned study, DPPC:Chol liposomes were regarded as classic
non-fusogenic liposomes and as fusogenic liposomes DPPC:DOPE:CHEMS li-
posomes were used. Activity tests were performed on the gram negative bac-
teria E. coli, Klebsiella spp., P. aeruginosa and Acinetobacter baumannii, which are
opportunistic bacteria that are intrinsically resistant to vancomycin since its
high molecular weight prevents it from passing through the outer membrane.
As expected, free vancomycin and the non-fusogenic liposomal formulation
had no activity against the tested strains, while the fusogenic liposomes did.
Electron microscopy images confirmed the interaction and possible fusion of
the fusogenic liposomes with the outer membrane of E. coli cells. [4]
The fluidity of the liposomal membrane also has an influence on the trans-
port of the liposomal formulation to the site of infection. For example, flexible
daptomycin-containing liposomes composed of soy phosphatidylcholine and
sodium cholate were found to rapidly distribute in skin tissue, making them
suitable for anti-biofilm topical skin therapy. After topical application they
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were found to inhibit S. aureus biofilm growth onto subcutaneously implanted
silicone membranes in mice to the same extent as intravenous injection of dap-
tomycin. [17] In addition to the specific liposomal composition, the properties
of the bacterial outer membrane might influence fusogenicity as well. The lat-
ter was extensively investigated by Drulis-Kawa and colleagues for liposome
interaction with P. aeruginosa cells. The outer membrane proteins, lipopolysac-
charides (LPS), hydrophobicity and electrostatic potential of the bacterial cells
were taken into account. [18] Using PC:Chol:DOTAP liposomes containing
the fluorophore rhodamine B, no influence of outer membrane proteins in-
volved in the efflux pump system on the fusion was found. Likewise, the LPS
did not have a significant impact on the interactions with the liposomes since
strains exposing the same kind of LPS showed a different uptake of liposo-
mal rhodamine B. The authors conclude that mainly hydrophobic and electro-
static interactions play a role in the initial binding of the liposomes but that
other elements or structures are likely involved in strengthening the interac-
tion. An 18 kDa outer membrane protein was observed in P. aeruginosa strains
that showed uptake of liposomal rhodamine B, suggesting that this protein
might have a role in the fusion of the liposomes with the outer membrane.
[18]
Protection of the antimicrobial agent
Nanoparticles can shield their cargo from the surrounding medium and pro-
tect it from enzymatic inactivation or binding to the biofilm matrix or other
components surrounding the biofilm infection site. The degradation of β-
lactam antibiotics by β-lactamases, the binding of aminoglycoside antibiotics
to the alginate matrix of mucoid P. aeruginosa biofilms and the inhibition of the
activity of tobramycin by lung mucus in cystic fibrosis patients are all exam-
ples of unwanted interactions of the antimicrobial agent with the biofilm or
the surrounding tissue. [19–21] Mugabe et al. evaluated the antimicrobial ac-
tivity of three different liposomes (DMPC:Chol, DPPC:Chol, DSPC:Chol) en-
capsulating gentamycin against biofilms of several clinical strains of P. aerug-
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inosa. [22] All liposomes showed a significantly higher antimicrobial activity
compared to the free antibiotic. The authors attribute this effect to protec-
tion of gentamycin against binding or enzymatic inactivation. An example
of protection of the β-lactam antibiotic piperacillin against staphylococcal β-
lactamase by encapsulation into PC:Chol liposomes was given by Nacucchio
et al. Encapsulated piperacillin showed a higher activity against S. aureus com-
pared to the free piperacillin, even when exogenous β-lactamase was added.
[12] In cystic fibrosis (CF) sputum, tobramycin or polymyxin B incorporated
in DMPC:Chol or DPPC:Chol liposomes, respectively, were shown to be pro-
tected from binding to polyanionic polymers commonly found in CF mucus.
The liposome encapsulated antibiotics demonstrated a significant increase in
antimicrobial activity towards P. aeruginosa bacteria in the presence of DNA,
F-actin, lipopolysaccharides and lipoteichoic acid. [23]
It is worth noting that co-encapsulation of other antimicrobial substances
together with an antibiotic into liposomes could improve the antimicrobial
efficacy. Omri and coworkers showed that the co-encapsulation of gallium
or bismuth-ethanedithiol with gentamycin or tobramycin in DPPC:Chol or
DSPC:Chol, respectively, can increase the vulnerability of the bacterial cells
and interfere with the expression of virulence factors, alginate, quorum sens-
ing molecules and biofilm formation compared to the free antibiotic or the
free antibiotic and the free metal combined. The cytotoxicity of the gallium or
bismuth-ethanedithiol containing particles was evaluated on a human lung
carcinoma epithelial cell line. The toxicity was reduced for the liposomal met-
als compared to the free metals. [24, 25] Co-encapsulation thus seems to facil-
itate a synergistic effect between the antibiotic and the metals. [26–29]
Prolonged contact time
Also, longer contact times between the antibiotic and the biofilm bacteria have
been suggested to be responsible for the increased antimicrobial effect. [30, 31]
This can for example be achieved by using liposomes that have a surface
charge opposite to the surface charge of the bacteria. The antimicrobial ac-
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tivity of clarithromycin encapsulated into negatively (DPPC:DCP:Chol), pos-
itively (DPPC:DDAB:Chol) or neutrally charged (DPPC:Chol) liposomes was
tested against 9 P. aeruginosa strains. [31] With the negatively and positively
charged liposomal formulation, complete eradication of the biofilms could
be achieved. The positively charged liposomes were able to eradicate the
biofilms at a lower concentration than the negatively charged liposomes. This
could be attributed to greater binding of the positively charged liposomes to
the negative bacteria due to electrostatic attraction, possibly inducing fusion
with the outer membrane. The cytotoxicity of these liposome preparations
and the free drug was investigated on a human lung carcinoma epithelial cell
line. Clarithromycin incorporated into the neutral or negatively charged lipo-
somes was found to be significantly less cytotoxic than clarithromycin incor-
porated into positively charged liposomes and the free clarithromycin.
Longer contact times between the biofilm and the antimicrobial agent can
also be obtained by incorporating the liposomes into biodegradable scaffolds.
These have mainly been designed and tested in the context of chronic os-
teomyelitis, where the skin associated S. aureus is the main pathogen. A po-
rous β-tricalciumphosphate biodegradable scaffold impregnated with genta-
mycin sulfate encapsulated into DPPC:Chol or a nano-hydroxyapatite/β-tri-
calciumphosphate scaffold impregnated with PC:SA:Chol liposomes contain-
ing ceftazidime showed increased anti-biofilm activity against S. aureus com-
pared to the free drug. Both formulations showed an initial burst release fol-
lowed by a slower, sustained release of the antibiotic. [32, 33] With a nano-
hydroxyapatite/chitosan/konjac glucomannan scaffold containing liposomal
(PC:SA:Chol) vancomycin, better inhibition of S. aureus biofilm growth was
observed compared to the scaffold containing the free drug or the scaffold
alone. This was attributed to sustained release of vancomycin from the lipo-
somes. [34]
On the other hand, liposomes can also be used for the prevention of colo-
nization and subsequent biofilm formation on a surface. For the prevention of
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orthopedic device related osteomyelitis, a biomineral-binding liposomal for-
mulation which could be loaded with different antibiotics was developed. To
achieve binding to hydroxyapatite, an alendronate-tri(ethyleneglycol)-choles-
terol conjugate was designed and used together with DSPC to form liposomes
for the encapsulation of oxacillin. The potential of these ’biomineral bind-
ing liposomes’ (BBL) to inhibit S. aureus biofilm growth on hydroxyapatite
discs pretreated with this formulation was investigated. The BBL showed
strong affinity and rapid binding to hydroxyapatite. This allows to quickly
load the liposomes onto the implant surface just before surgery. Furthermore,
a fast release of most of the oxacillin from the BBL during 6 hours was ob-
served, which can reduce the likelihood of surgery-related bacterial coloniza-
tion and subsequent chronic prosthetic joint infection. The BBL pretreated
discs showed almost complete biofilm inhibition. [35] Similarly, liposomes
that can adhere to the dental surface can prevent caries by sustained release
of antimicrobial agents. It was shown that cariogenic Streptococci can deposit
insoluble glucans on the dental enamel which provide support for bacterial
colonization. The encapsulation of nisin, which is able to inhibit the glu-
can synthesis by S. mutans, into liposomes composed of PC:PS prolonged the
period over which the glucan synthesis was inhibited due to controlled re-
lease from the liposomes. [36] It should be mentioned that micelles, which in
contrast to liposomes consist only of a single layer of amphiphilic molecules,
were proposed for the prevention of dental caries for the same reasons as lipo-
somes. Micelles of Pluronic 123-alendronate and Pluronic P85 containing the
hydrophobic antibacterial agent farnesol were formed. The alendronate moi-
ety has a high affinity for hydroxyapatite and caused the micelles to quickly
bind to the hydroxyapatite. The tested tooth binding micelles were capable
of preventing S. mutans biofilm formation on hydroxyapatite discs, even af-
ter extensive washing. [37] The prevention of catheter related infections on
the other hand can be achieved by embedding liposomal ciprofloxacin into
a gelatin-polyethylene glycol (PEG) hydrogel that can be applied to silicone
catheter material. Ciprofloxacin was released from this system for seven days.
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When challenging the system with P. aeruginosa, adhesion of the bacteria was
completely inhibited. [38]
In vivo studies
A few studies made the transition from in vitro to in vivo evaluation and used
a rat model for chronic pulmonary infections with P. aeruginosa to compare
classical treatment with the liposomal formulation. [10, 30, 39] Meers et al
encapsulated amikacin into DPPC:Chol liposomes. In an in vivo model for
chronic lung infections, rats infected with P. aeruginosa were treated using
nebulized liposomal or free amikacin. [30] The free amikacin was relatively
ineffective while the liposomal amikacin was able to reduce the amount of
colony forming units by two orders of magnitude. The liposomal formulation
was found to maintain higher antibiotic levels in the lungs over longer peri-
ods of time than the free antibiotic, explaining the improved efficacy. In one
study however, the liposomal formulation of antibiotics did not achieve the
desired effect. [39] The activity of tobramycin encapsulated in DPPC:DMPG
liposomes was evaluated in vivo against B. cepacia. Encapsulation in liposomes
lead to slower clearance of tobramycin from the lungs, increasing the level of
exposure of the bacteria to the drug. Twelve hours after intratracheal adminis-
tration of the free or liposomal drug, a significant difference could be noted in
the amount of colony forming units cultured from the lungs of the rats while
this was not the case in the first 12 h. This proves the beneficial effect of a
prolonged exposure. Although encapsulation into liposomes improved the
efficacy of the treatment, a higher antimicrobial effect than currently observed
was expected for the liposomes since the amount of tobramycin detected in
the lungs was much higher for the liposomal formulation compared to the
free tobramycin. The authors attribute this to the difference in localization
of the liposomes and the infection site in the lungs. The liposomes are likely
sequestered in more lipophilic environments of the lungs while the bacteria
are more likely to reside in the interstitial fluids. Thus, the total amount of
antibiotic recovered from the lungs in the experiment is not necessarily repre-
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sentative for the amount at the infection site.
In vivo tests with liposomes were also conducted in the context of preven-
tion and treatment of osteomyelitis. The treatment of osteomyelitis with li-
posomal (DPPC:SA:Chol) gentamycin impregnated calcium sulfate in a rab-
bit model yielded promising results over treatment with gentamycin impreg-
nated calcium sulfate or liposomal gentamycin alone. When using the lipo-
somal formulation, gentamycin was released for at least 12 days with a burst
release directly after implantation. Complete sterilization of the bones was
only observed in cultures taken from animals treated with the liposomal gen-
tamycin impregnated calcium sulfate. [40]
A number of companies are developing liposomal formulations for the
treatment of biofilm infections which are currently being evaluated in clinical
trials. For the treatment of Candida albicans, a pathogen that is able to form fun-
gal biofilms and cause infections in immunocompromised patients, several li-
posomal formulations, AmBisome® (Astellas, Northbrook, IL, USA), Abelcet®
(Sigma-Tau PharmaSource, Inc., Indianapolis, IN, USA) and Amphotec® (Ben
Venue Laboratories, Inc., Bedford, OH, USA), are already on the market. There
are currently no liposomal formulations on the market for the treatment of
bacterial biofilm infections. Arikace®, which is based on the above mentioned
publication by Meers et al., is to the best of our knowledge the only nanofor-
mulation for the treatment of bacterial biofilm infections that is currently in
phase III clinical trials. The results of the phase II clinical trial have been pub-
lished and showed a durable improvement in lung function and a reduced
P. aeruginosa sputum count. [41] Furthermore, Arikace® is also being inves-
tigated as a treatment for nontuberculous mycobacterial lung disease (phase
II clinical trial) and for non-CF bronchiectasis patients with P. aeruginosa lung
infections (phase II clinical trial), which both likely involve biofilm formation.
No clinical data are available at this moment. Pulmaquin™ and Lipoquin™
(Aradigm, Hayward, CA, USA) are liposomal formulations of ciprofloxacin
and have both been tested in a phase IIb clinical trial for non-CF bronchiec-
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tasis involving chronic P. aeruginosa infections. The two formulations differ
in release kinetics, with Pulmaquin™ showing the slowest release. Lipoquin™
was also evaluated for the treatment of pulmonary infections in cystic fibro-
sis patients in a phase IIa clinical trial. [42] Fluidosomes™-tobramycin (Ax-
entis Pharma, Zurich, Switzerland) is another liposomal formulation for the
treatment of bacterial lung infections in CF patients. In this case, Burkholde-
ria cepacia bacteria are the prime target. However, no information on the
progress regarding Fluidosomes™-tobramycin in clinical trials is available at
the moment. MiKasome (NeXstar Pharmaceuticals, Inc., Boulder, COL, USA),
is a liposomal amikacin formulation for complicated urinary tract infections,
whose development was stopped after a phase II clinical trial.
Absence of increased anti-biofilm effect
Not in all studies an increased anti-biofilm effect was observed for liposome
encapsulated antimicrobial agents. No increased anti-biofilm effect was ob-
served for tobramycin encapsulated into neutral DPPC:Chol or into anionic
DOPC:DPPG liposomes in 5 different B. cepacia complex strains. For the an-
ionic liposomes, electrostatic repulsion could limit fusion events. Fusion of
the neutral liposomes with the bacteria could be hampered by a layer of ma-
trix polymers in close proximity to the bacteria. The relatively large size of
the neutral liposomes, i.e. 430 nm, could also limit their penetration into the
biofilm, limiting the available amount of antibiotic in the denser parts of the
biofilm. [43] When comparing the activity of two types of cationic liposomes,
DOTAP:DOPE:PC or DOTAP:Chol:PC, loaded with either meropenem, gen-
tamycin or ciprofloxacin on nine different ATCC strains of P. aeruginosa, Kleb-
siella pneumoniae and E. coli, variable results were obtained when comparing
the MIC values of the liposomal and free form of the drugs. [44] Most of
the tested strains were more sensitive towards both liposomal formulations
of ciprofloxacin while a lower number of strains were more sensitive to li-
posomal meropenem and almost no strains were more sensitive to liposomal
gentamicin. For ciprofloxacin and gentamycin, the electrostatic interaction
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between the liposomes and the bacteria can increase the amount of antibiotic
transported through the outer membrane. The slight amphiphilic character
of meropenem causes it to pass the inner membrane easily while gentamycin
can pass the inner membrane by means of hydrophobicity. [45] The increased
intracellular concentration of the drug leads to higher antibacterial efficacy of
the liposomal formulation. For gentamycin, ionic binding to the outer mem-
brane of the bacteria is important for its antimicrobial activity. [46] When en-
capsulated into liposomes, this binding of the drug to the outer membrane is
hampered, explaining the lack of efficacy of liposomal gentamycin towards all
the tested strains. [44] The physicochemical properties of the antibiotics and
the location of their target in the bacterial cells can thus influence the antimi-
crobial activity of the liposomal formulation.
In addition to its detrimental effect on the free antibiotic, the environment
in which the biofilm is residing can also influence the antimicrobial efficacy
of liposomal antimicrobial agents. For example, when treating pulmonary
infections in cystic fibrosis patients, mucin, DNA and F-actin present in the
lung mucus and alginate produced by mucoid P. aeruginosa strains might pre-
vent liposome-bacteria interactions. In this case, no advantage of the liposo-
mal (DMPC:Chol) tobramycin, gentamycin and amikacin formulations over
the free drug was observed. This can be attributed to the increase in vis-
coelasticity which limits the diffusion of the liposomes or a stabilization of
the liposomes by the mucus which reduces the release of the antibiotic from
the liposomes. [23] Alternatively, the liposomes might bind to alginate, pre-
venting the nanocarrier to bind to the bacteria themselves or destabilizing the
liposomes leading to premature release and subsequent inactivation of the
antibiotic. [47] Although the addition of DNase and alginate lyase improved
the activity of the free and liposomal antibiotics, no superiority of the liposo-
mal formulation was observed. Likely, alginate-derived oligosaccharides still
prevents the interaction of the liposomes with the bacterial membrane or still
causes a destabilization of the liposomes. Nonetheless, this approach presents
a viable way of enhancing the antimicrobial activity and can possibly be im-
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proved and extended to other biofilms.
Encapsulation efficiency
In order to deliver a sufficiently high dose of antimicrobial agents to the bio-
film, a high encapsulation efficiency of the antimicrobial agent in the nanocar-
rier is required. In the case of liposomes, some options to improve the en-
capsulation efficiency are available. The options include active drug loading,
reverse phase evaporation and dehydration-rehydration (freeze-drying). We
refer the reader to a recent review where this was described in detail. [48]
Of note is an optimized encapsulation method by Mugabe et al. which made
use of freeze-drying of the liposomes in the presence of sucrose to improve the
loading of aminoglycoside and macrolide antibiotics in DPPC:Chol liposomes.
[49] These two classes of antibiotics are known for their low encapsulation ef-
ficiency into liposomes. By using this optimized method, the encapsulation
efficiency is now high enough to use them for liposomal drug delivery. This
optimized protocol was used to prepare the liposomes in several studies dis-
cussed in this section. [15, 16, 23, 47]
2.3.2 Polymer and lipid-polymer hybrid nanoparticles
In contrast to the various beneficial traits described above, the use of lipo-
somes can also have several disadvantages. The lipids show chemical instabil-
ity such as hydrolysis of the ester bond and oxidation and peroxidation of the
acyl chains. The composition of the lipids and the storage temperature play
an important role in this. Furthermore, physical instability can lead to drug
leakage during storage, which is especially problematic for liposomes with a
low phase transition temperature, such as the fusogenic liposomes discussed
in the previous section. Due to these limitations, polymer nanoparticles might
constitute a valuable alternative. The polymeric particles already described
in literature are typically formed from poly(lactic-co-glycolic) acid (PLGA) or
chitosan or a mixture of PLGA and lipids to form so called lipid-polymer hy-
brid nanoparticles (LPH) . [50, 51] PLGA is a biocompatible and biodegradable
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copolymer of lactic and glycolic acid and is FDA approved in various drug
delivery systems. [52] Chitosan is a cationic, non-toxic, linear polysaccharide
biopolymer and is obtained via deacetylation of chitin, the structural compo-
nent of the exoskeleton of crustaceans. [53] Similar to the liposomes, these
nanoparticles are biocompatible and biodegradable but less prone to chemical
and physical instability. [48]
Controlled release
Polymer nanoparticles can be tailored to control the rate and duration of drug
delivery. This can be useful to maintain high levels of antimicrobial agents
inside biofilms, improving the anti-biofilm effect of the formulation. Gen-
tamicin loaded PLGA nanoparticles were developed for the treatment of P.
aeruginosa infections. The formulation and the free drug were tested against
biofilms in vitro as well as in a peritoneal murine infection model. The PLGA
particles provided a sustained release of gentamycin, translating into a signif-
icantly enhanced anti-biofilm effect compared to the free drug. In the in vivo
model, the free and PLGA encapsulated gentamicin were equally potent in
clearing the infection but 96 h after administering the formulations, the anti-
biofilm effect of the free gentamicin was significantly reduced while biofilm
formation was still largely inhibited by the nanoformulation. Control experi-
ments showed that empty PLGA nanoparticles exhibited no antimicrobial ef-
fect against planktonic P. aeruginosa cells. [54] Cheow et al. compared the
activity of a polymer and a LPH nanoformulation encapsulating levofloxacin
against P. aeruginosa biofilms. [55] The polymer nanoparticles consisted of
PLGA while the LPH nanoformulation consisted of a PLGA core covered
with a lipid coat of phosphatidylcholine (PC) (Figure 2.2). Poly-(vinyl alco-
hol) (PVA) was added as a drying adjuvant to preserve the structural integrity
of the particles during spray drying and to ensure good aerosolization char-
acteristics of the nanoparticles.
The LPH particles loaded with levofloxacin had a higher anti-biofilm effi-
cacy compared to the polymer particles after 24 h of antibiotic exposure. While
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Figure 2.2: Schematic representation of polymer and lipid-polymer hybrid nanoparti-
cles. Reprinted with permission from [55]
the lipid coating of the LPH particles did not result in a higher affinity of these
particles for the biofilm, it did slow down the release rate of the antibiotic from
the particles. However, in a dose-kill experiment no significant impact of the
level of antibiotic exposure on biofilm eradication was observed. This indi-
cates that the release rate is not the cause for the observed superiority of the
LPH nanoformulation. The difference is thought to originate from a better
penetration into the biofilm matrix.
Formulations of ciprofloxacin and levofloxacin encapsulated either into
PLGA or in poly(caprolactone) (PCL) nanoparticles were evaluated in E. coli
biofilms. [56] The antibiotics showed a higher encapsulation efficiency in
PLGA, especially for the highly water soluble levofloxacin. Additionally, the
PLGA particles showed a faster biphasic release profile compared to the PCL
particles. This is important since the release profile can influence the anti-
biofilm efficacy of a formulation. A fast burst release followed by a sustained
release of the antibiotic is typically preferred. This is needed to prevent the
increase in antibiotic tolerance of the surviving biofilm cells. [57] In a time-kill
biofilm susceptibility test which was conducted over 5 days, in vivo condi-
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tions of drug removal were simulated by diluting the solution twofold every
24 h. This test takes into account the effect of biofilm age and could reveal
if the susceptibility of the biofilm is changed during a prolonged antibiotic
exposure. The results showed that in the case of levofloxacin PLGA parti-
cles, resistant bacteria can survive the initial antibiotic treatment and will re-
grow the biofilm, even in the presence of levofloxacin above the MBIC. For the
ciprofloxacin PLGA particles on the other hand, the growth of the surviving
biofilm cells was inhibited over most of the 5 day period of the test, even for
concentrations of ciprofloxacin as low as 1/16 of the MBIC. It was therefore
concluded that PLGA encapsulated ciprofloxacin is more promising for the
treatment of E. coli biofilms.
Antimicrobial polymers
Chitosan is another polymer that is used in drug delivery nanocarriers for
anti-biofilm therapy. Chitosan itself has antimicrobial activity by adsorption
onto the bacteria, causing aggregation and leakage of their intracellular con-
tent. Other mechanisms could be alteration of the cell permeability, binding
with the bacterial DNA or chelation of trace metals which interferes with the
production of virulence factors and bacterial growth. [58] The antimicrobial
activity of chitosan was demonstrated against clinical isolates of B. cepacia
complex. [53] The antimicrobial activity of chitosan nanoparticles was eval-
uated against S. mutans biofilms. The nanoparticles were found to induce cell
membrane damage, likely via direct interaction of the chitosan with the bac-
terial cells due to electrostatic interaction. These particles exhibit thus non-
specific targeting to the biofilm cells. Cell membrane damage was more pro-
nounced for chitosan with a lower molecular weight (below 200 kDa) than for
higher molecular weight (above 500 kDa) chitosans (Figure 2.3). This is likely
due to reduced diffusion of high molecular weight chitosan particles through
the biofilm since for these particles no cell membrane damage was detected
deeper into the biofilm. [59]
It is also possible to load antibiotics in chitosan derived nanoparticles. An
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Figure 2.3: Antimicrobial action of chitosan nanoparticles on biofilms of S. mutans at
different depths inside the biofilm. Green represents living biofilm cells and red dead
cells. Group A and C are chitosans with a MW below 200 kDa and group B is a chitosan
with a MW above 500 kDa Reprinted with permission from [60].
example is the loading of vancomycin onto carboxymethyl chitosan (CMC)
modified with folic acid (FA) and 2,2’-(ethylenedioxy)bis(ethylamine) (EDBE)
by physical adsorption. [60] The presence of folic acid has proven to be essen-
tial for the antimicrobial activity of this vancomycin formulation. [61] The ac-
tivity of this vancomycin nanoconjugate was evaluated against eight vancom-
cin susceptible or resistant S. aureus strains. The nanoconjugated vancomycin
significantly decreased biofilm formation of all the tested strains, while the
free vancomycin only decreased the biofilm formation of the vancomycin sus-
ceptible strains. The nanoconjugated vancomycin decreased the minimal in-
hibitory and bactericidal concentrations for planktonic cultures, delayed the
onset of the stationary phase and reduced the production of virulence fac-
tors. The chitosan derived compound likely causes membrane depolarization
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which could lead to permeabilization of the outer membrane of the bacteria.
Encapsulation efficiency
Similar to liposomes, the encapsulation efficiency of antibiotics in polymeric
nanoparticles determines how much antimicrobial agent can be delivered to
the biofilm. In the case of PLGA nanoparticles, several methods for improving
the encapsulation efficiency have been described. The preparation of PLGA
nanoparticles involves a nanoemulsion of a water phase and a water immisci-
ble solvent such as dichloromethane into which PLGA is dissolved. PLGA
nanoparticles are formed by slow evaporation of the dichloromethane. A
twofold increase in the encapsulation of highly water soluble antibiotics such
as levofloxacin was obtained by either adding lecithin to the aqueous phase
or by increasing the water miscibility of the oil phase. Lecithin, which has
a phospholipid structure, adsorbs on the nanoparticle surface and is able to
entrap levofloxacin. Increased water-miscibility of the oil phase speeds up
the precipitation of the PLGA due to faster exposure to the aqueous phase,
encapsulating the antibiotic before it can leak out. [62] A second way to in-
crease the encapsulation efficiency in PLGA particles is the addition of helper
hydrophilic moiety. One example is the addition of alginate that can increase
the encapsulation efficiency of positively charged antibiotics by virtue of elec-
trostatic interactions. These alginate containing particles showed a moderate
cytotoxicity (20-30 % reduction of cell viability) on adenocarcinomic human
alveolar basal epithelial cells at a concentration of 0.5 mg/ml. The cytotoxic-
ity increased in a dose dependent manner. [63] A third possibility is changing
the pH at which the nanoparticles are formed. [54] For example, for the load-
ing of gentamycin into the hydrophobic PLGA, increasing the pH from 5 to 7.4
allows deprotonation of the amino groups, thus reducing the hydrophilicity
of gentamyin and enhancing its entrapment in the nanoparticles.
When using LPH nanoparticles, encapsulation of charged antibiotics can
cause the nanoparticle formation to fail. To be able to encapsulate sufficient
amounts of antibiotics, charge reversal of the lipid by adding counterionic
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surfactants has successfully been used. [64] Alternatively, one can complex
the antibiotic with polyelectrolytes. [65] This complexation is fast, efficient,
organic solvent free and does not require specialized equipment. Up to 80 %
of the antibiotics were found to be incorporated by using this complexation
technique.
2.4 Targeted delivery
Functionalizing drug delivery nanoparticles with targeting ligands could be
beneficial to achieve accumulation of the nanoparticles close to the bacterial
cells and to promote close contact of the nanocarrier with the bacteria. Tar-
geting can also be beneficial in environments with high shear forces, such as
the oral cavity, where only short exposure times can be achieved (e.g. mouth-
wash). A distinction can be made between specific and non-specific targeting.
Non-specific targeting mainly relies on charge based interactions and hydro-
gen bonding of the nanocarrier with the biofilm. Specific targeting is based on
targeting ligands that selectively bind to a target molecule inside the biofilm.
While biofilm targeting strategies have extensively been developed for liposo-
mal drug delivery systems, to the best of our knowledge no studies regarding
the specific targeting of polymer or lipid-polymer hybrid nanoparticles have
been published to date.
2.4.1 Non-specific targeting
Jones and coworkers established that phosphatidylinositol (PI) and to a lesser
extent DPPG caused the adsorption of liposomes to biofilms formed by bac-
teria recovered from the skin and the oral cavity. [66] It was found that the
mole% of incorporated PI to obtain optimal interaction depends on the bac-
terial strain. [66, 67] They postulated that the hydroxyl content of the inosi-
tol and glycerol head groups of the lipids plays an important role, likely by
the formation of hydrogen bounds with teichoic acids in the glycocalix of the
bacteria. [68] Growth inhibition of S. epidermidis biofilms due to application
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of triclosan-containing DPPC:PI, DPPG:PI or DPPC liposomes was evaluated
and linked to the drug to lipid molar ratio’s. [66] All the liposomes tested
showed a certain degree of inhibition of the bacterial growth, but only for low
drug to lipid ratios an advantage of liposomal delivery was seen. The target-
ing to the biofilm was less pronounced for high drug/lipid ratios, which could
explain these results.
PI was also used for the passive targeting of so called ’reactive liposomes’,
i.e. liposomes containing enzymes that produce antibacterial substances in
the presence of the right substrates. This strategy was evaluated for the treat-
ment of S. gordonii biofilms. [67, 69] Glucose oxidase (GO) was incorporated
into DPPC:PI liposomes, as well as GO combined with horse radish perox-
idase (HRP) , GO combined with chloroperoxidase (CPO) or GO combined
with lactoperoxidase (LPO). The liposomes strongly adsorbed on the S. gor-
donii biofilms due to the presence of PI in the liposomes. Since the liposomes
presumably remain intact, the antimicrobial action is caused by the formation
of bactericidal substances such as hydrogen peroxide and oxyacids. These
formed bactericidal substances diffuse out of the liposome and can act di-
rectly on the biofilm bacteria due to the close contact of the liposomes and
the bacteria. This resulted in up to 50% inhibition of bacterial growth.
Stearylamine (SA) is another compound that can be used for the targeting
of biofilm bacteria. In this case, the interaction is mainly based on the opposite
surface charge of the SA containing liposomes and the bacterial membrane or
negatively charged biofilm matrix compounds. Binding to matrix compounds
might actually be disadvantageous since particles captured on matrix poly-
mers cannot interact directly with the bacterial surface anymore. However,
they can still serve as a depot for the release of antimicrobial agents in the di-
rect vicinity of the biofilm. The amount of liposomes deposited in the biofilm
was found to depend on the ionic strength of the surrounding medium, the
temperature and the hydrophobicity of the bacteria. [70, 71] More liposomes
are adsorbed at lower ionic strength, at higher temperatures and when the
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bacteria are more hydrophobic. It should be noted that although less lipo-
somes adhere at lower temperatures, the liposomes adsorb more strongly,
which is consistent with an electrostatic interaction. The SA content of the
liposomes was observed to influence the adsorption profile of the liposomes.
At a high concentration, SA is able to leak from the liposomes and binds to the
bacteria, reducing the adsorption of the liposomes by reducing the number of
binding sites available for the liposomes. [72]
In another report, the targeting capabilities of anionic PI bearing liposomes
to S. epidermidis was compared to those of cationic SA bearing liposomes.
[73] The SA bearing liposomes had a greater affinity to S. epidermidis biofilms
than their PI bearing counterparts. Likely, the ionic interactions between the
cationic liposomes and the anionic bacteria occur more efficiently compared
to the hydrogen bonding interactions between the oligosaccharides in the gly-
cocalyx of the bacteria and the anionic PI.
Cytotoxicity was reported for SA, likely limiting the use of this compound
in vivo. [74, 75] As a less toxic alternative to SA, the cationic compounds
dimethyldioctadecylammonium bromide (DDAB) or 3β-(N(N1N1-dimethyl-
aminoethane) carbamoyl) cholesterol (DC-chol) can also target several skin
and oral bacteria via electrostatic interactions. [70, 72, 76, 77] DC-chol contain-
ing liposomes showed the most effective targeting towards S. epidermidiswhile
DDAB was the least effective targeting agent. The difference in targeting effi-
ciency could be caused by the cationic nitrogen in the head group of DC-chol,
which protrudes more from the liposome surface. [76] DPPC:Chol:DC-chol
liposomes delivering penicillin G to S. aureus biofilms were found to be more
effective than the free drug when the overall drug concentration was lower
and the exposure time shorter. A possible explanation is the complexation
of penicillin G with the charged DC-chol of the liposome. At low penicillin
G concentrations, the equilibrium between the free and complexed form of
penicillin G is shifted towards the free form while at high penicillin G con-
centrations, the release of penicillin G is retarded. Over time, more and more
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liposomes adsorb onto the biofilm, increasing the penicillin G concentration
in the biofilm and slowing penicillin G release from the liposomes. [78] Thus
the interaction of the antimicrobial agent and the lipids can have an influence
on the antimicrobial efficacy of the liposomal formulation.
Even though the DDAB bearing liposomes showed less effective targeting,
approximately 60% of an S. aureus biofilm surface could still be covered by
these liposomes. [72] Therefore, these liposomes could still increase the an-
timicrobial efficacy. DDAB bearing liposomes containing vancomycin were
found to inhibit S. aureus growth more than free vancomycin for short (less
than 30 minutes) incubation times. When using longer incubation times, the
liposomes lose their advantage over free vancomycin, likely by disruption of
the liposomes, which lowers the concentration of the antibiotic in close prox-
imity to the biofilm cells. [72]
2.4.2 Specific targeting
Another targeting possibility is the use of immunoliposomes which carry co-
valently bound antibodies on the outer surface. These have the advantage of
increased specificity and affinity compared to the aforementioned targeting
strategies. The increased antibacterial action of immunoliposomes compared
to the free antimicrobial agent is, like for other targeting compounds, the re-
sult of the retention of the immunoliposomes in the biofilm, which facilitates
release of the antimicrobial agent in close proximity of the bacteria over longer
periods of time.
The activity and affinity of immunoliposomes composed of DPPC, PI and
the anti-S. oralis antibody conjugate of DPPE were tested against S. oralis bio-
films in vitro. [79, 80] S. oralis is a commensal of the oral cavity and is able
to cause opportunistic infections. In immunocompromised patients and pa-
tients with hematological malignancy, S. oralis can cause bacterial endocardi-
tis, adult respiratory distress syndrome and shock. The immunoliposomes
strongly adsorbed to S. oralis biofilms and showed decreased affinity to other
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oral commensal bacteria tested (S. gordonii, S. sanguis C104 and S. salivarius
DBD and 8618), indicating that targeting of an antimicrobial agent to a specific
organism can be achieved. The targeting was found to be independent of the
charge of the lipids when comparing negatively charged DPPC:PI:DPPE-anti
S. oralis immunoliposomes, positively charged DPPC:Chol:SA: DPPE-anti S.
oralis and neutral DPPC:DPPE-anti S. oralis immunoliposomes. Likely, the an-
tibodies mask the surface charge of the liposomes. [80] When comparing the
antimicrobial effect of free and immunoliposome encapsulated chlorhexidine
it was found that at low concentrations of chlorhexidine, the immunolipo-
somes were more effective in inhibiting growth of an S. oralis biofilm than the
free drug. However, increased antimicrobial activity at low antimicrobial con-
centration was less apparent for immunoliposomes containing triclosan likely
due to a difference in release profile of the lipophilic triclosan versus the hy-
drophilic chlorhexidine. [79] When comparing the affinity of DPPC:PI:DPPE-
anti S. oralis immunoliposomes and liposomes of the same composition but
without the antibody, the non-targeted liposomes showed up to five times less
affinity to the S. oralis biofilms. [80] Furthermore, the affinity of the DPPC:PI-
:DPPE-anti S. oralis immunoliposomes was compared to that of the cationic
DPPC:Chol:SA liposomes and the anionic DPPC:PI liposomes. The cationic
liposomes adsorbed best onto the biofilm, followed by the PI bearing lipo-
somes. The immunoliposomes showed the lowest affinity. This can be ex-
plained by the fact that immunoliposomes only bind to specific antigens while
the SA and PI bearing liposomes can adsorb electrostatically or via hydrogen
bonding to many components in the biofilm. [73, 80]
As an alternative for antibodies, lectins can be used for the targeting of li-
posomes. One example is concanavalin A (Con-A) , which selectively binds
to α-mannopyranosyl and α-glucopyranosyl residues that can be found in
the extracellular polysaccharide matrix of many biofilms. [81–83] This ap-
proach can again be used to target bacteria in the oral cavity, such as S. mu-
tans, which is a significant contributor to dental caries. Increased binding
of the targeted liposomes to S. gordonii or S. mutans biofilms was observed
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when comparing liposomes with and without Con-A. This Con-A mediated
enhanced binding depends on the phospholipid composition of the liposomes
and the surface density of Con-A. For example, the targeting to S. mutans by
Con-A modified DPPC:PI:DPPE liposomes was less effective for increasing
amounts of PI. [84, 85] When treating S. gordonii with triclosan, it was ob-
served that Con-A modified liposomes carrying triclosan had an increased
anti-biofilm efficacy compared to the free drug for short exposure times of the
biofilm. [85] In a follow-up study, the anti-biofilm efficacy of Con-A modified
PC:Chol:SA liposomes containing metronidazole was tested against S. mutans
biofilms. Metronidazole encapsulated in untargeted liposomes led to a more
pronounced growth inhibition than the free drug, likely due to protection of
the drug from β-lactamases produced by the bacteria and/or by fusion of the
liposomes with the bacteria. The use of lectin functionalized liposomes led to
an increased biofilm growth inhibition compared to the use of the same lipo-
somes without Con-A. [84] However, not all biofilm forming organisms are as
effectively targeted with Con-A. Examples of organisms for which this target-
ing was less effective are S. epidermidis and P. vulgaris. [86, 87] This is likely
due to the absence of the binding site for Con-A.
Another lectin often used as a targeting ligand is wheat germ agglutinin
(WGA) that binds to N-acetylglucosamine and N-acetylneuraminic acid resi-
dues present in the extracellular matrix of many biofilms. [83, 88] Like for
Con-A, not all organisms are as effectively targeted by WGA, with P. vulgaris
again showing little liposome binding. [86, 87] Targeting of liposomes with
WGA was successfully combined with photodynamic therapy. [89] The lat-
ter involves the use of a photosensitizer that produces reactive oxygen species
(ROS) upon exposure to light. ROS are cytotoxic since these are able to oxidize
proteins, nucleic acids and lipids. It was found that WGA modified DPPC-
:DOTAP:DSPE-PEG2000 liposomes were able to deliver more sensitizer to the
bacterial cells compared to non-targeted liposomes. This resulted in the com-
plete eradication of methicillin resistant S. aureus and an increased antimicro-
bial effect on P. aeruginosa bacteria in suspension.
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2.5 Triggered release inside biofilms
Triggered release of the antibiotic from nanoformulations in close proximity
to the biofilm bacteria is another approach to increase the local concentration
of antibiotics in the biofilm. Generally speaking, the trigger can come from an
external physical stimulus (e.g. electro-magnetic radiation, heat, ultrasound),
or from the local biochemical environment (e.g. enzymes, virulence factors or
pH changes). [90]
The only reported trigger in the context of biofilm treatment is the pres-
ence of rhamnolipids in P. aeruginosa biofilms (and CF sputum) that, due to
their surfactant-like properties, could trigger the release of amikacin from
DPPC:Chol liposomes. [30] As the rhamnolipid concentration will be higher
in close proximity of the biofilm, liposomes will release their content prefer-
entially at the site of infection. A formulation of DPPC:Chol liposomes en-
capsulating amikacin for the treatment of pulmonary P. aeruginosa biofilms is
currently being evaluated in phase 3 clinical trials.
The same concept was also evaluated for lipid-polymer hybrid nanopar-
ticles composed of a PLGA core and PC coating. It was shown that rham-
nolipids could trigger release from these formulations, but only for certain
classes of encapsulated molecules. Levofloxacin and ofloxacin already show-
ed a rapid release from the LPH particles in the absence of rhamnolipids. This
was attributed to the fact that both drugs are able to pass lipid membranes.
LPH particles loaded with calcein, a water soluble dye with a low permeabil-
ity through lipid membranes, showed no significant release of calcein in the
absence of rhamnolipids. Upon addition of rhamnolipids, a fast release of all
the calcein could be observed. [91]
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2.6 Studying the interaction and transport of nano-
particles in biofilms
Apart from testing a nanoformulation’s anti-biofilm efficacy, it is important
to obtain detailed information on how these nanoparticles interact with and
behave inside biofilms in order to rationally develop improved nanomaterials.
This section presents an overview on the measurement and visualization of
the nanoparticle transport inside biofilms and the interaction of nanoparticles
with biofilm components.
The ability of nanoparticles to penetrate into the biofilm is a first aspect that
needs to be investigated. The nanoparticles likely penetrate into the biofilm by
means of diffusion. In studies using fluorescent dyes, diffusion was found to
be the main mode of transport inside biofilm clusters. [92–96] Two important
parameters in this respect are the particle size and the surface characteristics
of the nanoparticles. Good penetration into biofilms is essential to deliver
the antimicrobial agent to all bacterial cells inside the biofilm. As highlighted
above, the nanoparticles will often interact with the biofilm, either with the
bacteria or with the biofilm matrix. On the one hand this is a disadvantage
as it may hamper the distribution of particles throughout the entire biofilm.
On the other hand it can be advantageous since the particles will accumulate
in the biofilm and form a depot for sustained drug release. In addition, if
lipid-based nanoparticles bind to bacteria, fusion with the bacterial wall may
be induced, allowing antibiotic delivery directly into the cytoplasm (see 2.3.1).
[19, 97] A classic way to determine the amount of liposomes adsorbed to the
biofilm is to calculate the percentage apparent monolayer coverage (%amc) .
This is done by radioactive labeling of the liposomes and scintillation count-
ing of a biofilm which is exposed to the liposomes and rinsed to remove non
adhered liposomes. The %amc is calculated as the ratio of moles of lipid ad-
sorbed to the biofilm to the theoretical number of moles of lipid that would be
adsorbed if the biofilm was covered with a close-packed monolayer of lipo-
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somes. [66] While the %amc allows quantitative comparison between exper-
iments, it should be noted that this method is unable to distinguish between
liposomes adsorbed to the bacteria and the biofilm matrix. Microscopy exper-
iments can provide complementary information in that sense.
To observe in detail the interaction of liposomes with bacterial cells, trans-
mission electron microscopy (TEM) is often used since it allows the observa-
tion of subcellular features such as the bacterial membrane. Malcolm Jones
and coworkers have extensively investigated the adsorption of liposomes on
bacterial biofilms using TEM to visualize the binding of targeted liposomes to
S. epidermidis or S. oralis biofilms. [73] They studied the interaction of phos-
photungstenic acid labeled DPPC:PI liposomes or DPPC:Chol:SA liposomes
with S. epidermidis biofilms. Phosphatidylinositol and stearylamine are known
targeting ligands for several oral and skin associated bacteria (see also 2.4.1).
[66, 70, 86, 87] It was observed with TEM that both types of liposomes clus-
ter around the bacteria in a similar way. [73] They also studied the binding
of anti-S. oralis immunoliposomes and found that the immunoliposomes were
located on the surface of the bacterial cells with a preference for the septal
region between dividing cells. [73]
Later, Jones and coworkers established a protocol to investigate the ad-
sorption of fluorescent liposomes to immobilized biofilms using confocal mi-
croscopy. [98] Confocal microscopy has the advantage over TEM that it of-
fers the possibility of observing living, fully hydrated biofilms, while requir-
ing less extensive sample preparation. However, confocal microscopy has a
substantially lower resolution than TEM and does not allow to resolve the
liposome-biofilm interface in great detail. TEM and confocal microscopy can
thus be considered as complementary techniques. Jones et al. added anionic,
cationic and PEG modified cationic liposomes to an S. aureus biofilm grown
in culture chambers suited for optical microscopy. Confocal imaging revealed
that cationic liposomes were not able to penetrate into the biofilm, but rather
accumulated on the surface of the biofilm in a 20 µm thick layer. The an-
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ionic liposomes on the other hand did neither penetrate in nor adsorb to the
biofilm, which was attributed to repulsion by the negative surface charge of
the bacteria. [99] The pegylated cationic liposomes showed reduced adsorp-
tion onto the biofilm. This is expected since pegylation reduces non-specific
interactions of the liposomes with biological materials. [100] In a follow up
study, the influence of the liposomal zeta potential on the strength of their ad-
sorption on an S. aureus biofilm was investigated using confocal microscopy.
[99] Fluorescently labeled cationic liposomes of similar size but with a zeta
potential ranging from 1 to 41 mV were added to an S. aureus biofilm in a flow
cell. The critical shear stress required to completely remove the adsorbed lipo-
somes from the biofilm increased slightly but not significantly with increasing
zeta potential.
Meers et al. studied the penetration of liposomes in bacterial clusters of
P. aeruginosa biofilms using confocal microscopy. [30] Neutral, fluorescent
DPPC:Chol liposomes of about 0.3 µm in diameter were synthesized and ad-
ded to a the biofilm in a flow cell together with 1 µm fluorescent polystyrene
beads. The liposomes seemed to accumulate in the periphery of the cluster
while in the center, the concentration appeared to be the same as in the fluid
surrounding the biofilm. The 1 µm polystyrene particles on the other hand did
not significantly penetrate into the bacterial cluster. It was observed before
that the size of solutes and nanoparticles influences their diffusion coefficient
and penetration into biofilms. [101]
Confocal microscopy was also the method of choice of Miller et al. to inves-
tigate the deposition of pegylated L-tyrosine polyphosphate (LTP) microparti-
cles onto P. aeruginosa biofilms in a flow cell. [102] Z-stacks were recorded after
infusion of the fluorescently labeled LTP nanoparticles with an average diam-
eter of 1.2 µm. The particles were mostly located at the fluid-biofilm interface
up to 2 hours after deposition. After 4 hours, the particles were distributed
more evenly throughout the biofilm. Due to their adherence to the biofilm,
the final concentration of LTP nanoparticles was estimated to be 2 orders of
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magnitude higher inside the biofilm as compared to the starting suspension.
More advanced fluorescence microscopy methods can be used to measure
diffusion coefficients in different locations of a biofilm. One of these tech-
niques is fluorescence correlation spectroscopy (FCS) . By measuring fluores-
cence fluctuations caused by fluorescent particles or molecules diffusing in
and out the focused laser beam of a confocal microscope, their local diffusion
coefficient can be calculated. [103] This technique was applied to measure the
diffusion of fluorescent polymer nanoparticles (57, 92 and 135 nm in diameter)
in P. fluorescens biofilms. [104] By varying the growth conditions of the bac-
teria, either biofilms consisting of dense clusters or loose biofilm flocks were
grown. The particles showed little penetration in dense biofilms while in loose
biofilms, a steep decrease in the diffusion coefficient was observed for larger
nanoparticles. Comparison with the diffusion of differently sized fluorescent
molecules revealed an estimated pore size of 50 nm for a loose biofilm while
this decreased below 10 nm for a dense biofilm. In another study, FCS re-
vealed that the hydrophobicity of Lactococcus lactis cells affected the diffusion
of 50 nm anionic carboxylate modified polystyrene nanoparticles through the
biofilm matrix. [105] The more hydrophobic the surface of the cells, the lower
the fraction of freely diffusing nanoparticles.
Single particle tracking (SPT) microscopy is another method to measure
the diffusion coefficient of nanoparticles inside biofilms. In SPT, a time-lapse
video of the movement of the nanoparticles inside the biofilm is recorded from
which the motion trajectories of individual particles are calculated using im-
age processing. From the trajectories, the diffusion coefficient and mode of
motion (free diffusion, anomalous diffusion or directed motion) can be de-
rived on a particle by particle basis. [106] SPT was applied to study the diffu-
sion of polystyrene nanoparticles with different surface modifications in liv-
ing, hydrated Burkholderia multivorans and P. aeruginosa biofilms. [107] These
two pathogens are able to cause chronic pulmonary infections in CF patients.
Although B. multivorans infections occur less frequent, the increased virulence
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compared to P. aeruginosa causes the lung function to decline more rapidly.
Both anionic and cationic beads were largely immobilized to biofilm com-
ponents, reducing their average diffusion coefficient considerably. Pegylated
beads on the other hand were nearly as mobile as in water (Figure 2.4). Confo-
cal images showed that positively charged nanoparticles attached to wire-like
compounds of the biofilm matrix, likely biofilm matrix polymers and extra-
cellular DNA (eDNA) . Unexpectedly, the negatively charged particles were
observed to bind in close proximity to the bacteria (Figure 2.5). Also other in-
teractions such as hydrophobic interactions between the polystyrene and the
bacteria were likely involved in overcoming the electrostatic repulsion with
the negatively charged cell membrane.
Figure 2.4: Diffusion coefficients of the modified 0.1 µm polystyrene nanoparticles in B.
multivorans biofilms. The diffusion of the charged nanoparticles is considerably lower
compared to pegylated particles. [107]
In a follow up study, the transport of 0.2 µm positively and negatively
charged fluorescent polystyrene nanoparticles was evaluated in 5 different
B. cepacia complex strains in the presence or absence of DNase. In the ab-
sence of DNase, both anionic and cationic particles strongly interacted with
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Figure 2.5: (A) Anionic polystyrene nanoparticles (green) bind in close proximity of
B. multivorans bacteria (red). The arrows in the insert show bacteria surrounded by
particles. (B) Cationic polystyrene nanoparticles (green) attached as beads on a thread
to matrix polymers surrounding the bacteria (red). [107]
all the tested biofilms, resulting in diffusion coefficients up to 10 times lower
compared to water. However, when the biofilms were grown in the pres-
ence of DNase to break down eDNA, the diffusion coefficient of the positively
charged nanoparticles increased approximately twofold. [43]
2.7 General discussion and future outlook
Biofilm formation plays a major role in the persistence of bacterial infections as
cells in biofilms are able to evade host immune defenses and show increased
antibiotic resistance. Little success has been achieved in treating biofilm in-
fections with classical antibiotic therapy and innovative ways to deliver an-
timicrobial substances in a sufficiently high concentration to the biofilm bac-
teria are expected provide therapeutic benefit. The ability of liposomes and
polymer nanoparticles to deliver antimicrobial substances into biofilms has
been extensively studied in the past decade. As reviewed here, many re-
searchers have confirmed improved anti-biofilm activity of lipid and polymer-
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encapsulated antibiotics.
Mechanisms behind the increased activity of nanoparticle incorporated an-
tibiotics include fusion of liposomes with the bacterial cells, protection of the
antibiotic against degrading enzymes, prevention of inactivation by binding
to components surrounding the biofilm, increased transport of the nanofor-
mulation into the biofilm and increased contact time between the bacteria
and the antibiotic. For non-targeted nanoparticles, liposomes with fusogenic
properties are preferred since they are able to deliver the antimicrobial agent
through the outer membrane of the bacteria. In this way, high doses of an-
timicrobial agents can be delivered directly into the bacteria. An additional
advantage of fusogenic liposomes is their flexible membrane which in some
cases can aid in the transport of the liposomes to the infection site. Apart from
liposomes, also polymer and lipid-polymer hybrid nanoparticles have been
evaluated. Although positive results have been reported, a comparative study
of the antimicrobial activity of liposomes, polymer and lipid-polymer hybrid
nanoparticles is currently lacking. Several factors contribute to the overall an-
timicrobial efficacy of a nanoformulation, such as the release profile, the ability
of the nanocarrier to interact with the biofilm, the occurrence of fusion or re-
lease of the antimicrobial agent under influence of substances secreted by the
bacteria. All of these factors would need to be investigated to clarify why a
certain formulation fares better than the other. Having this information would
contribute to the development of even more efficient nanoformulations.
Targeting of the nanoparticles to the biofilm is an interesting approach to
achieve longer contact times and the delivery of the antibiotic in close prox-
imity of the bacterial cells. Adding PI and SA as non-specific targeting moi-
eties to liposomes resulted in an increased adhesion to biofilms as compared
to the use of immunoliposomes. If this actually improves anti-biofilm ther-
apy remains to be demonstrated. However, one can envisage that the use
of immunoliposomes is advantageous when a certain type of bacteria needs
to be targeted (e.g. dental caries or periodontal pocket disease) or when the
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biofilm resides in a complex biological medium (e.g. lungs of CF patients).
Clearly further studies are needed, both in vitro and in vivo, to fully assess the
potential of immunoliposomes. Lectin binding Con-A and WGA are interest-
ing alternative ligands to achieve nanoparticle targeting to biofilms. As they
are less expensive than antibodies, they could be attractive when targeting to
a specific bacterial species is not required, although not all biofilms contain
the target for Con-A and WGA. Comparative studies of the anti-biofilm effi-
cacy and the specificity of liposomes targeted using these lectins or antibodies
would be useful.
The addition of substances that modify the biofilm structure or the sur-
rounding medium could improve the anti-biofilm efficacy of nanoparticle de-
livered antimicrobial agents. For example, alginate lyase can degrade the ma-
trix of a mucoid P. aeruginosa biofilm or DNase can degrade extracellular DNA
in the biofilm matrix or in cystic fibrosis mucus. [47] Another biofilm structure
modifier is carvacrol, a component of essential oils which has a wide spectrum
of antimicrobial activity. Carvacrol encapsulated in PLGA nanocapsules sig-
nificantly influenced the elastic and viscous moduli of S. epidermidis biofilms
compared to free carvacrol as measured by a cone-plate rheometer, indicat-
ing fluidification of the biofilm matrix. [108] Possibly, this approach could
increase the penetration of antimicrobial agents into the deeper regions of the
biofilm where persisters are believed to reside.
It should be noted that not in all studies an improved efficiency of nanopar-
ticle encapsulated antibiotics was observed. It is important to find a balance
between protecting the encapsulated drug and being able to release the drug
near the bacteria. Triggered release of the antibiotic from the particles could
be a complementary strategy to overcome biofilm resistance in this respect. By
suddenly releasing high amounts of antibiotics in close proximity to the bac-
teria, the upregulation of resistance mechanisms may be prevented. Rham-
nolipids, a surfactant-like virulence factor of P. aeruginosa, have proven to be
an efficient endogenous trigger for release of antimicrobial agents from lipo-
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somes and lipid-polymer hybrid nanoparticles. Arikace®, a liposomal formu-
lation of amikacin which shows triggered release upon contact with rhamno-
lipids, is in final stages of clinical trials for treating P. aeruginosa infections in
cystic fibrosis. Other physical or chemical triggers could be explored in the
future, such as pH changes, enzymes present at the infection site, heat, elec-
tromagnetic radiation and ultrasound.
Although a lot of research is focused on the antimicrobial efficacy of drug
delivery nanocarriers, only few studies are looking into the transport and pen-
etration of nanoparticles inside biofilms. Advances in optical imaging tech-
niques allows to study the interactions of these nanoparticles with the biofilm
as well as their capability to penetrate into the biofilm. Confocal microscopy,
SPT and FCS all have proven to provide valuable information. Electron mi-
croscopy serves a complementary role as it can provide direct evidence for
fusion of liposomes with bacteria. By comparing different nanocarriers, the
properties that can lead to optimized drug delivery can be identified as well.
The present overview indicates that the use of nanoparticles for anti-bio-
film therapy is a viable approach. However, the majority of papers discussed
in this review are based on in vitro observations. Since the in vitro environment
is far less complex than the in vivo situation, future work needs to be directed
towards in vivo studies. In this context, it is important to mention that the in
vitro cytotoxicity of the nanoformulations is only rarely tested on eukaryotic
cells. Although many lipid and polymer nanoparticles are regarded as being
biocompatible, cytotoxicity towards eukaryotic cells can still occur and is a
factor that needs to be taken into account, preferably before in vivo studies are
undertaken. Also, information about the relative partitioning of the nanopar-
ticles between the biofilm bacteria and eukaryotic cells could be useful in this
respect. The information gathered from in vitro experiments now allows the
rational design of nanocarriers for in vivo treatment of biofilm infections. Spe-
cial attention will need to be paid to adapting the formulations to the chosen
delivery route while still retaining the characteristics necessarily for increased
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delivery of antibiotics to the biofilm. The complexity of the situation likely ex-
plains why so little companies are running clinical trials with nanomedicines
for the treatment of biofilm infections. In an era which is increasingly domi-
nated by resistant bacterial strains, it is paramount to make the transition from
in vitro to in vivo studies as fast as possible.
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Table 2.1: Lipid nanoparticles evaluated for drug delivery to biofilms.
Nanoparticle com-
position
Antimicrobial
agent
Size
(µm)
Charge Interaction
with the
bacterial
membrane?
Triggered
release?
Improved an-
timicrobial
effect?
Mechanism of ac-
tion
Biofilm Reference
DPPC:DMPG Tobramycin 0.4 Anionic Yes ND Yes Fusion with bacte-
rial membrane
P. aeruginosa,
S. maltophilia,
B. cepacia, E.
coli, S.aureus
[11–13]
DPPC:Chol Amikacin, Genta-
mycin or Tobra-
mycin
0.2 Neutral Yes ND Yes, complete
eradication
Fusion with bacte-
rial membrane
P. aeruginosa [16]
DSPC:Chol Amikacin, Genta-
mycin or Tobra-
mycin
0.2 Neutral Yes ND Yes Fusion with bacte-
rial membrane
B. cenocepacia [15]
DPPC:Chol Vancomycin 0.1 Neutral Yes ND No Fusion with
bacterial
membrane
E. coli, P.
aeruginosa, A.
baumannii,
Klebsiella spp.
[4]
DPPC:DOPE:-
CHEMS
Yes
DPPC:DMPG Tobramycin 0.4 Neutral to
anionic
Yes ND Yes, complete
eradication
Fusion with the
bacterial
membrane (In vivo
study)
P. aeruginosa [10]
DSPC:DMPC Yes No
Continued on next page
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Nanoparticle com-
position
Antimicrobial
agent
Size
(µm)
Charge Interaction
with the
bacterial
membrane?
Triggered
release?
Improved an-
timicrobial
effect?
Mechanism of ac-
tion
Biofilm Reference
DPPC:DMPC Meropenem 0.12 Neutral No ND No Inhibition of fu-
sion with bacterial
membrane
P. aeruginosa [14]
Soy-PC:Sodium
cholate
Daptomycin 0.055 Neutral ND ND ND Increased penetra-
tion of daptomycin
into the biofilms (in
vivo study)
S. aureus [17]
DMPC:Chol,
DPPC:Chol,
DSPC:Chol
Gentamycin 0.4 Neutral ND ND Yes Protection of gen-
tamycin against
degradation or fu-
sion with bacterial
membrane
P. aeruginosa [22]
PC:Chol Piperacillin ND Neutral ND ND Yes Protection against
β-lactamase degra-
dation
S. aureus [12]
DMPC:Chol Tobramycin 0.3 Neutral ND ND Yes Protection against
binding to
non-target material
and degradation
P. aeruginosa [23]
DPPC:Chol Polymyxin B 0.45 Yes
DPPC:Chol Gentamycin-
gallium
0.34 Neutral ND NS Yes Increased vulnera-
bility of the
P. aeruginosa [24–29]
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Nanoparticle com-
position
Antimicrobial
agent
Size
(µm)
Charge Interaction
with the
bacterial
membrane?
Triggered
release?
Improved an-
timicrobial
effect?
Mechanism of ac-
tion
Biofilm Reference
DSPC:Chol Tobramycin-
bismuth
0.9 Neutral ND ND Yes, complete
eradication
bacteria against
co-encapsulated
metal, interference
with quorum
sensin, virulence
factor production
and biofilm
formation
DDAB:DPPC:Chol Clarithromycin 0.17 Cationic ND ND Yes, complete
eradication
Electrostatic
attraction possibly
followed by
fusion, protection
of the antibiotic
P. aeruginosa [31]
DCP:DPPC:Chol 0.2 Anionic Yes, complete
eradication
DPPC:Chol 0.22 Neutral Yes, but to a
lesser extent
DPPC:PI Glucose oxidase
alone or com-
bined with horse
radish peroxidase,
chloroperoxidase
or lactoperoxidase
0.1-
0.22
Anionic Yes ND Yes Formation and re-
lease of antibacte-
rial hydrogen per-
oxidase and oxy-
acids directly into
the biofilm
Streptococcus
gordonii
[67, 69]
Continued on next page
Table 2.1 – Continued from previous page
Nanoparticle com-
position
Antimicrobial
agent
Size
(µm)
Charge Interaction
with the
bacterial
membrane?
Triggered
release?
Improved an-
timicrobial
effect?
Mechanism of ac-
tion
Biofilm Reference
DPPC:Chol Amikacin 0.3 Neutral ND Yes Yes Sustained release
of the antibiotic
near the infection
site by triggered
release ( in vivo
study, Arikace®)
P. aeruginosa [30]
DPPC:DMPG Tobramycin 0.23-
0.4
Anionic ND ND Yes Sustained release
of the antibiotic (in
vivo study)
B. cepacia [39]
DATAP:DOPE:PC,
DOTAP:Chol:PC
Ciprofloxacin,
gentamycin,
meropenem
0.1-
0.15
Cationic Likely ND Not for all the
tested strains
Possibly sustained
release of the an-
tibiotic and/or fu-
sion
P. aeruginosa
, K. pneu-
moniae, E.
coli
[44]
DPPC:Chol:DC-
Chol
Benzyl penicillin 0.14 Cationic Yes ND Yes, under cer-
tain conditions
Sustained release
of the antibiotic
S. aureus [78]
DMPC:Chol Tobramycin, gen-
tamicin, amikacin
0.35-
0.4
Neutral ND ND Not in the pres-
ence of mucin
and CF sputum
Binding of the li-
posomes to mucin,
alginate or sputum
components
P. aeruginosa [47]
DMPC:Chol Tobramycin 0.42 Neutral ND ND No EPS layer on the
biofilm cells pre-
vents fusion
B. cepacia com-
plex
[43]
Continued on next page
Table 2.1 – Continued from previous page
Nanoparticle com-
position
Antimicrobial
agent
Size
(µm)
Charge Interaction
with the
bacterial
membrane?
Triggered
release?
Improved an-
timicrobial
effect?
Mechanism of ac-
tion
Biofilm Reference
DOPC:DPPG 0.23 Anionic Electrostatic repul-
sion
DPPC:SA:Chol lipo-
somes impregnated
calcium sulphate
Gentamycin ND Cationic ND ND Yes, complete
eradication
Burst release
followed by a pro-
longed sustained
release (in vivo
study)
S. aureus [40]
DPPC:Chol liposo-
mes impregnated
porous β-trical-
ciumphosphate
scaffold
Gentamicin sul-
phate
0.11-
5.2
Neutral ND ND Yes Burst release
followed by a pro-
longed sustained
release (in vivo
study)
S. aureus [32]
PC:SA:Chol lipo-
somes impregnated
nano-hydroxya-
patite/β-trical-
ciumphosphate
scaffold
Ceftazidime 0.16 Cationic ND ND Yes Burst release
followed by a pro-
longed sustained
release (in vivo
study)
S. aureus [33]
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Nanoparticle com-
position
Antimicrobial
agent
Size
(µm)
Charge Interaction
with the
bacterial
membrane?
Triggered
release?
Improved an-
timicrobial
effect?
Mechanism of ac-
tion
Biofilm Reference
PC:SA:Chol lipo-
somes impregnated
nano-hydroxyapa-
tite/chitosan/kon-
jac glucomannan
scaffold
Vancomycin 0.185 Cationic ND ND Yes Sustained release
(in vivo study)
S. aureus [34]
DSPC:Chol:ALN-
TEG-Chol
Oxacillin 0.16 Anionic ND ND Yes Fast release over
several hours
S. aureus [35]
DSPC:Chol Oxacillin 0.15 Neutral ND ND No Low binding of
these liposomes to
the hydroxyapatite
DPPC:Chol:DSPE-
PEG liposomes
impregnated hydro-
gel
Ciprofloxacin 0.1 Neutral ND ND ND Prevention of bac-
terial adhesion
P. aeruginosa [38]
PC:PS Nisin 1 Neutral ND ND ND Inhibition of insol-
uble glucan syn-
thesis for the pre-
vention of caries
S. mutans [36]
DPPC:DPPA / 0.12 -
0.44
Anionic ND ND ND Protection against
caries by adsorp-
tion of
/ [109]
Continued on next page
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Antimicrobial
agent
Size
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with the
bacterial
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Triggered
release?
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timicrobial
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Mechanism of ac-
tion
Biofilm Reference
DPPC:DPTAP / Cationic ND ND ND liposomes on teeth /
DPPC:DPTAP
pectin coated
/ Anionic ND ND ND /
DPPC:PI Triclosan 0.1 Anionic Yes ND No Sufficient targeting
of the biofilm only
for low drug:lipid
ratios
S. epidermidis [66]
DPPG:PI Anionic Yes
DPPC Neutral No
DPPC:Chol:SA / 0.12 Cationic Yes ND Likely Targeting could
lead to sustained
release
S. epidermidis [70, 71]
DPPC:Chol:SA Triclosan/Chlor-
hexidine
0.1 Cationic Yes ND Yes Targeting and sus-
tained release
S. epidermidis,
S. mutans,
Streptococcus
sanguis
[76]
DPPC:PI Triclosan No
DPPG:DPPC Triclosan No
DPPC:Chol:DDAB / ND
DPPC:DC-Chol / ND
DPPC:Chol:SA / 0.12 Cationic Yes ND ND Targeting and
sustained release
S. aureus [72]
DPPC:Chol:DDAB Vancomycin Yes
DPPC:DC-Chol / ND
Continued on next page
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Nanoparticle com-
position
Antimicrobial
agent
Size
(µm)
Charge Interaction
with the
bacterial
membrane?
Triggered
release?
Improved an-
timicrobial
effect?
Mechanism of ac-
tion
Biofilm Reference
DMPC:Chol:DDAB triclosan 0.12 Cationic Yes ND No Anionic liposomes
fare better than
cationic due to
increased triclosan
permeability
S. sanguis, S.
salivarius
[77]
DMPC:PI Anionic ND
DPPC:PI:DPPE-
anti-S. oralis
Chlorhexidine,
triclosan
0.1 Anionic Yes ND Yes Targeting and sus-
tained release
S. oralis [79, 80]
DPPC:PI / 0.1 Anionic Yes ND Likely
Targeting and
sustained release
S. epidermidis,
S. oralis
[73]
DPPC:Chol:SA Cationic
DPPC:PI:DPPE-
anti-S. oralis
Anionic
DPPC:PI / 0.75-
0.11
Anionic Yes ND Likely
Targeting and
sustained release
S. epidermidis,
S. sanguis, C.
hofmanni, P.
vulgaris
[86]
DPPC:PI:DPPE-
Con-A
DPPC:PI:WGA
PC:Chol:SA Metronidazole 2.9 Cationic Yes ND Yes Targeting and S. mutans [84]
Continued on next page
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position
Antimicrobial
agent
Size
(µm)
Charge Interaction
with the
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membrane?
Triggered
release?
Improved an-
timicrobial
effect?
Mechanism of ac-
tion
Biofilm Reference
PC:Chol:SA:Con-A Cationic
or anionic
depending
on Con-A
content
Yes sustained release,
protection against
degradation
DPPC:PI:Con-A Triclosan 0.1 Anionic Yes ND Yes Targeting and
sustained release
S. epidermidis,
S. gordonii, S.
sanguis, S.
mutans
[87]
DPPC:PI:WGA Anionic Yes
DPPC:Chol:SA Cationic Yes
DPPC:PI Anionic Yes
DPPC:PI:DPPE-
Con-A
Triclosan 0.035-
0.31
Anionic Yes ND Yes Targeting and
sustained release
S. sanguis, S.
mutans
[85]
DPPC:PI:DPPE Anionic ND
DPPC:DOTAP:-
DSPE-PEG-WGA
Temoporfin 0.1-
0.11
Anionic Yes ND Yes, compared
to the other 2
liposomes
Targeting and
increased delivery
of temoporfin
S. aureus, P.
aeruginosa
[89]
DPPC:DOTAP:-
DSPE-PEG
Neutral No
DPPC:DPPG Anionic No
Table 2.2: Polymer and LPH nanoparticles tested for drug delivery to biofilms.
Nanoparticle compo-
sition
Antimicrobial
agent
Size
(µm)
Charge Interaction
with the
bacterial
membrane?
Triggered
release?
Improved an-
timicrobial
effect?
Mechanism of action Biofilm Reference
PLGA Carvacrol 0.21 Anionic ND ND ND Fluidification of the
biofilm matrix
S. epidermidis [108]
PLGA Gentamycin 0.24-
0.36
Neutral ND ND Yes Controlled/sustained
release of antibiotic
P. aeruginosa [54]
PLGA Levofloxacin 0.24-
0.42
Anionic No ND Yes, but to a
lower extent
PLGA-PC particles
could ebhance
antibiotic diffusion
into the biofilm
P. aeruginosa [55]
PLGA-PC Yes
PLGA Ciprofloxacin 0.17-
0.24
ND ND ND Yes, with
ciprofloxacin
loaded PLGA
performing the
best
Biphasic release pro-
file
E. coli [56]
PCL Levofloxacin
PLGA-PC Calcein (as a
model)
0.28 Anionic ND Yes ND Triggered release by
rhamnolipids
P. aeruginosa [91]
Chitosan / 0.02-1 Neutral ND / Yes Induction of cell
membrane damage
S. mutans [59]
CMC-EDBE-FA Vancomycin 0.21-
0.26
Cationic Likely ND yes Induction of cell
membrane damage
S. aureus [60]
Continued on next page
Table 2.2 – Continued from previous page
Nanoparticle compo-
sition
Antimicrobial
agent
Size
(µm)
Charge Interaction
with the
bacterial
membrane?
Triggered
release?
Improved an-
timicrobial
effect?
Mechanism of action Biofilm Reference
PLGA Levofloxacin 0.08-
0.23
ND ND ND Yes Biphasic release
profile
E. coli [57]
PCL
Chapter 2. Lipid and polymer nanoparticles for drug delivery to biofilms
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The use of nanomedicines is a promising approach to improve the success
rate of biofilm infection treatment. Lipid and polymer nanoparticles are ex-
tensively investigated for this purpose as their composition, surface charge
and surface functionalization can be tuned. This has led to several clinical
trials using antibiotic-loaded liposomes for the eradication of chronic pul-
monary biofilm infections in cystic fibrosis (CF) patients. However, these
studies thus far failed to prove a clear therapeutic benefit despite promising
results with in vitro biofilms. An in-depth analysis of the available literature
showed that all too often, new formulations of nanoparticle-encapsulated an-
timicrobial agents are developed on a trial-and-error basis, resulting in lim-
ited success. More fundamental research on how nanoparticles behave inside
biofilms would expedite the rational development of improved formulations.
In particular, studies on the influence of the size and surface functionalization
of nanomedicines on their transport into biofilms are lacking. This is crucial
information as the nanomedicines need to be able to penetrate into the biofilm
in order to deliver a high dose of antibiotics in close proximity to the bacteria.
The first goal in this thesis is to investigate the influence of the surface
charge on the nanoparticle transport in Burkholderia multivorans and Pseudo-
monas aeruginosa biofilms. Model fluorescent polystyrene nanoparticles func-
tionalised with either polyethyleneglycol, carboxylic groups or amine groups
are used for this purpose. Their transport into the biofilms will be carefully
monitored using single particle tracking microscopy. As both biofilms cause
recalcitrant pulmonary infections in CF patients, the nanoparticles would also
need to be able to cross the barrier the tenacious mucus poses in order to reach
the infection site. Therefore, the transport of the same nanoparticles will be
evaluated in human CF sputum as well.
Knowing the size range for maximal penetration into biofilm clusters is
important for developing nanocarriers that are able to reach all the bacteria
inside the biofilm. Therefore, the second goal is to investigate the size limit
for maximal nanoparticle penetration into dense bacterial clusters of B. mul-
tivorans and P. aeruginosa biofilms. This will be measured by making use of
polyethleneglycol-modified polystyrene nanoparticles of different sizes. From
single confocal images, the percentage of particles which penetrates into dense
biofilm clusters will be determined via image analysis.
Even when a nanocarrier is able to reach the biofilm through the CF mu-
cus and is able to penetrate into the dense bacterial clusters, the antimicrobial
cargo still needs to be released in order to eradicate the bacteria. The third
goal of this thesis is therefore to investigate potential release mechanisms of
liposomal formulations. Two types of triggers can be used, namely an inter-
nal, local biochemical trigger and an externally applied physical trigger. First,
the feasibility of using an internal trigger, being phospholipases produced by
the bacteria, will be investigated. Next, a promising, relatively new way of
evoking triggered release via plasmonic vapor nanobubbles will be evaluated.
The latter has the advantage of being independent from the local biochemical
environment, making it more broadly applicable.
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3
Transport of nanoparticles in cystic
fibrosis sputum and bacterial
biofilms
Graphical abstract summarizing the evaluation of the transport of model nanoparti-
cles in biofilms and cystic fibrosis sputum. PEG ensures mobility in both biological
samples and revealed patient variation of the transport in cystic fibrosis sputum.
This chapter was published as: K. Forier, A.-S. Messiaen, K. Raemdonck, H. De-
schout, J. Rejman, F. De Baets, H. Nelis, S. C. De Smedt, J. Demeester, T. Coenye, K.
Braeckmans, ”Transport of nanoparticles in cystic fibrosis sputum and bacterial bio-
films by single-particle tracking microscopy,” Nanomedicine, vol. 8, no. 6, pp. 935-949,
2013.
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3.1 Abstract
The aim of this study was to evaluate the effect of the surface functionalization
of model nanoparticles on their mobility in bacterial biofilms and cystic fibro-
sis (CF) sputum. With single particle tracking (SPT) microscopy the mobil-
ity of 0.1 and 0.2 µm fluorescent PEGylated, carboxylate- and N,N-dimethyl-
ethylenediamine-modified polystyrene nanospheres was evaluated in fresh
CF sputum as well as Burkholderia multivorans and Pseudomonas aeruginosa
biofilms. PEGylation increased the mobility of the particles in sputum and
biofilms, while the charged nanospheres were strongly immobilized. How-
ever, the transport of the PEGylated nanoparticles was lower in sputum com-
pared to biofilms. Furthermore, the particle transport showed heterogeneity
in samples originating from different patients. Our data suggest that for future
nanocarrier design it will be essential to combine PEGylation with a targeting
moiety to ensure sufficient mobility in mucus and a better accumulation of the
nanoparticles in the biofilm.
3.2 Introduction
Cystic fibrosis (CF) is the most common autosomal recessive genetic disease
among Caucasians. Mutations in the cystic fibrosis transmembrane conduc-
tance regulator (CFTR) gene result in a deficiency of a cyclic adenosine mono-
phosphate-regulated chloride ion channel, which is normally situated on the
apical membrane of epithelial cells lining various mucosal membranes. [1, 2]
This deficiency leads to altered viscoelastic properties of the secreted mucus
and impaired mucociliary clearance. [3, 4] In the lungs, the viscous mucus
builds up instead of being constantly cleared to keep the lungs free from dust
and pathogens. [5, 6] This mucus build-up facilitates bacterial colonization,
resulting in chronic infections and reducing pulmonary function over time.
Chronic infections with Pseudomonas aeruginosa are common in CF patients.
Infections with pathogens belonging to the Burkholderia cepacia complex (Bcc)
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occur in about 10 % of the CF patients. [7] Compared to P. aeruginosa, in-
creased morbidity and mortality can be associated with Bcc infections. [8–12]
Additionally, infections with Bcc bacteria put the patient at risk of develop-
ing cepacia syndrome, which is an acute and often fatal clinical deterioration
characterized by high fever, necrotizing pneumonia and possibly septicemia
and respiratory failure. [13, 14] Although less frequent than P. aeruginosa, Bcc
bacteria are thus important pulmonary pathogens in the CF population.
After colonization, both pathogens form biofilms in the lungs of CF pa-
tients. [15–19] Biofilms are complex and differentiated communities of bacte-
ria embedded in a self-produced matrix of extracellular polymeric substances
which enables the bacteria to evade the immune system and increases their
tolerance to antibiotics. As a consequence, bacteria residing in biofilms are
nearly impossible to eradicate. [20, 21] The constant immune response result-
ing from chronic biofilm infections causes prolonged inflammation and the
destruction of lung tissue, leading to respiratory failure and early death. [22]
Despite the advances in biofilm research, the growing knowledge on CF and
the improved antibiotic treatment regimes, there is still no cure for chronic
biofilm infections in the lungs of CF patients. However, it has been demon-
strated in vitro that liposomal formulations of antibiotics are more efficient
against bacteria growing in biofilms than the free antibiotic. The observed
effect is likely a combination of several factors: direct interaction of the li-
posomes with the bacterial membrane [23, 24], penetration of the liposomes
in the biofilm followed by a sustained release of the antibiotic [25], and the
protection of the antibiotic against inactivation by sputum components or
bacterial enzymes. [26, 27] Currently, a liposomal formulation of amikacin
(Arikace®) for the treatment of chronic P. aeruginosa infections in CF patients
passed phase II clinical trials.
Nevertheless, it was recently reported that there is no advantage of em-
ploying liposomal preparations in the presence of mucin since it was observed
that the activities of both free and liposomal aminoglycosides were strongly
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inhibited in this case. [28] However, the activity of the antibiotics was im-
proved by adding DNase and alginate lyase, suggesting that hindered dif-
fusion through the sputum and the biofilm matrix could play an important
role. In this line, another study reports that the effectiveness of liposomal
tobramycin decreases in the presence of higher concentrations of polyanions
like DNA and F-actin, possibly because the resulting increased viscoelastic-
ity hinders the diffusion of the liposomes and thus the interaction between
the liposomes and the bacteria. [26] In contrast to CF sputum, only little
information is available on the transport of nanoparticles in biofilms. Some
fundamental studies of liquid flow and mass transport have been conducted
in biofilms using fluorescent nanoparticles [29–31] and one study showed a
higher nanoparticle transport when using magnetic nanoparticles. [32] To the
best of our knowledge, one study looked at biofilm penetration of drug loaded
liposomes, but only in a qualitative way. [25] Therefore, in order to develop
a drug delivery system with optimal activity against biofilm bacteria in the
lungs of CF patients, there is a need to systematically study the mobility of
nanoparticles both in biofilms and CF mucus in a quantitative way.
Single particle tracking (SPT) microscopy has shown to be a neat and ac-
curate method to study the transport of fluorescent nanoparticles in com-
plex biological media in a quantitative way. [33, 34] However, as far as we
know, this technique has not yet been used to study nanoparticle transport
in biofilms. In this study, the transport of model polystyrene nanospheres of
different sizes and with different surface modifications was investigated in
biofilms of Burkholderia multivorans and Pseudomonas aeruginosa, as well as in
freshly obtained human CF sputum using SPT. The knowledge obtained from
this study will contribute to the further development of improved nanocarri-
ers, allowing a more efficient transport of antibiotics through the mucus and
the delivery of a sufficiently high dose of antibiotics into the biofilm.
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3.3 Materials and methods
3.3.1 Bacterial strains
P. aeruginosa G 139, a non-mucoid clinical isolate from a CF patient, was kindly
provided by Dr. Mario Vaneechoutte (University Hospital of Ghent, Belgium).
B. multivorans LMG 18825, also isolated from a CF patient, was obtained from
the Belgian co-ordinated collection of microorganisms (BCCM)/Laboratory
for Microbiology Ghent (LMG) Bacteria Collection (Ghent, Belgium).
3.3.2 Biofilm formation
Biofilms were cultured in uncoated 35 mm Glass Bottom Culture Dishes (Mat-
Tek, Ashland, MA, USA) that were inoculated with 2 ml of Mueller Hinton
(MH) broth. The inoculum contained approximately 5 x 107 colony form-
ing units and was prepared by direct suspension of colonies from a MH agar
plate into MH broth (max. 24 h old). The culture dishes were incubated at
37 °C and after 4 h the supernatant with non-adhered planktonic bacteria was
removed. The adhered cells were washed carefully with 0.9 % NaCl (w/v)
(Sigma-Aldrich, St.Louis, MO, USA), covered with 2 ml of fresh MH broth
and incubated for an additional 20 h at 37 °C to allow biofilm formation. Be-
fore starting an experiment, the biofilms were gently washed with 0.9 % NaCl
(w/v) (Sigma-Aldrich) to remove non-adhering cells once more.
3.3.3 Sputum samples
Freshly expectorated sputum samples were obtained from the University Hos-
pital of Ghent. Sputum samples are collected by autogenic drainage, a phys-
iotherapeutic technique considered as the golden standard for mucus clearing
in cystic fibrosis patients. [35] This technique allows patients to gather sputum
from deeper regions of the lung. The last expectorated sputum coming from
the small airways, which represents the environment in which biofilms occur,
was studied while samples expectorated in the beginning of the physiothera-
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peutic session were omitted. Samples from individual patients were stored at
4 °C until the start of the experiment on the same day. None of the patients
were infected with Bcc bacteria but all of the patients were chronically infected
with P. aeruginosa according to the European consensus criteria. [36] Patient 1
was a 9 year old male and was intermittently infected with Stenotrophomonas
maltophilia and Haemophilus influenza at the time of the sample collection.
Patient 2 was a 19 year old female and did not have positive cultures for other
microorganisms at the time of the sample collection. Patient 3 was a 32 year
old female and was intermittently infected with with Stenotrophomonas mal-
tophilia at the time of the sample collection. The three studied patients inhaled
recombinant human DNase once a day. Additionally, patient 2 inhaled acetyl-
cystein twice a day and patient 3 inhaled hypertonic saline (7%) twice a day.
The collection of sputum samples was approved by the Ethics Committee of
the University Hospital of Ghent.
3.3.4 Nanoparticles
Yellow-green (505/515) fluorescent carboxylate-modified polystyrene Fluo-
Spheres® of 0.1 and 0.2 µm in diameter were purchased from Invitrogen (Car-
lsbad, CA, USA). Nanospheres modified with N,N-dimethylethylenediamine
(DMEDA) (Sigma-Aldrich, St.Louis, MO, U.S.A.) and with 2 and 5 kDa metho-
xy-polyethyleneglycol-amine (mPEGa) (Creative PEGWorks, Winston Salem,
NC, U.S.A.) were prepared from the carboxylate-modified FluoSpheres®. The
functionalization with DMEDA was carried out as described before. [37] To
modify the FluoSpheres® with 2 or 5 kDa mPEGa, N-(3-dimethylaminopro-
pyl)-N’-ethylcarbodiimide hydrochloride (EDC) , N-hydroxysulfosuccinimi-
de sodium salt (sulfo-NHS) (both from Sigma-Aldrich) and the mPEGa were
dissolved in HEPES Buffered Saline (HBS, 10 mM HEPES (Sigma-Aldrich),
150 mM NaCl (Sigma-Aldrich) , adjusted to pH 8). The FluoSpheres® were
added to this mixture at final concentrations of 4 mg/ml EDC, 1.13 mg/ml
Sulfo-NHS, 10 mg/ml mPEGa and 1 % solids for the FluoSpheres®. The mix-
ture was allowed to shake overnight at 200 RPM and was purified by cen-
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trifugation over a centrifugal filter (Amikon ultra centrifugal filters, 100 K
membrane, Millipore, Billerica, MA, U.S.A.) for 12 min at 14000 RPM. This
was followed by two washing steps with HBS (12 min, 14000 RPM). The PE-
Gylated nanospheres were collected by placing the filter upside down in a
new vial followed by centrifugation at 1000 RPM for 3 min. The nanospheres
were resuspended in 500 µl HBS. (Protocol adapted from [38]) The size and
ζ-potential of the modified nanospheres were measured in HEPES (pH 7.3, 20
mM) using the Zetaziser Nano-ZS (Malvern, Worcestershire, UK).
3.3.5 SPT setup and analysis
All SPT measurements were performed on a custom-built laser widefield flu-
orescence microscope setup as described in reference. [39] Briefly, two solid
state lasers, a 100 mW Calypso 491 nm (Cobolt, Solna, Sweden) and a 100 mW
Spectra Physics Excelsior 642 nm (Newport, Irvine CA, U.S.A.), were used
to excite the fluorophores in samples mounted on a TE2000-E (Nikon BeLux,
Brussels, Belgium) inverted microscope equipped with a Plan Apo VC 100x
1.4 NA oil immersion objective lens (Nikon). Videos of the moving nanoparti-
cles were acquired with the NIS Elements software package (Nikon) using an
EMCCD camera (Cascade II:512; Roper Scientific, Tucson, AZ, U.S.A.). Anal-
ysis of the videos was performed off-line using in-house developed software.
[39] Individual fluorescent particles were identified in each frame of a movie
and the motion trajectories of the fluorescent particles were calculated using
a nearest neighbor algorithm. For each trajectory, the mean squared displace-
ment was calculated for the available time lags (i.e. multiples of the time t be-
tween the images). In case of free diffusion, the mean squared displacement
(MSD) was described by
MSD = 4Dt− 43D∆t+ 4σ
2(D,∆t), (3.1)
where D is the diffusion coefficient, ∆t the image acquisition time, and σ
the localization precision that depends both on D and ∆t. [40, 41] In case of
anomalous diffusion, D was often replaced by a time-dependent parameter
137
Chapter 3. SPT in cystic fibrosis sputum and bacterial biofilms
1
4Γt
α−1, (3.2)
with Γ the transport coefficient. [42] The anomalous exponent α is a mea-
sure for the mode of diffusion. For free diffusion α=1, while α¡1 and α¿1 repre-
sent anomalous sub- and superdiffusion, respectively. [43] For α=1 the trans-
port coefficient reduces to the constant diffusion coefficient: Γ = 4D. Thus, Eq.
3.1 becomes:
MSD = Γtα − 13Γ∆t+ 4σ
2(Γ/4,∆t). (3.3)
Since ∆t t in our experiments, diffusion during illumination can be con-
sidered to be free so that the diffusion coefficient in the second and third term
are simply replaced by D = Γ/4. The MSD vs. t plots were analyzed by a
weighted fit of this anomalous diffusion model (with only Γ and α as free fit-
ting parameters). [44] By analyzing the trajectories of individual particles, a
distribution of α-values could be obtained. Besides this, the apparent diffu-
sion coefficient Da corresponding to the first time-lag t was calculated using
the formula:
Da =
MSD
4t , (3.4)
because the distribution of theseDa values can be refined with a maximum
entropy analysis method (MEM). MEM analysis improves the precision of the
distributions and removes features (noise) from the distributions that are not
statistically warranted by the data. [39]
3.3.6 SPT measurements in water
The mobility of the differently functionalized 100 nm and 200 nm was also
evaluated in demineralized water using SPT. This was done in order to com-
pare the transport of the nanoparticles in the biofilms and sputum. The retar-
dation the particles experience in both biological materials can be calculated
by dividing the apparent diffusion coefficient of the particles in water (Dw)
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by the apparent diffusion coefficient of the particles in the biofilms or spu-
tum (Da). Dilutions with a final concentration ranging between 0.0001 and
0.004 % solids were obtained by diluting the nanoparticles in demineralized
water. 5 µl of this dilution was mounted on a microscopy slide using an ad-
hesive spacer (Secure-Seal™ spacer, 9 mm diameter, 0.12 mm deep, Molecular
Probes, Eugene, OR, U.S.A.) and 20 movies of 5 s with a temporal resolution
of 23.2 ms were recorded at different locations within the sample. The image
acquisition time was 3 ms. The experiment was carried out in triplicate at 22
and 37 °C.
3.3.7 SPT measurements in biofilms
24 h old biofilms of B. multivorans LMG 18825 and P. aeruginosa G 139 were
fluorescently stained with a SYTO® 59 (Invitrogen) solution (20 µm in 0.9 %
NaCl (w/v), Sigma-Aldrich). After 15 min of incubation at room temperature,
the biofilm was gently washed with a solution of 0.9 % NaCl (w/v) and di-
lutions of the various functionalized nanoparticles were carefully added. The
nanoparticle stock suspensions were sonicated for 10 min prior to dilution in
0.9 % NaCl (w/v). The final concentration of the dilutions ranged between
0.0003 % and 0.01 % solids to ensure unambiguous tracking of individual par-
ticles and depended on the structure of the biofilm and the surface modifi-
cation of the nanoparticles. Movies of 5 s in total with a temporal resolution
of 39.2 ms were recorded at a sufficient number of different locations in the
biofilm to ensure a representative measurement. Dual color image acquisition
was used to allow easy navigation within the biofilm. The image acquisition
time was 3 ms. Depending on the experiment, between 1460 and 14300 trajec-
tories were analyzed. Each experiment was carried out in triplicate at room
temperature.
3.3.8 SPT measurements in sputum
Aliquots of freshly obtained sputum samples (50 - 150 µl) were pipetted into
an 8-well glass chamber (Lab-Tek® II Chambered 1.5 German Coverglass Sys-
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tem, Thermo Fisher Scientific, Rochester, NY, U.S.A.). 1 µl of sonicated func-
tionalized nanoparticles was added followed by gentle stirring. The samples
were incubated for 10 min at 37 °C on the microscope using a stage top in-
cubator (Tokai Hit, Fujinomiya, Japan) and 5 s long movies with a temporal
resolution of 23.2 ms were recorded at a sufficient number of different loca-
tions within the sputum to ensure a representative measurement. The image
acquisition time was 3 ms. The final concentration of the nanoparticles in spu-
tum ranged between 0.0001 % and 0.02 % solids, depending on the mobility of
the particles in the sputum sample (lower concentration for higher mobility to
ensure unambiguous tracking of individual particles). The temperature was
kept at 37 °C during the measurements using the stage top incubator (Tokai
Hit) and between 280 and 2650 trajectories were analyzed depending on the
experiment. The mobility of each type of particle was investigated in spu-
tum samples obtained from 3 different CF patients. The sputum samples from
the different patients were not pooled. Furthermore, the time a nanoparticle
needs to cross a 10 µm thick mucus layer, referred to as the diffusion time,
was calculated using the time dependent diffusion coefficient obtained from
the SPT experiments and Fick’s second law according to the formula
t = (4x
2
2Γ )
1/α (3.5)
where x is the layer thickness.
3.3.9 Confocal imaging
Confocal images were acquired with a Nikon C1si confocal laser scanning mi-
croscope system equipped with a Plan Apo VC 60x 1.4 NA oil immersion ob-
jective lens (Nikon). SYTO® 59 was excited using a 636 nm diode laser (CVI
Melles Griot, Albuquerque, NM, U.S.A.). The emitted light was filtered over a
660 nm long pass filter (Nikon) and pseudo-colored red with the EZ-C1 soft-
ware (Nikon). The yellow-green fluorescent FluoSpheres® were excited using
a 488 nm argon-ion laser (CVI Melles Griot) and the emitted light was filtered
over a 515 nm filter with a bandpass of 50 nm (Nikon). The emitted light of
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the FluoSpheres® was pseudo-colored green.
3.3.10 Dornase alpha degradation of extracellular DNA
B. multivorans LMG 18825 biofilms were grown in µ clear black 96 well plates
(Greiner Bio-One, Wemmel, Belgium) for 24 h and stained with SYTO® 59
(Invitrogen) as described earlier. 100 µl of a 1 to 500 (v/v) dilution of the 200
nm DMEDA modified nanoparticles in 0.9 % NaCl (w/v) (Sigma-Aldrich) was
added to each well and incubated for 15 min to allow particles to adhere to the
biofilm matrix. After the incubation, the liquid was removed from the biofilm
and the matrix network was imaged by confocal microscopy. While imaging,
100 µl of a 100 mg/l solution of dornase alpha (Pulmozyme , Roche, Brussels,
Belgium) diluted in physiological water was added to the biofilm and a time-
lapse was recorded for 30 min with 30 s being the time between 2 images.
Controls where the 100 µl dornase alpha solution was replaced by 0.9 % NaCl
(w/v) (Sigma-Aldrich) were recorded in the same way.
3.4 Results
3.4.1 Transport of nanoparticles in Burkholderia multivorans
LMG 18825 biofilms
Negatively charged fluorescent nanospheres of 0.1 and 0.2 µm were function-
alized with DMEDA or PEG to also obtain positive and neutral variants, re-
spectively (Table 3.1). The nanospheres were added to the biofilm and their
trajectories were analyzed in terms of anomalous diffusion. Representative
movies are available online (Movie 1-5). [45] For reference, the diffusion of
the nanoparticles was also measured in water.
To quantify the change of the diffusion rate when the different nanopar-
ticles are added to the B. multivorans biofilms, the apparent diffusion coeffi-
cient Da was calculated for the shortest time-scale available from the mea-
surements, i.e. the time between the images in the SPT movies. The resulting
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Table 3.1: The average hydrodynamic diameter and ζ-potential of the
functionalized 0.1 µm and 0.2 µm nanospheres (3 repeats )
Functionalization Average St.D. ζ − potential St.D.
(nm) (nm) (mV) (mV)
0.1 µm carboxylate 108.50 1.13 −44.50 2.95
0.1 µm 2 kDa PEG 124.13 0.67 −10.63 1.85
0.1 µm 5 kDa PEG 129.27 0.85 −2.35 0.18
0.1 µm DMEDA 116.70 0.20 29.87 1.76
0.2 µm carboxylate 223.97 0.67 −48.43 0.68
0.2 µm 2 kDa PEG 241.67 0.96 −11.10 0.36
0.2 µm 5 kDa PEG 249.83 0.42 −1.77 0.41
0.2 µm DMEDA 231.93 1.21 30.37 0.55
Da distributions are shown in Figure 3.1 for both sizes of nanospheres. The
average Da values of the different nanospheres in the B. multivorans biofilms
were also compared to their average apparent diffusion coefficients in wa-
ter (Dw), as expressed by the Dw/Da ratio in Table 3.2. The Dw/Da ratio of
the PEGylated nanoparticles is almost equal to 1, indicating that the PEGy-
lated nanoparticles diffuse at similar speeds in both water as in B. multivorans
biofilms. The slight broadening of the Da distribution for the PEGylated par-
ticles in the biofilms is likely caused by the somewhat lower diffusion of the
fraction of the nanospheres that pass through denser structures (e.g. clusters
of cells) of the biofilm or due to an increase in viscosity caused by excreted
biofilm components. The average α-value for the PEGylated particles in the
biofilms (Table 3.2) is located around 1, indicating that unobstructed diffusion
is the main mode of their motion.
In contrast, the movement of the carboxylate- and DMEDA-modified na-
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Figure 3.1: From the trajectories, the distributions of the average apparent diffusion
coefficient (Da) of the 0.1 µm (A) and 0.2 µm (B) nanospheres after MEM analysis are
calculated in B. multivorans LMG 18825 biofilms (3 repeats). The Da distributions of
the 0.1 µm and 0.2 µm 5 kDa PEGylated particles measured in water are shown as a
reference.
noparticles is strongly impeded in the biofilm as can be seen from the shift
in the Da distributions and the Dw/Da ratios of these nanoparticles. This
is due to binding of the particles to biofilm constituents when also taking
into consideration the α-values of these data-sets, which are shifted towards
lower values and thus indicate anomalous subdiffusion. Taken together, we
observed that both negatively and positively charged nanospheres strongly
interact with biofilm components, in contrast to the PEGylated ones.
The nature of these particle-biofilm interactions was further investigated
by confocal microscopy (Figure 3.2). Interestingly, negatively and positively
charged particles seem to have different interaction sites in the B. multivorans
biofilm. The carboxylate-modified nanoparticles interact with the bacteria,
causing an enrichment of particles in the outer edge of bacterial clusters (Fig-
ure 3.2A), whereas the DMEDA-modified particles are associated with wire-
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like structures in the biofilm matrix (Figure 3.2B). These wires very likely con-
tain strands of extracellular DNA since they fracture within minutes upon
treatment with DNase (dornase alpha, see Supplementary Movies 6 and 7
[45]), indicating the possibility that the extracellular DNA contributes to main-
taining the 3D structure of the biofilm as has been observed before for biofilms
of other bacterial species. [46, 47] The PEGylated nanospheres on the other
hand do not bind to the biofilm material, but remain mobile in the spaces be-
tween the bacterial clusters and only occasionally pass through the clusters.
Similar results were obtained with the 0.2 µm functionalized nanospheres, re-
vealing no clear correlation between the size of the particles and their mobility
in the tested size range.
Figure 3.2: Confocal image of (A) 0.1 µm carboxylate modified nanospheres and (B)
0.1 µm DMEDA modified nanospheres in a B. multivorans LMG 18825 biofilm. The
bacteria are shown in red and the nanospheres in green. The insert in (A) shows car-
boxylate modified nanopsheres adhered to the bacteria. Some bacteria that are coated
with nanospheres are indicated with an arrow.
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Table 3.2: The average apparent diffusion coefficients (Da) of the nanospheres in B. multivorans LMG 18825 biofilms, P. aeruginosa G139
biofilms and sputum are compared to their average apparent diffusion coefficients in water (Dw) (n=3). The standard deviations on
Dw reflect the variability between 3 repeats in an identical environment while the standard deviation on Da represent the variability
between the biofilms or in case of sputum, the variability between patients. The alpha value is a measure for the anomaly of the
diffusion of the particles in a data set. For free diffusion: alpha = 1, anomalous subdiffusion: alpha ¡ 1. (* Average alpha value without
taking into account the bimodality of the distribution). The diffusion time (t) needed for the nanoparticles to cross a 10 µm mucus
layer is calculated from their diffusion in sputum (NA = Not Applicable).
Sample Functionalization Da St. D Dw St. D Da/Dw St. D. Alpha t
(µm/s2) (µm/s2) (µm/s2) (µm/s2)
B. multivorans
0.1 µm 2 kDa PEG 3.21 0.08 3.51 0.04 1.03 0.03 1.03 NA
0.1 µm 5 kDa PEG 3.07 0.11 3.38 0.08 1.10 0.05 1.13 NA
0.1 µm carboxylate 0.18 0.11 4.08 0.09 22.74 13.69 0.78 NA
0.1 µm DMEDA 0.25 0.15 3.76 0.21 14.88 9.11 0.58 NA
0.2 µm 2 kDa PEG 1.71 0.12 1.89 0.01 1.10 0.08 1.01 NA
0.2 µm 5 kDa PEG 1.67 0.11 1.78 0.05 1.07 0.07 1.00 NA
0.2 µm carboxylate 0.14 0.03 1.96 0.02 14.09 3.09 0.82 NA
0.2 µm DMEDA 0.11 0.06 1.88 0.09 116.88 8.64 0.58 NA
Continued on next page
Table 3.2 – Continued from previous page
Sample Functionalization Da St. D Dw St. D Da/Dw St. D. Alpha t
(µm/s2) (µm/s2) (µm/s2) (µm/s2)
P. aeruginosa
0.1 µm 5 kDa PEG 2.28 0.08 3.38 0.08 1.20 0.04 1.03 NA
0.1 µm carboxylate peak 1 0.03 0.00 4.08 0.09 122.09 17.34 1.17* NA
0.1 µm carboxylate peak 2 2.48 0.10 4.08 0.09 1.64 0.07 1.17* NA
0.1 µm DMEDA 0.04 0.01 3.76 0.21 94.20 27.80 0.78 NA
Sputum
0.1 µm 2 kDa PEG 0.67 0.55 4.98 0.08 7.39 6.04 1.06 32 s
0.1 µm 5 kDa PEG 0.88 0.45 4.74 0.18 5.38 2.77 1.07 29 s
0.1 µm carboxylate 0.23 0.18 5.47 0.18 23.76 18.36 0.53 4.38 h
0.1 µm DMEDA 0.16 0.12 4.41 0.05 28.33 22.40 0.53 31.79 h
0.2 µm 2 kDa PEG 0.49 0.20 2.49 0.01 5.09 2.09 0.85 238 s
0.2 µm 5 kDa PEG 0.50 0.31 2.36 0.05 4.74 2.97 0.81 290 s
0.2 µm carboxylate 0.32 0.30 2.69 0.02 8.33 7.72 0.55 1.49 h
0.2 µm DMEDA 0.11 0.04 2.41 0.11 21.89 7.20 0.48 286.51 h
3.4. Results
3.4.2 Transport of nanoparticles in Pseudomonas aeruginosa
G 139 biofilms
To verify if the previous results are specific for the B. multivorans LMG 18825
biofilm or are of a more general nature, the 0.1 µm nanoparticles were also
evaluated in P. aeruginosa G 139 biofilms.
Figure 3.3: For a subset of the 0.1 µm nanospheres, the distributions of the apparent
diffusion coefficient (Da) after MEM analysis were calculated in P. aeruginosa G 139
biofilms (n3¯). The Da distribution of the 0.1 µm 5 kDa PEGylated particles measured
in water is shown as a reference.
As shown in Figure 3.3, theDa distribution of the PEGylated nanoparticles
is almost similar to the Da distribution of the same particles in water, indicat-
ing that these particles are highly mobile in the P. aeruginosa biofilm. This is
also reflected by the α-value which is equal to 1 and thus indicates free diffu-
sion for the PEGylated particles (Table 3.2). The Da distributions, and also the
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α-values, are shifted towards lower values for the carboxylate- and DMEDA-
functionalized nanoparticles. However, it should be noted that the Da distri-
bution of the carboxylate-modified nanospheres is bimodal in the case of the
P. aeruginosa biofilm, indicating a fraction of the particles with a higher trans-
port rate and an immobile fraction of particles. These results are also reflected
in theDw/Da ratios summarized in Table 3.2. The PEGylated particles diffuse
in the P. aeruginosa biofilms at almost the same speed as in water, while the
DMEDA-functionalized particles are slowed down by almost two orders of
magnitude. In case of the carboxylate-modified nanospheres, the diffusion of
the fast and slow fraction is on average approximately 1.6 times and 122 times
slower than in water, respectively.
These findings were confirmed by confocal microscopy, where it was ob-
served that the PEGylated particles do not interact with the P. aeruginosa G
139 biofilm, and that only very few carboxylate-modified nanospheres attach
to biofilm material (Figure 3.4A). The DMEDA-modified nanospheres on the
other hand strongly bind to components of the extracellular matrix (Figure
3.4B). In general, these results are similar to those obtained for the B. multivo-
rans biofilms.
3.4.3 Transport of nanoparticles in CF sputum
The mobility of the nanospheres was also investigated in freshly expectorated
human CF sputum. Each type of nanosphere was tested in sputum samples
obtained from 3 different patients. The samples were not pooled, thus provid-
ing information on the inter-patient variability.
The Da distributions obtained for the 0.1 µm and 0.2 µm nanospheres are
presented in Figures 3.5 and 3.6, respectively. In contrast to the Da distribu-
tions in biofilms (Figures 3.1 and 3.3), the Da distributions of the PEGylated
nanospheres in sputum no longer overlap with the Da distribution of the ref-
erence in water. Interestingly, the Da distributions obtained for the 0.1 µm
PEGylated nanospheres clearly show that the diffusion of the nanospheres is
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Figure 3.4: (A) One frame of a confocal time measurement in a P. aeruginosa G 139
biofilm with 0.1 µm carboxylate modified nanoparticles. Only the particles indicated
with an arrow are immobilized. (B) 0.1 µm DMEDA modified nanoparticles attached
to matrix material which holds together small groups of bacteria in the G 139 biofilm.
The bacteria are shown in red and the nanospheres in green.
slowed down the most for patient 3 (Figure 3.5A and B). The α-values for
the 0.1 µm PEGylated nanospheres are equal to 1, indicating free diffusion of
the particles (Table 3.2). For the 0.1 µm carboxylate- and DMEDA-modified
nanoparticles, there is a progressive decrease in the apparent diffusional mo-
bility from patient 1 to patient 3 (Figure 3.5 C and D), indicating increasing
hindered diffusion. The average apparent diffusion coefficients in CF spu-
tum over the 3 patients compared to water are summarized in Table 3.2. The
Dw/Da ratios indicate that the charged nanospheres are less mobile than the
PEGylated nanospheres. The low alpha value for the charged nanoparticles,
combined with the low Da, indicate that these particles interact with sputum
components resulting in anomalous subdiffusion. This is also apparent from
the longer time that the charged nanoparticles need in order to cross a 10 µm
layer of mucus (Table 3.2). The same analysis was performed for the 0.2 µm
nanospheres, leading to similar results for the sputum samples of the same 3
patients (Figure 3.6).
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Figure 3.5: The Da distributions of the 0.1 µm nanospheres after MEM analysis mea-
sured in CF sputum obtained from 3 different patients. The distributions of the diffu-
sion of the 0.1 µm 5 kDa PEGylated nanospheres measured in water are shown as a
reference.
3.5 Discussion
For some time already, it is known that the mucus present in the lungs of CF
patients poses a strong barrier against nanoparticle transport in general, and
thus also against the transport of nanomedicines. [33, 48] In contrast, little is
currently known about the mobility of nanoparticles in biofilms, although the
diffusion of (macro)molecules has been investigated in a few studies. [49–51]
Yet this would be of interest for future development of nanoformulations to
efficiently deliver antimicrobial agents to the bacteria residing inside biofilms.
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Figure 3.6: The Da distributions of the 0.2 µm nanospheres after MEM analysis mea-
sured in CF sputum obtained from 3 different patients. The distributions of the diffu-
sion of the 0.2 µm 5 kDa PEGylated nanospheres measured in water are shown as a
reference.
Single particle tracking (SPT) microscopy is a powerful technique for mea-
suring the mobility of fluorescent nanoparticles in various biological media.
So far, SPT has not been used before to study the mobility of nanoparticles
in biofilms. In the present study, SPT was used to investigate the influence
of the size and surface chemistry of model nanoparticles on their mobility
in B. multivorans LMG 18825 and P. aeruginosa G 139 biofilms, as well as in
freshly obtained human CF sputum. Nanoparticles of 0.1 and 0.2 µm in di-
ameter were chosen because many nanocarriers used for drug delivery can be
found in this size range (e.g. liposomes). For both sizes of nanospheres, three
different surface chemistries were investigated: the nearly uncharged, hy-
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drophilic PEGylated nanospheres, strongly negatively charged carboxylate-
modified nanospheres and strongly positively charged DMEDA-modified na-
nospheres. The charged nanoparticles likely interact with biofilm and sputum
components via hydrophobic interactions of the polystyrene and electrostatic
interactions. PEGylation on the other hand is known to significantly reduce
interactions of biopharmaceuticals (e.g. therapeutic proteins and peptides)
and nanoparticles with biological compounds. [52–54] For instance, Hanes et
al. observed that PEGylated nanoparticles show a significantly higher mobil-
ity in cervicovaginal mucus compared to carboxylate-modified nanoparticles
of the same size. [33] They also found that the molecular weight of the PEG
should be sufficiently low, in the order of 2 to 5 kDa, and the surface coverage
of the PEG sufficiently high to minimize interactions with mucus components.
[53] In line with these observations we decided to use 2 and 5 kDa PEG in the
present study.
In the B. multivorans biofilm, the PEGylated nanoparticles exhibit primar-
ily unobstructed free Brownian motion. When examining the SPT movies
and confocal images, it can be concluded that the PEGylated nanospheres
mainly diffuse in the channels within the biofilm and only occasionally dif-
fuse through bacterial clusters. Although PEGylated nanoparticles do not ad-
here to biofilm material, they appear less interesting as a drug delivery vehi-
cle to transport antibiotics into the biofilm as no enrichment of particles in the
biofilm clusters was observed. It remains to be investigated whether smaller
PEGylated nanoparticles would penetrate more easily into the clusters. The
charged nanoparticles on the other hand clearly interact with biofilm compo-
nents. In the SPT analysis, this resulted in a pronounced shift towards lower
α-values, indicating anomalous subdiffusion. Their apparent diffusion coef-
ficient was reduced on average 19 and 15 times compared to water for the
0.1 and 0.2 µm nanospheres, respectively (Figure 3.2). It should be noted
that, since the biofilm is grown in a highly hydrated environment, constant
movements of biofilm components can be observed (see also Supplementary
Movies 2-5 [45]). Evidently, this will lead to a slight overestimation of the mo-
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bility of nanospheres that are bound to these biofilm structures. To limit this
overestimation, the biofilms are imaged at 22 °C instead of 37 °C. The interac-
tions of the nanospheres with the biofilms are expected to be similar at both
temperatures. However, the biofilm structures will move more vigorously at
37 °C, leading to a higher overestimation of the particle mobility. With regard
to the influence of the size on the mobility of the particles in the B. multivorans
biofilms, it can be concluded from the Dw/Da ratios that there is no substan-
tial difference between the 0.1 and 0.2 µm particles. Both the 0.1 and 0.2 µm
PEGylated nanoparticles are small enough to diffuse through the watery chan-
nels between the bacterial clusters of the biofilm. From confocal microscopy, it
was apparent that the charged nanoparticles are trapped by biofilm material
in the same manner regardless of their size (data not shown).
Very similar results were found for the P. aeruginosa biofilm for PEGy-
lated and positively charged nanospheres. The mobility of the carboxylate
nanospheres was slightly different since less binding was observed as com-
pared to the B. multivorans biofilm (see also Figure 3.4A). This led to a bi-
modal distribution of the diffusion coefficients (Figure 3.3), representing par-
ticles that diffuse trough the water channels and particles bound to biofilm
components. Similar as for the B. multivorans biofilm, the positively charged
nanospheres also seem to interact with matrix components of the P. aeruginosa
biofilm. However, only few wire-like structures were seen in this case. The
positively charged particles were mostly attached to clumps of matrix mate-
rial which surrounds small groups of bacteria (Figure 3.4B). This also explains
why the positively charged particles appear to be slowed down more in the
P. aeruginosa biofilms than in the B. multivorans biofilms. The heavier clumps
of matrix material present in the P. aeruginosa biofilm are less prone to bulk
movements than the wire-like structures of the B. multivorans biofilm (com-
pare supplemented Movies 5 and 8 [45]), causing a lower Da for the particles
in the P. aeruginosa biofilm (0.04 µm2/s versus 0.25 µm2/s in case of the B.
multivorans biofilm). This demonstrates the necessity of interpreting the mo-
bility measurements along with the image material from which they are de-
153
Chapter 3. SPT in cystic fibrosis sputum and bacterial biofilms
rived. The α-values in Table 3.2 are indicative of the level of interactions of
nanoparticles with biofilm components. As for the B. multivorans biofilm, the
PEGylated nanospheres do not interact with biofilm components while the
charged nanoparticles show binding to the biofilm components, resulting in
lower α-values. Taken together, we find the same trends for the P. aeruginosa
biofilm and the B. multivorans biofilm, suggesting that similar results could
also be observed with other bacterial strains.
Since our final aim is to eradicate bacterial biofilms present in the mu-
cus of CF patients, the transport of the different types of nanoparticles was
also investigated in sputum originating from 3 different CF patients. Hanes
et al. linked the degree of PEGylation to the ζ-potential of the particle. The
more negative the ζ-potential, the less dense the PEG coating and the more
likely adhesion to sputum components will occur. From their experiments,
they derived that the PEGylated particles become mucoadhesive when the
ζ-potential is more negative than -7 to -10 mV. [53] The ζ-potentials of the
nanospheres used in this work are reported in Table 3.1. The particles PEGy-
lated with 2 and 5 kDa PEG have a ζ-potential around -11 mV and -2 mV, re-
spectively. However, our data show that both types of PEGylated nanospheres
are equally inert towards mucus from CF patients. Although rheology mea-
surements could not be performed due to the low volume of the sputum sam-
ples, it was clear from macroscopic observations that the sample from patient
3 was substantially more viscoelastic than the samples from patients 1 and
2. The difference between patient 1 and 2 was only moderate, with the sam-
ple from patient 1 being the least viscoelastic. These differences arise from
the different disease states of the patients. Since the severity of the lung dis-
ease progresses with age, it was within expectations that the most visco-elastic
sputum could be obtained from patient 3. These differences are clearly re-
flected in the Da distributions of the 0.1 µm and 0.2 µm nanospheres (Figures
3.5 and 3.6). The increased hindrance of movement observed for the PEGy-
lated nanospheres in sputum derived from patient 3 was likely due to the
higher viscoelasticity of this sputum (Figures 3.5A, 3.5B, 3.6A and 3.6B). The
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charged nanospheres showed a strong decrease in the apparent diffusion with
increasing viscoelasticity of the sputum (Figures 3.5C, 3.5D, 3.6C and 3.6D).
Since this was not the case for the PEGylated nanospheres, we concluded that
this cannot be caused by sterical hindrance but must be due to interactions
of the charged nanoparticles with sputum components. This is also appar-
ent from the low α-values and the longer diffusion times for the two sizes of
the charged nanospheres compared to the PEGylated nanospheres (Table 3.2).
The diffusion time, given by Equation 3.5, is the time a certain particle need to
cross a 10 µm mucus layer. A thickness of 10 µm was chosen based on litera-
ture, although it should be kept in mind that the amount of mucus present in
the lungs highly depends on the progression of the disease. [55] The difference
between the diffusion times of the carboxylate and amine modified nanopar-
ticles can be explained by the interactions the nanoparticles can undergo with
the sputum components. The mucins and the abundant amounts of free DNA
and filamentous actin present in the sputum are all negatively charged, caus-
ing the positively charged amine-modified nanospheres to interact with these
polymers. The polystyrene of the negatively charged carboxylate modified
nanospheres likely interacts with the hydrophobic domains on the mucins.
The abundant amounts of DNA and filamentous actin in contrast to the lim-
ited amounts of intact mucins could account for the observed difference in
diffusion times of the charged nanospheres. [56] However, further research
is required to reveal the nature of these interactions and the components the
nanospheres bind to. Additionally, the carboxylate- and DMEDA-modified
particles of both sizes demonstrate a similar pattern of interactions with the
sputum components based on the Da distributions (patient 1 > patient 2 >
patient 3) (Figures 3.5C, 3.5D, 3.6C and 3.6D). An important conclusion from
these data is that the diffusion of nanoparticles can vary substantially in sam-
ples derived from different patients. Nonetheless, similar trends are observed
for the differently modified nanospheres in all 3 patient samples. Because of
the differences in age and severity of the lung disease, it is not possible to
correlate the usage of the different mucolytics to the observed differences in
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particle transport between the patients at this stage.
For both the biofilms and sputum, it cannot be excluded that the size and
surface properties of the nanospheres can be influenced by binding of matrix
or sputum components. For example, the formation of a protein corona on
nanoparticles is a known phenomenon in this respect. [57] However, this ef-
fect should not be of concern since the pragmatic approach used in this work
was aimed at investigating how the transport of the nanospheres was influ-
enced in these biological media.
3.6 Conclusions
Single particle tracking microscopy as presented in this study has not been
used before to study the mobility of nanoparticles in biofilms. However, it can
be a valuable tool in biofilm research, allowing a more fundamental under-
standing on biofilm structure and heterogeneity in various clinical and non-
clinical settings as well as the evaluation of different types of drug delivery
nanocarriers for the treatment of biofilm infections.
With regard to the combined biofilm and sputum experimental data, a
number of conclusions can be drawn. Firstly, the carboxylate-modified nano-
spheres show an interesting binding pattern to the biofilms, especially in the
B. multivorans LMG 18825 biofilm, since they accumulate in the outer edges of
bacterial clusters and are closely associated with the bacteria themselves. This
suggests that negatively charged nanomedicines could be suitable candidates
for the targeting of antibiotics to the bacterial clusters. However, the diffusion
of these carboxylate-modified particles is strongly hindered in sputum, which
means that such a carrier will probably not efficiently reach the site of infec-
tion in the mucus of a CF patient. Secondly, the PEGylated nanospheres have
a much better mobility in sputum than the charged nanospheres. The draw-
back of using PEGylated nanospheres is that these particles do not interact
with biofilm material and thus show no preferential targeting to the biofilm.
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Thirdly, the DMEDA-modified nanospheres are captured on matrix material
and bind extensively to sputum components. Thus, cationic drug delivery
nanocarriers do not seem suited for treating biofilm infections in the lungs of
CF patients.
If we combine the aforementioned conclusions, a drug loaded nanocarrier
should ideally have the combined properties of both the PEGylated and the
carboxylate-modified nanospheres for optimal drug delivery. For example, a
carrier with a sheddable PEG coating could be designed or PEGylation could
be combined with active targeting moieties to enable preferential binding to
biofilm components. PEGylation and active targeting of drug delivery nano-
carriers has already been extensively investigated for various applications in
the medical field, for example in the treatment of specific cancers. [58, 59]
However, this approach is to the best of our knowledge not thoroughly ex-
plored for biofilm treatment and could be a new direction worth of further
investigation.
3.7 Future perspectives
The data obtained in this study could be used to develop drug delivery na-
nocarriers for the treatment of pulmonary biofilm infections in CF patients.
These drug loaded particles, e.g. liposomes, polymer based nanoparticles etc.,
can be modified according to the findings of this study and their transport can
be evaluated in biofilms and CF sputum using SPT. SPT allows screening and
comparing of the different synthesized nanocarriers and thus the selection of
a promising nanocarrier for further in vitro susceptibility testing of biofilm
bacteria, bringing improved drug delivery methods for this kind of infections
one step closer.
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Chapter 4. Probing the size limit for nanomedicine penetration into biofilms
4.1 Abstract
Encapsulation of antibiotics into nanoparticles is a potential strategy to eradi-
cate biofilms. To allow further optimization of these nanomedicines, the influ-
ence of the nanoparticle size on their penetration into dense biofilm clusters
needs to be investigated. In the present study, the penetration of nanoparti-
cles with diameters ranging from 40 to 550 nm into two biofilms, Burkholderia
multivorans LMG 18825 and Pseudomonas aeruginosa LMG 27622, was evalu-
ated using confocal microscopy. Through image analysis, the percentage of
particles able to penetrate into dense biofilm clusters was calculated. The size
cut off for optimal penetration into biofilm clusters was located around 100
- 130 nm for both biofilms. The mesh size of the biofilm matrix and the size
of the channels in between the bacteria are two factors which likely play a
role in the exclusion of the larger particles. For B. multivorans, a sharp drop
in the penetration into the clusters is seen for particles larger than 130 nm
while for P. aeruginosa, a more gradual decrease in penetration could be ob-
served. The overall penetration of the nanoparticles was slightly lower for
P. aeruginosa than for B. multivorans. Based on these results, it could be con-
cluded that nanocarriers of about 100 nm and smaller are good candidates
to improve the treatment of chronic pulmonary biofilms in CF patients. Fur-
thermore, the confocal microscopy method demonstrated here is a useful tool
to assess the penetration of nanomedicines in biofilm clusters. Such informa-
tion is important to optimize nanomedicine formulations for the treatment of
biofilm infections.
4.2 Introduction
Burkholderia multivorans, a member of the Burkholderia cepacia complex (Bcc),
and Pseudomonas aeruginosa are well known micro-organisms in the context
of respiratory tract infections in cystic fibrosis (CF) patients. [1, 2] CF is the
most common genetic disease among Caucasians. The genetic defect results in
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a dysfunctional cystic fibrosis transmembrane conductance regulator protein
which in turn causes an imbalance in the hydration of mucosal membranes
throughout the body. [3] The main cause of morbidity and mortality in CF are
pulmonary complications, the mechanism of which is not fully understood
yet. What is known is that the disturbed hydration of the airways has an in-
fluence on the innate immune defense mechanisms. [4, 5] As a consequence,
these patients often suffer from chronic pulmonary infections with the most
commonly occurring pathogen being P. aeruginosa. [6–8] Besides this, up to
12 % of the CF patients suffer from chronic infections with Bcc bacteria, which
are associated with increased morbidity and mortality compared to other com-
mon pulmonary CF pathogens. [8–11] Treatment of the chronic infections is
problematic since the CF pathogens are known to form biofilms within the
lungs. [12–15] Biofilms are structured and organized communities of bacteria
which are enclosed in a self-produced extracellular matrix. [16] The biofilm
mode of growth allows the bacteria to survive and thrive in otherwise hos-
tile environments. In the human body, this translates into the evasion of the
immune system and a reduced antimicrobial susceptibility, which hampers
eradication of the infection. [17–19] In CF, the chronic biofilm infections lead
to prolonged inflammatory reactions and tissue damage and thus a decline
in the pulmonary function over time. Extensive treatment with antibiotics is
only partially successful in preventing chronic pulmonary biofilm infections
and once biofilms are formed, eradication is nearly impossible. [13, 20, 21]
One of the important reasons for reduced susceptibility of biofilms to an-
tibiotics is hindered penetration of the latter through biofilms. [22] If the rate
of antibiotic penetration through a biofilm is decreased, the organisms may
initially be exposed to a low concentration of the antibiotic and may have
time to mount a defensive response. [23] Hindered diffusion is on the one
hand caused by the fact that cells are often packed together in dense clusters
of tens to hundreds of micrometers in size and on the other hand by the biofilm
matrix composed of exopolysaccharides (EPS), proteins, enzymes and extra-
cellular DNA (eDNA) which surrounds the bacterial cells. The biofilm matrix
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can hinder antibiotics diffusion by physicochemical interactions of antibiotics
with matrix constituents or via enzymatic inactivation. [24–26] By encapsu-
lating antibiotics in nanocarriers, these interactions can be avoided. [27–29]
Liposomes and other nanoparticles such as polymer and lipid-polymer hy-
brid nanoparticles loaded with antimicrobial agents show promising results
in eradicating biofilm infections. [29–34] Several nanomedicine formulations
have even entered clinical trials. One example is Arikace (Insmed), now re-
named to Arikayce®, a liposomal formulation of amikacin which achieves a
higher killing of P. aeruginosa in chronic pulmonary infections in cystic fibro-
sis patients compared to conventional treatment. [29, 35] A prerequisite for
such a nanomedicine strategy to work is that these nanoparticles are capable
of getting close to the bacteria and preferably enter into the tightly-packed
cell clusters. Although a few reports describe the interaction of nanoparti-
cles with biofilms [29, 36–42] or the distribution of the particles within the
biofilm [29, 43], detailed information on which parameters influence parti-
cle transport inside biofilms is scarce. Having this information is paramount
for the rational design of optimal nanomedicine formulations. In the present
study, we have investigated for the first time the ability of nanoparticles to
penetrate into dense cell clusters in P. aeruginosa and B. multivorans biofilms
in function of the nanoparticle size. Cluster penetration was quantified using
confocal microscopy and image processing for model nanoparticles and lipo-
somes of different sizes. These nanoparticles and liposomes were coated with
poly(ethylene glycol) (PEG) as we have demonstrated in a previous study
that this efficiently prevents binding interactions of nanoparticles with com-
ponents of the biofilm as well as with biopolymers in CF sputum. [40] Using
these non-interacting PEG-coated nanoparticles, the influence of size could
exclusively be assessed.
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4.3 Materials and methods
4.3.1 Biofilms
Burkholderia multivorans LMG 18825 and Pseudomonas aeruginosa LMG 27622,
both clinical isolates from a CF patient, were obtained from the BCCM/LMG
Bacteria Collection (Ghent, Belgium). The biofilms were cultured in 96 well
SensoPlates™ (Greiner Bio-One) with a microscopy grade glass bottom. For
the formation of B. multivorans biofilms, the wells were inoculated with 100 µl
of Mueller Hinton (MH) broth containing approximately 5 x 107 colony form-
ing units. The inoculum was prepared by direct suspension of colonies from a
Mueller Hinton (MH) agar plate into MH broth (max. 24 h old). The well plate
was incubated at 37 °C and after 4 h the adhered cells were washed carefully
with 0.9 % NaCl (w/v) (Sigma-Aldrich, St.Louis, MO, USA) to remove any
remaining planktonic bacteria. The developing biofilm was covered with 100
µl of fresh MH broth and incubated for an additional 20 h at 37 °C. The same
procedure was used for the P. aeruginosa biofilms, but the bacteria were grown
on a tryptic soy agar plate and in tryptic soy broth instead.
4.3.2 Nanoparticle preparation
25 nm green fluorescent, carboxylate modified Fluorophorex™ polystyrene
nanospheres were purchased from Phosphorex Inc. (Hopkinton, Ma, USA)
and 60 nm dragon green fluorescent, carboxylate modified polystyrene nan-
ospheres were purchased from Bangs Laboratories Inc. (Fishers, IN, USA).
The 0.1, 0.2 and 0.5 µm yellow-green fluorescent and 0.2 µm orange fluo-
rescent carboxylate modified FluoSpheres® were purchased from Invitrogen
Ltd. (Paisley, UK). These nanoparticles were covalently coated with 2 kDa
poly(ethylene glycol) (PEG) using amine coupling, as described previously.
[40] For the sub 0.1 µm particles, the protocol was modified slightly to en-
sure maximal PEGylation of these smaller particles. Briefly, 2 kDa methoxy-
PEG-amine (mPEGa) (Creative PEGWorks, Winston Salem, NC, USA), N-(3-
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dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) (Sigma -
Aldrich) and N-hydroxysulfosuccinimide sodium salt (sulfo-NHS) (Sigma-Al-
drich) were dissolved in HEPES Buffered Saline (HBS) (10 mM HEPES (Sigma-
Aldrich) and 150 mM NaCl (Sigma-Aldrich), adjusted to pH 8). The nanopar-
ticles were added to this mixture to give final concentrations of 4 mg/ml EDC,
1.13 mg/ml Sulfo-NHS, 10 mg/ml mPEGa and 0.5 % solids for the nanopar-
ticles. The mixture was allowed to rotate for 5 days using a Hulamixer (Life
Technologies, Carlsbad, CA, USA) at 30 rpm. Next, the reaction mixture was
dialyzed using a 10 000 Da molecular weight cut off Slide-A-Lyzer™ dialy-
sis cassette (Thermo Scientific, Waltham, MA, USA) for 6 hours, followed by
ultracentrifugation (L8-70M, Beckman, Coulter, Fullerton, CA, USA) to sedi-
ment all the nanoparticles. The supernatant was discarded and the nanoparti-
cles were resuspended to their original volume (1 % solids) using HBS buffer.
The size and zeta potential were measured in HEPES buffer (20 mM, pH 7.5)
using a Zetasizer Nano (Malvern, Worcestershire, United Kingdom) (Table 1)
and the particles were stored at 4 °C until use.
4.3.3 Liposome preparation
Pegylated liposomes were prepared using the phospholipids 1,2-dipalmitoyl-
sn-glycero-3-phosphocholine (DPPC) (Corden Pharma, Lestal, Switzerland)
and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(poly eth-
ylene glycol)-2000] (DSPE-PEG 2000) (Avanti Polar Lipids, Alabaster, AL, U-
SA) and cholesterol (chol) (Sigma-Aldrich). The lipids and cholesterol were
dissolved in chloroform (Sigma-Aldrich). Liposomes were formed using the
lipid film hydration method. A mixture containing 52 mol % DPPC, 32.4 mol
% cholesterol, 0.6 mol % cholesteryl BODIPY FL and 15 mol % DSPE-PEG 2000
with a total amount of 20 mg/ml of lipids-cholesterol was added to a round
bottom flask. A lipid film was formed by rotary evaporation of the chloroform
at 45 °C under vacuum. This film was hydrated with HEPES buffer (20 mM,
pH 7.4) heated to 45 °C and liposomes were formed by vigorously vortexing
until the lipid film detached completely from the flask. Two different sizes
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of liposomes were fabricated: liposomes of approximately 0.1 µm in diame-
ter obtained by extrusion through 2 stacked 0.2 µm Nuclepore track-etched
membranes (Whatman, Maidstone, Kent, UK) and liposomes with a diameter
below 0.1 µm using a tip sonicator (Branson Ultrasonics Corp., Danbury, CT,
USA) (amplitude: 10 %, 6 cycles of 10 sec on and 10 sec off with a total sonica-
tion time of 1 minute). The size and zeta potential were measured in HEPES
buffer (20 mM, pH 7.5) using a Zetasizer Nano (Malvern) and the liposomes
were stored at 4 °C until use.
4.3.4 Nanoparticle concentration measurements
Accurately measuring nanoparticle concentrations is not straight forward due
to a lack of suitable methods. However, we recently published a method
based on single particle tracking microscopy capable of accurately measur-
ing nanoparticle concentrations. [44, 45] Dilutions of 1000 x, 200 x and 250 x in
demineralized water were prepared for the 0.1, 0.2 and 0.5 µm nanoparticles,
respectively. 5 µl of each dilution was mounted on a microscopy slide using
a Secure-Seal™ adhesive spacer (9 mm in diameter, 0.12 mm deep, Life Tech-
nologies, Carlsbad, CA, USA) and 15 movies of 5 seconds were recorded of the
moving particles using a custom-built laser widefield fluorescence microscope
setup. [40, 46] The image analysis and calculation of nanoparticle concentra-
tion was performed off-line using in-house developed software. [47]
4.3.5 Confocal imaging
The 24 h old biofilms were gently washed with 0.9 % NaCl (w/v) (Sigma-
Aldrich) to remove non-adhering cells. 100 µl of a 20 µM SYTO 59 (Invitro-
gen) solution was added to each well and the plate was incubated at room
temperature and protected from light for 15 minutes. SYTO 59 is a red fluo-
rescent nucleic acid staining which stains both living and dead bacteria. The
biofilms were rinsed with 0.9 % NaCl (w/v) (Sigma-Aldrich) once more and
100 µl of nanoparticle suspension was added to each well. The liposomes were
added undiluted to the biofilm. For the 0.1, 0.2 and 0.5 µm nanoparticles, a
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concentration of 4 x 1011 particles per ml was used. For the 25 nm and 60 nm
nanoparticles, a concentration of 1 % solids was maintained, corresponding to
a particle concentration of 7.08 x 1014 and 3.64 x 1013, respectively. A higher
concentration was used for these smaller particles as their fluorescence sig-
nal was substantially lower compared to the bigger particles. Images of the
biofilm were recoded using a Nikon C1si confocal laser scanning microscope
system equipped with a Plan Apo VC 60x 1.4 NA oil immersion objective
lens (Nikon). The software used to capture the images was the NIS Elements
Advanced Research package (Nikon). SYTO 59 was excited using a 636 nm
diode laser and the fluorescence was collected using a 660 nm long pass filter
(Nikon). The nanoparticles were excited using a 488 nm laser and the flu-
orescence was collected using a 595/50 nm bandpass filter. Per biofilm, 10
different bacterial clusters were imaged in dual color. The experiment was car-
ried out in triplicate for each type of nanoparticle and liposome. As a control
for the maximal achievable percentage of penetration into the clusters, FITC-
dextran 4000 (Sigma-Aldrich) was added to the biofilm at a concentration of
4 mg/ml and images were collected as described above. This concentration
was chosen as it allows easy detection of the fluorophore. FITC-dextran 4000
did not show quenching at this concentration.
A second experiment, mixing both yellow-green 0.1 µm particles and or-
ange fluorescent 0.2 µm particles, each color at a concentration of 4 x 1011 par-
ticles per ml, was also conducted. Due to the spectral overlap of the yellow-
green and orange fluorescent particles, the images were recorded using the
spectral detector of the confocal microscope. The 3 colors (bacteria and 2 types
of nanospheres) were separated by spectral unmixing of the images using pre-
viously recorded spectra of each fluorophore, which were collected separately
by preparing samples with only one of the fluorophores present and confo-
cal spectral detection. Image sequences consisting of 40 consecutive images
were recorded. Spectral unmixing was performed using the NIS Elements
Advanced Research software package (Nikon). The image sequences were
projected into one single image via the maximum intensity projection tool in
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ImageJ (National Institutes of Health, Bethesda, MA, USA).
4.3.6 Image analysis
Figure 4.1: Image processing. A: Red channel containing the signal from the bacteria.
B: Mask obtained by applying a threshold to image A. The yellow contours delineate
a region of interest (ROI) based on the mask and includes groups of bacteria with a
surface area larger than 2 µm2. C: Overlay of the obtained ROI and image A. D: ROI
applied to the green channel containing the fluorescent nanoparticles.
Image analysis for quantifying the penetration of nanoparticles in cell clus-
ters was performed off-line using ImageJ (National Institutes of Health). Part
of the image analysis was converted into a macro. More details on this macro
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and the analysis protocol are included in the Supplementary Information A.
Firstly, the image of the bacteria was processed to create a mask demarcat-
ing the position of the biofilm cluster (Figure 4.1A and 4.1B). A median filter
with a radius of 2 pixels was first applied to reduce noise. Next, an inten-
sity threshold was applied to separate the fluorescent bacteria from the back-
ground. The thresholded image was converted into a mask and this mask was
further converted into a binary image. Using the ’fill holes’ feature in ImageJ,
holes within the biofilm cluster binary image that are not connected to the
surrounding bulk fluid were included in the mask. Next, by using the ’ana-
lyze particles’ function in ImageJ, all the groups of bacteria with a minimal
surface area of 2 µm2 (avoiding the selection of single cells) were converted
into a region of interest (ROI) (Figure 4.1B and C). These ROIs, which mark
the location of biofilm clusters in the image, were applied to the nanoparti-
cle image (Figure 4.1D) and the mean fluorescence intensity (Ic) within each
ROI was measured. The average fluorescence intensity from the inverse ROI
(Ib), thus containing the fluorescence of the particles which are present in the
surroundings of the cluster, was also measured. The region surrounding the
biofilm cluster will be referred to as ’bulk’. A correction for the autofluores-
cence of the biofilm was applied to quantify the fluorescence signal coming
from the nanoparticles only. The background fluorescence was determined by
recording images of SYTO 59 stained biofilms in the absence of particles using
the same imaging settings as before (triplicate). The average background flu-
orescence/autofluorescence signal present in the 595/50 nm channel (green
channel) was calculated in the area of the cluster (Ibgc) and in the bulk area
(Ibgb) using the same image analysis protocol as described above. The per-
centage of particles which is able to penetrate into the cluster was calculated
as follows:
% penetrated nanoparticles = (Ic − Ibgc)(Ib − Ibgb)100 (4.1)
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4.3.7 Statistical analysis
A pairwise comparison was used to verify if the mean difference in the per-
centage of penetrated particles differs significantly between all possible pairs
of nanoparticle sizes tested in the same type of biofilm. A one way ANOVA
could not be used due to the absence of homogeneity of variances (homo-
scedasticity). A correction for the heteroscedasticity of the data was there-
fore done based on the residuals and predicted values obtained using a linear
mixed model. With this correction, weights were constructed for each dataset.
To obtain the pairwise comparison, a linear mixed model using the well num-
ber in which the dataset was recorded as a random effect was used. As resid-
ual weight, the weights obtained for each dataset were used. The estimated
marginal means for the percentage of penetration of each size of the particles
were compared using the Bonferroni confidence interval adjustment. A sig-
nificance level of 0.05 was used to determine if the percentage of penetrated
nanoparticles differs significantly. The statistical analysis was performed us-
ing SPSS 20 (IBM, Armonk, NY, USA).
4.4 Results
4.4.1 Synthesis and characterization of the nanoparticles
All the nanoparticles used in this study were modified with 2 kDa poly ethy-
leneglycol (PEG). The size and zeta potential before and after PEGylation are
summarized in Table 4.1. For the liposomes, no data before PEGylation are
available since the PEGylation is already achieved during the formation of the
liposomes. The polystyrene nanoparticles all showed a pronounced negative
zeta potential before functionalization. After PEGylation, the surface charge of
the particles is strongly reduced as indicated by the zeta potentials which are
now in the range of -6 to -9 mV. The PEGylation also caused the hydrodynamic
diameter to increase on average with 13 nm.
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Table 4.1: Hydrodynamic diameters (Z-average size) and ζ-potentials of the particles
before and after PEGylation. PDI = polydispersity index, B.m. = B. multivorans, P.a. =
P. aeruginosa, N.A. = Not Applicacle. (N = 3)
Particle type Before PEGylation After PEGylation
Diameter
(nm)
PDI ζ-potential
(mV)
Diameter
(nm)
PDI ζ-potential
(mV)
Polystyrene 28.3 (±0.03) 0.08 -50.7 (±11) 41.5 (±0.5) 0.1 -6.3 (± 0.6)
Polystyrene 59.0 (±1.0) 0.07 -38.3 (±2.0) 67.9 (±0.3) 0.03 -6.4 (± 1.4)
Polystyrene 108.5 (±1.3) 0.02 -44.5 (±2.9) 128.8 (±5.2) 0.03 -9.2 (±1.0)
Polystyrene 224.0 (±0.7) 0.04 -48.4 (±0.7) 239.4 (±1.1) 0.02 -9.0 (±5.5)
Polystyrene 548.1 (±6.1) 0.05 -27.0 (±4.8) 555.2 (±9.9) 0.2 -9.3 (±0.3)
Liposome B. m. NA NA NA 68.9 (±0.9) 0.2 -16.7 (±1.4)
Liposome B. m. NA NA NA 101.8 (±1.4) 0.2 -14.6 (±0.5)
Liposome P. a. NA NA NA 74.4 (±0.7) 0.2 -9.5 (±1.0)
Liposome P. a. NA NA NA 97.7 (±0.7) 0.2 -10.3 (±0.3)
4.4.2 B. multivorans biofilms
B. multivorans LMG 18825 biofilms were cultured in 96 well plates with glass
bottom for microscopic observation. Biofilms were incubated with fluorescent
polystyrene nanospheres or fluorescently labeled liposomes covering a size
range from 40 to 555 nm. Both nanospheres and liposomes were functional-
ized with a coating of 2 kDa PEG to avoid binding interactions and immobi-
lization to biofilm constituents. [40] That way, the influence of size on penetra-
tion in bacterial clusters can be studied without interference by nonspecific in-
teractions. After a 10 min incubation, images of dense bacterial clusters were
recorded using laser scanning confocal microscopy for quantification of the
percentage of nanoparticles that could penetrate into these clusters relative to
the surrounding biofilm material (mainly consisting of water). (Figure 4.2)
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Figure 4.2: Representative images of clusters of B. multivorans with polystyrene
nanoparticles of A: 41 nm, B: 129 nm and C: 555 nm polystyrene nanoparticles. Similar
results were obtained with P. aeruginosa.
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Table 4.2: The percentage of polystyrene nanoparticles or liposomes which are able to
penetrate into the tested biofilms. (N = 3) (* Control molecule with maximal penetra-
tion: FITC-dextran 4000 Da, hydrodynamic diameter as reported by the manufacturer.)
Biofilm Particle type Diameter (nm) % in cluster SD
B. multivorans
FITC-dextran* 2.8 74.96 3.98
Polystyrene 41.50 59.38 8.15
Polystyrene 67.96 67.23 4.48
Liposome 68.95 68.14 3.39
Liposome 101.80 58.11 4.23
Polystyrene 128.80 61.16 6.72
Polystyrene 239.40 43.19 4.16
Polystyrene 555.20 20.90 4.39
P. aeruginosa
FITC-dextran* 2.8 73.69 4.04
Polystyrene 41.50 61.96 6.75
Polystyrene 67.96 48.75 7.39
Liposome 74.39 57.09 6.51
Liposome 97.73 46.42 5.34
Polystyrene 128.80 29.74 8.11
Polystyrene 239.40 18.58 9.01
Polystyrene 555.20 10.79 8.79
The results are summarized in Table 4.2 and Figure 4.3A. No significant
difference was found at the 0.05 level between the between the penetration
of the 41 nm polystyrene particles, the 101 nm liposomes and the 129 nm
polystyrene particles. Neither did the 68 nm polystyrene particles and 69 nm
liposomes show a significant difference in penetration. The apparent penetra-
tion levels off at 60-70 % (rather than 100 %) due to the presence of bacteria
in the clusters that are impermeable to the particles. Therefore, the space in
the images taken up by the bacteria cannot contain nanoparticles. To measure
the maximum achievable penetration according to our quantification method,
a solution of FITC-dextran (4000 Da) was added to the biofilm. The dextran
molecule has a hydrodynamic diameter of 2.8 nm and showed 75 % penetra-
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tion. (Table 4.1 and 4.2) This value is regarded the maximal achievable pene-
tration in a B. multivorans LMG 18825 biofilm and is significantly higher than
the penetration observed for the other particle sizes.
Figure 4.3: The penetration of polystyrene nanoparticles (PS, open boxes), liposomes
(LIP, dashed boxes) and the FITC-dextran 4000 control (DEX, gray box) into B. multivo-
rans LMG 18825 (A) and P. aeruginosa (B) biofilms. (N = 3) When comparing all possible
pairs for their penetration, only the ones indicated by the brackets do not differ signif-
icantly from each other (significance level = 0.05).
For particles larger than 130 nm, the percentage of particles inside the clus-
ters rapidly decreases with increasing particle size. The percentages of the 239
and 555 nm polystyrene nanospheres were found to be significantly differ-
ent from each other and from the other data sets at the 0.05 level. As can be
seen in Figure 4.2, the 555 nm particles are almost completely excluded from
the cluster. Additionally, by using a mixture of differently colored 129 and
239 nm polystyrene particles, differences in the penetration pattern for both
sizes of nanoparticles could be compared within the same cluster. By using
a maximum intensity projection of the recorded image sequences, it could be
observed that the 129 nm particles can reach most locations in the cluster while
the 239 nm particles mainly reside in locations where the spacing between the
bacteria is wider. (Figure 4.4)
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Figure 4.4: A mixture of 129 nm green fluorescent and 239 nm orange fluorescent
nanoparticles applied to a B. multivorans biofilm. Panel A shows the stained bacte-
ria. Panel B and C are maximum intensity projections of 40 consecutive images at the
same location. The 129 nm particles are able to reach most places of the biofilm cluster
(B) while the 239 nm particles are mainly found at locations where the cluster is less
dense (C).
4.4.3 P. aeruginosa biofilms
The same experiments were carried out with P. aeruginosa biofilms. As shown
in Figure 4.3B, a similar trend was observed. Note that a different batch of
liposomes was used for these experiments. The small differences in the size
and zeta potential between both batches are not expected to influence the data
interpretation. (Table 4.1) The apparent penetration levels off at 50 to 60 %
for the nanoparticles. The FITC-dextran control shows the highest penetra-
tion but does not differ significantly from the 41 nm particles. This is slightly
lower than for B. multivorans. For the sub-100 nm particles, a significant differ-
ence (significance level = 0.05) is only found between the 41 nm polystyrene
particles and the 68 nm polystyrene particles and both liposomes. For the
polystyrene nanoparticles larger than 100 nm, a significant difference was ob-
served between the 129 nm and 555 nm particles, but not between the 239
and 555 nm particles and the 239 and 129 nm particles, indicating that the
penetration is also leveling off towards low penetration for the largest particle
sizes. All the other possible pairs of nanoparticle sizes were found to differ
significantly from each other (significance level = 0.05).
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In contrast to the B. multivorans biofilm, the penetration of the 98 nm li-
posomes and the 129 nm polystyrene particles differs significantly in the P.
aeruginosa biofilm. Another difference with the B. multivorans biofilm is the
gradual drop in the percentage of penetrated particles when their diameter
exceeds 100 nm. When assessing the penetration of a mixture of green fluo-
rescent 129 nm and orange fluorescent 239 nm polystyrene particles in the P.
aeruginosa biofilm, a similar result as for the experiment in B. multivorans was
obtained. (Figure 4.5)
Figure 4.5: A mixture of 129 nm green fluorescent and 239 nm orange fluorescent
nanoparticles applied to a P. aeruginosa biofilm. Panel A shows the stained bacteria.
Panel B and C are maximum intensity projections of 40 consecutive images at the same
location. Similar to the B. multivorans biofilm, the 129 nm particles show better pene-
tration and a more uniform distribution compared to the 239 nm particles (C).
4.5 Discussion
Treating biofilm infections remains a major challenge. Since high doses of an-
timicrobial agents are often required, the efficiency of the treatment can be im-
proved by maximizing the amount of antibiotic that reaches the biofilm bacte-
ria. Binding of the antibiotic to biofilm matrix components or degradation by
enzymes present in the matrix are known to reduce the concentration at which
the bacteria are exposed. [24–26] It was reported that by packaging the antibi-
otic into nanoparticles increased killing of biofilm bacteria could be achieved
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compared to the free antibiotic. One of the proposed mechanisms for this ob-
servation is the protection of the antibiotic from enzymatic degradation and
binding to matrix components. [27–29] Although the penetration of solutes
into bacterial biofilms has already been investigated extensively using image
analysis and other techniques, the penetration of nanoparticles of different
sizes into living, hydrated biofilms has not been investigated thoroughly yet.
[48–51] Since considerable attention is being paid to the use of nanomedicines
for the treatment of biofilm infections, information about the barrier these
biofilms pose to nanoparticles is of importance to allow nanomedicine opti-
mization. We recently demonstrated that PEGylation of nanoparticles is re-
quired to ensure free diffusional mobility of 0.1 and 0.2 µm nanoparticles in B.
multivorans biofilms and in CF sputum. [40] However, until now, it remained
unclear if a size limit existed for efficient penetration of nanoparticles into
dense cell clusters of living, fully hydrated biofilms.
In this study, two bacterial species which cause chronic lung infections in
CF patients were selected. P. aeruginosa is a common CF pathogen. All CF
patients become chronically or intermittently infected with this pathogen at
some point during their life. The LMG 27622 strain, also called LESB58, is a
β-lactam resistant CF isolate. This strain is characterized by its good biofilm
formation and high transmissibility and virulence. [52] B. multivorans LMG
18825 is also characterized by its good biofilm formation and their virulence
is generally not higher than for P. aeruginosa. However, this strain can poten-
tially behave invasive and cause cepacia syndrome. [9] This life threatening
condition is characterized by a rapid clinical deterioration, fever, respiratory
failure, necrotizing pneumonia and sometimes septicemia. [10] It occurs in
approximately 20 % of the patients infected with Bcc pathogens, making this
a significant and feared complication.
PEGylated polystyrene nanoparticles with diameters ranging from 41 to
555 nm were used as a model to assess the penetration of nanoparticles into
dense bacterial clusters as a function of the particle size. PEGylation is re-
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quired to avoid nonspecific binding of the nanoparticles to different compo-
nents of the biofilm. It was previously observed that carboxylate modified
polystyrene particles accumulate in the outer edges of biofilm clusters of B.
multivorans biofilms. [53] This effect would bias the particle penetration mea-
surement. PEGylation reduced the surface charge of the particles (Table 4.1)
and masked the hydrophobic polystyrene surface. Therefore, interactions of
the particles with the biofilm material are prevented.
Two sizes of liposomes were included in the study as well since the incor-
poration of antimicrobial agents into liposomes was already found to increase
the antimicrobial effect against biofilm bacteria compared to the free antibi-
otic. [34, 54] Moreover, liposomes are currently being evaluated in clinical
trials for the treatment of pulmonary infections in CF patients. [35, 55] In
analogy with the polystyrene nanoparticles, a PEGylated lipid was added to
the formulation to prevent binding of the liposomes to biofilm constituents.
For both investigated biofilms, a decrease in particle penetration with in-
creasing particle size was observed. In the B. multivorans biofilm, particles
with a diameter up to 129 nm showed an equally good penetration in cell clus-
ters. (Figure 4.3A, Table 4.2) This indicates that the mesh size of the matrix and
the spacing between the bacteria in the biofilm clusters is likely larger than 130
nm for this biofilm. For the two largest particle sizes, a sharp decrease in the
penetration was seen. The 555 nm particles were almost completely excluded
from the clusters. (Figure 4.2) In some cases, a dark rim containing no fluo-
rescent particles could be clearly observed around the cluster. (Figure 4.6A)
Likely, this effect is caused by the particles being excluded from the biofilm
matrix surrounding the cluster. Not all clusters show this rim, which points
to heterogeneity within the biofilm. Near complete exclusion was also ob-
served for clusters not showing this rim, indicating that the spacing between
the bacteria and/or the mesh size of the biofilm matrix present in the chan-
nels in between the bacteria likely is too small as well to allow the particles
to penetrate. For the 239 nm polystyrene particles, intermediate penetration
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was seen. To examine more in detail how these particles behave in the cluster
compared to the 129 nm polystyrene particles, a mixture of green fluorescent
129 nm and orange fluorescent 239 nm polystyrene particles was added to
the biofilm. The smaller 129 nm particles were observed throughout the en-
tire cluster while the 239 nm particles were mainly found in locations where
larger channels between the matrix embedded bacteria are present. (Figure
4.4)
Figure 4.6: 555 nm polystyrene nanoparticles in a B. multivorans biofilm (A) and 239 nm
polystyrene nanoparticles in a P. aeruginosa biofilm (B). In both cases, a dark rim sur-
rounding the cluster which is presumably space taken up by biofilm matrix material,
can be observed. This was not observed for the smaller nanoparticles.
For the P. aeruginosa biofilm, the percentage of penetrated particles was in
general lower compared to the B. multivorans biofilm. (Figure 4.3, Table 4.2)
In P. aeruginosa, maximal penetration was observed for particles up to 100 nm.
The size cut off for maximal penetration of nanoparticles thus seems to be
slightly lower compared to B. multivorans biofilms. However, the most pro-
nounced difference between both biofilms was seen for the particles with a
diameter larger than 100 nm. In the P. aeruginosa biofilm, the decrease in the
penetration was more gradual compared to B. multivorans. The most likely
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causes are differences in the mesh size and the level of heterogeneity in the
mesh size of the biofilm matrix as well as differences in the spacing between
the bacteria. For this biofilm, a dark rim around the clusters was already ob-
served for particles of 239 nm in diameter. (Figure 4.6B) This further points
towards a difference in the mesh size of the matrix compared to B. multivo-
rans.
4.6 Conclusions
In this study, the penetration of nanoparticles of different sizes into biofilm
clusters was investigated using B. multivorans LMG 18825 and P. aeruginosa
LMG 27622 biofilms. The larger the particle diameter, the more the parti-
cles were excluded from the smaller channels within the clusters up to the
point where the particles are completely excluded. For B. multivorans, parti-
cles smaller than 130 nm were found to maximally penetrate into the clusters
while the cut off for P. aeruginosa was 100 nm. For larger particles, the per-
centage of particles which is able to penetrate into the clusters drops rapidly
with increasing particle sizes in B. multivorans biofilms, but a more gradual
decrease in penetration was observed in case of P. aeruginosa. A possible ex-
planation is that the P. aeruginosa biofilm matrix is more heterogeneous than
the B. multivorans biofilm matrix. Differences in the biofilm matrix composi-
tion and in the width of the channels between the bacteria are other factors
which could contribute to this.
From a drug delivery point of view, knowing the largest nanoparticle size
which still penetrates sufficiently into the dense biofilm clusters is important
information. The larger the nanoparticle, the more cargo it can carry and de-
liver to the target site. Liposomes are regarded as good drug delivery nanocar-
riers due to their biocompatibility and versatility. This study shows that lipo-
somes, or other nanocarriers, of 100 nm or smaller could be viable candidates
for the treatment of pulmonary biofilm infections in cystic fibrosis patients.
However, it remains unclear how representative these in vitro biofilms are for
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the in vivo situation at this point.
Besides this, we have presented a straight forward microscopy method to
measure nanoparticle penetration into bacterial clusters. This method can eas-
ily be applied to other biofilms and nanocarriers to assess cluster penetration.
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5 Triggered release from liposomes
Graphical abstract showing the various types of triggers that can be used to induce
drug release from liposomes. Internal triggers rely on the local biochemical environ-
ment, such as the presence of specific enzymes at the infection site. Externally applied
triggers on the other hand require a build-in trigger which can induce release upon
activation by a stimulus. Vapor nanobubble generation by applying laser pulses to
gold nanoparticles either inside or attached to the outside of liposomes is an example
hereof.
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5.1 Introduction
It is well established in literature that nanocarriers can protect their therapeu-
tic cargo against degradation or binding to non-target materials. Enzymes ex-
creted by the biofilm bacteria, e.g. β-lactamases, and aspecific binding to the
biofilm matrix or components present in the surrounding biological medium,
e.g. the binding of tobramycin to negatively charged biopolymers, are ex-
amples in the context of this thesis. [1–3] By nanoparticle encapsulation, an
increased amount of drug is able to reach the biofilm bacteria where it needs
to be released from the nanocarier in order to exert an effect. However, the
ability of a nanocarrier to release its content is directly opposed to the require-
ment that drug leakage from the particle should be minimal while traveling
to the target site and to allow storage of the formulation. One possibility to
combine minimal leakage with release at the target site is using triggered re-
lease. In the context of biofilm treatment, a sudden release of a high dose
of the antimicrobial agent in close proximity to the bacterial cells could be
beneficial as it minimizes the possibility of the bacteria to upregulate defense
mechanisms. Additionally, triggered release close to the bacteria would limit
the loss of antimicrobial agent by non-specific interactions with the surround-
ing complex biological medium. [4, 5] This means that a lower dose can be
administered, thus reducing side effects. Furthermore, the trigger could also
induce a sustained release of the antimicrobial agent over longer periods of
time, preventing regrowth of the biofilm. [4]
One can discriminate between two major types of triggers for drug release:
internal and external triggers. An internal trigger makes use of the presence
of certain molecules or enzymes or a deviating physiological condition at the
target site, e.g. altered pH levels, to induces drug release from the nanocar-
rier. An example of such an internal trigger in a biofilm context is the rham-
nolipid virulence factor produced by P. aeruginosa. These molecules behave
as surfactants and can destabilize the lipid bilayer of drug-loaded liposomes.
Their concentration will be higher close to the infection site, ensuring release
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in the vicinity of the bacteria. In a comparative study between a liposomal
formulation of amikacin and the free drug, the liposomal formulation ensured
longer exposure times of amikacin in the lungs via sustained release induced
by the rhamnolipids. Furthermore, the side effects caused by the amikacin
were reduced and a better reduction in bacterial load in an in vivo rat model
for chronic pulmonary P. aeruginosa infection was achieved. [4] Another exam-
ple is the triggered release from liposomes by the pore forming virulence fac-
tor α-toxin produced by the methicillin resistant S. aureus. [6] Other promising
virulence factors for triggered liposomal release are lipases or phospholipases.
[7, 8]
External triggers on the other hand typically rely on locally applied stim-
uli such as heating, ultrasound or electromagnetic radiation to induce drug
release. [9] Temperature sensitive liposomes have a low phase transition tem-
perature and by heating, imperfections in the arrangement of the phospho-
lipid double layer are induced and lead to drug leakage. Heating can for
example be achieved using magnetic resonance imaging. [10] Ultrasound re-
sponsive liposomes either contain or are attached to gas bubbles. Because of
the expansion and compression of the air bubble in the ultrasound wave, the
liposomes can form transient pores or are disrupted. [11, 12] A final exam-
ple is the use of liposomes containing synthetic phospholipids that are able to
undergo photoisomerisation upon irradiation with light. The bulky photoiso-
mer causes defects in the lipid bilayer which facilitate drug leakage. [13] An
advantage of using an externally applied trigger is that the place and time of
the release generally can be controlled more precisely. Additionally, not all
bacterial infections lead to the presence of virulence factors that are able to
induce release and the virulence factor production may fluctuate over time.
Therefore, an external trigger can be more broadly applied, regardless of the
bacterial species involved in the infection. The downside of external triggers
is that the site of infection should be known precisely and that it must be pos-
sible to apply the physical stimulus in the target tissue. To date, literature
regarding the use of external triggers for improved treatment of biofilm in-
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fections is surprisingly absent, despite it being heavily investigated for cancer
therapy. [9–11, 14, 15]
An interesting concept to induce forced release of drugs from liposomes
is the use of metal nanoparticles irradiated by laser light. [16, 17] Metallic
nanoparticles such as gold and silver show localized surface plasmon reso-
nance (SPR) when irradiated with light in the visible range. Surface plasmons
are defined as coherent oscillations of the conducting electrons of a metal at
the metal-dielectric interface which are excited by electromagnetic irradiation.
[18] When the diameter of the nanoparticles is much smaller than the wave-
length of the incident light, localized SPR can take place. The conducting elec-
trons of the nanoparticle will move in phase with the incident electric field of
the light, inducing the formation of dipoles. [19] This leads to the selective
absorption of certain wavelengths giving the nanoparticle suspensions their
typical color. (Figure 5.1)
Figure 5.1: Localized surface plasmon resonance in a noble metal nanoparticle with a
diameter smaller than the wavelength of the incident light (left) causes the particles
to absorb part of the visible spectrum of light, resulting in the typical color for the
colloidal nanoparticle suspension (right). [18, 20]
When using a relatively low light flux (i.e. energy per second and per
unit of area), the temperature of plasmonic nanoparticles can be increased
with a few tens of degrees. By functionalizing liposomes with such plasmonic
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nanoparticles, the fluidity of the phospholipid bilayer can be increased due the
photothermal effect, thus releasing the incorporated drug molecules. How-
ever, when using high light fluxes, e.g. by using short (< 10 ns) intense laser
pulses, the particles can heat up very rapidly above 100 °C, thereby immedi-
ately evaporating the surrounding water. In that case, a vapor nanobubble,
termed a plasmonic nanobubble (PNB), is formed around the nanoparticle
that will quickly expand to a size of tens to hundreds of nanometers, depend-
ing on the laser energy used. When the thermal energy is consumed, the PNB
collapses violently, creating shock waves that can cause local mechanical dam-
age. [21, 22] This relatively newly discovered photothermal phenomenon is
currently gaining considerable interest for life sciences applications. [23] An
advantage of this approach over the classic photothermal heating of the gold
nanoparticles and their surrounding medium is that there is no substantial
heat transfer into the surrounding medium, as the energy is almost entirely
converted to mechanical energy, thus limiting unwanted thermal toxic side ef-
fects. [24, 25] In one proof-of-concept publication it was shown that PNBs can
indeed destabilize liposomes functionalized with AuNPs and induce light-
triggered drug release. [26]
This chapter will cover the work that was performed during this PhD
project in order to develop a liposomal formulation for triggered release of
antibiotics. Several species belonging to the Burkholderia cepacia complex are
able to produce lipases and phospholipases. A first part will therefore cover
the use of phospholipases as an internal enzymatic trigger. Since not all bacte-
rial species that infect CF patients will continuously produce phospholipases,
the second part covers the optimization of AuNP functionalized liposomes to
achieve light-triggered drug release.
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5.2 Materials and methods
5.2.1 Enzymatic triggered release
Release by phospholipases secreted by the biofilm
Liposomes composed of the phospholipids dipalmitoylphosphatidylcholine
(DPPC) , 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(poly
ethylene glycol)-2000] (DSPE-PEG 2000) and cholesterol (Chol) at a molar ratio
of 52:15:33 were synthesized by mixing the appropriate amounts of the chlo-
roform dissolved lipids in a round bottom flask. The chloroform was evap-
orated by rotary evaporation under vacuum. The resulting lipid film was
rehydrated with a solution of 100 mM calcein (Sigma-Aldich, St.Louis, MO,
USA) at pH 7.2 by vigorous vortexing. The final lipid concentration was 16
mg/ml. The liposome mixture was extruded 11 times through two stacked
200 nm filters (Nuclepore Track Etch Membranes, Whatman-GE healthcare,
Diegem, Belgium) and was dialyzed overnight to remove non-encapsulated
calcein (Spectra/Por MWCO 10000 dialysis membrane, VWR , Leuven, Bel-
gium).
Release was verified by incorporating quenched calcein into the liposomes.
When the calcein is released, the quenching is inhibited, resulting in a clearly
increased fluorescent signal. Therefore, this mechanism is often used to ver-
ify the release from liposomes upon various triggers. [16, 27] The calcein
release caused by destabilization of the liposomes by compounds such as
(phospho)lipases secreted the biofilm was evaluated by diluting the liposomes
1/1000 (v/v) into the sterile filtrate of Mueller-Hinton growth medium that
was removed from a 4h old Burkholderia cenocepacia LMG 16656 biofilm. Fresh
Mueller-Hinton broth was used as a blanc, a dilution of 1/1000 (v/v) of lipo-
somes into fresh Mueller-Hinton broth was used as a negative control while
for the positive control sodium dodecylsulfate (10 % v/v) was added to com-
pletely degrade the liposomes. The fluorescence of the samples and controls
were evaluated using a fluorimeter (Amico Bowman 2, Spectronic instruments
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inc., Rochester, USA). The excitation wavelength used was 492 nm and detec-
tion of the fluorescence was done at a wavelenth of 514 nm.
Degradation of liposomes by commercial phospholipase-C
Phospholipase-C (PL-C) derived from Clostridium perfringens was bought from
Sigma-Aldrich. The medium used to test degradation of the liposomes by this
enzyme was tris(hydroxymethyl)aminomethane (Tris) buffer at pH 6 which
contained 10 mM Tris (Sigma-Aldich), 0.9 % NaCl (w/v) (sigma-Aldrich), 3
mM CaCl2 (Sigma-Aldrich), 5 µM ZnSO4 (Sigma-Aldrich) and 0.1 % (w/v)
bovine serum albumin (fatty acid free, Sigma-Aldrich). The latter 3 substances
are needed to ensure optimal activity of the enzyme. [28]
The same DPPC:Chol:DSPE-PEG 2000 liposomes containing calcein as de-
scribed above were used. PLC-C was diluted in the Tris buffer to a final con-
centration of 5 µg/ml. The fluorescent signal of liposomes that were diluted
1/1000 in the Tris buffer containing PL-C was measured every 20 min for 1h
(incubation at room temperature, protected from light). A positive control
containing liposomes diluted 1/1000 (v/v) times in Tris buffer in which Triton
X-100 (Sigma-Aldrich) was diluted 1/400 times (v/v) and a negative control
containing liposomes 1/1000 (v/v) times diluted in Tris buffer were also mea-
sured at each time point. The fluorescence signal was measured as described
above.
5.2.2 Triggered release by laser induced plasmonic nanobub-
bles
DPPC:Chol:DSPE-PEG 2000 liposomes with 8 nm Au
Gold nanoparticles (AuNPs) of approximately 9 nm in diameter at a concen-
tration of 1012 particles/ml were a kind gift of Prof. Dr. Andre Skirtach (Cen-
ter for nano- and biophotonics, Ghent University). These AuNPs were encap-
sulated into liposomes composed of DPPC:Chol:DSPE-PEG 2000 (52:33:15).
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The liposomes were synthesized by mixing the appropriate amounts of chlo-
roform dissolved lipids in a round bottom flask. The chloroform was evap-
orated by rotary evaporation under vacuum. The resulting lipid film was
rehydrated with a solution of 100 mM calcein (Sigma-Aldich) at pH 7.2 to
which AuNPs were added to obtain a final lipid concentration of 20 mg/ml
and a final concentration of 1011 AuNPs/ml. Liposomes of approximately
100 nm in diameter were obtained by tip sonication at an amplitude of 10%
at a total sonication time of 1 min. To limit heating of the sample, the son-
ication was done in cycles of 10 sec of sonication interrupted by 15 seconds
without sonication. The liposomes were separated from the free calcein by
elution over a Sephadex G-75 column with a bore of 1 cm and a height of 10
cm using HEPES buffer (20 mM, pH 7.5) as running buffer. The absorption
spectra of the AuNPs containing liposomes (1/2 diluted in HEPES buffer, 20
mM, pH 7.5) and of the free AuNPs (1/6 diluted in HEPES buffer, 20 mM, pH
7.4) were recorded using a Nanodrop 2000 spectrophotometer (Thermo scien-
tific, Wilmington, DE, USA). The size and zeta potential of the liposomes were
determined by dynamic light scattering (DLS) (Zetasizer Nano ZS, Malvern,
Worcestershire, UK).
DOPC:DPPG liposomes with 70 nm Au
Liposomes consisting of the neutral phospholipid 1,2-dioleoyl-sn-glycero-3-
-phosphocholine (DOPC) and the anionic phospholipid 1,2-dipalmitoyl-sn-
glycero-3-phospho-(1’-rac-glycerol) (DPPG) (Avanti Polar Lipids) at a molar
ratio of 8:2 containing calcein (100 mM, pH 7.2) (Sigma-Aldrich) and with
a total lipid concentration of 20 mg/ml were prepared as described above.
The resulting lipid film was rehydrated with a solution of 100 mM calcein
(Sigma-Aldich) at pH 7.2 without AuNPs. The liposomes were purified on a
Sephadex G-75 column with a bore of 2 cm and a height of 14 cm using HEPES
buffer (20 mM, pH 7.5) as running buffer. Cationic AuNPs (Nanopartz, Love-
land, CO, USA) with a hydrodynamic diameter of approximately 70 nm ac-
cording to the manufacturer were added to the purified liposomes at differ-
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ent AuNP to liposome ratios. The absorption spectra of the bare and AuNPs
conjugated liposomes (1/2 diluted in HEPES buffer, 20 mM, pH 7.5) and of
free AuNPs (1/100 or 1/10 times diluted in HEPES buffer, 20 mM, pH 7.4)
were recorded using a Nanodrop 2000 spectrophotometer (Thermo scientific).
The size and zeta potential of the liposomes, the AuNP conjugated liposomes
and free AuNPs were determined by dynamic light scattering (DLS) (Zetasizer
Nano ZS, Malvern). The concentration of the purified liposomes (number of
liposomes/ml) was determined by NanoSight measurement (NanoSight Lim-
ited, Amesbury, UK).
Pulsed laser irradiation and calcein release evaluation
Samples containing 8 or 95 nm cationic AuNPs to 1000 purified DOPC:DPPG
liposomes were 1/2 diluted in HEPES buffer (20 nM, pH 7.5) and used for cal-
cein release testing upon pulsed laser irradiation. 5 µl of the AuNPs-liposome
mixture was mounted on a glass slide using an adhesive spacer (Secure-Seal™
spacer, 9 mm diameter, 0.12 mm deep, Molecular Probes, Eugene, OR, USA).
An non-irradiated AuNPs-liposome sample diluted 1/2 in HEPES buffer (20
nM, pH 7.5) was used as a negative control. As a positive control, AuNPs-
liposomes 1/2 (v/v) diluted in Triton X-100 (10% w/v, Sigma Aldrich) were
used. As a control for the effect of the laser treatment on the liposomes in the
absence of AuNPs, DOPC:DPPG 8:2) liposomes diluted 1/2 in HEPES buffer
(20 mM, pH 7.5) were used. The control samples were mounted on a glass
slide as described above.
Pulsed laser treatment was done on a custom-build wide field laser set-
up. [29] In brief, this set-up consists of an Opolette HE 355 DL pulsed laser
(OPOTEK inc., Carlsbad, CA, USA), an energy meter (J-25MB-HE&LE, En-
ergy Max-USB/RS sensor, Coherent, Santa Clara, CA, USA) and an inverted
TE2000 inverted microscope (Nikon, Nikon BeLux, Brussels, Belgium) equip-
ped with a plan APO 20x objective lens (Nikon), dark field condensor (Nikon)
and a Prior Proscan II automated stage (Prior scientific Ltd., Cambridge, UK).
The laser was tuned to a wavelength of 561 nm and a pulse duration of ±
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7 ns. The whole sample was treated by scanning the laser beam line by line
over the sample using the automated stage. The diameter of the laser beam,
and therefore also the spacing between the scan lines, was 0.1 mm. By using
a scan speed of 2 mm/s and a 20 Hz pulse frequency, each location in the
sample received a single laser pulse. The average radiant exposure the sam-
ple received was 1.95 x 10−2 (± 4.62 x 10−3) µJ/µm2 . A single scan of the
entire well enclosed by the sticker was run. The pulsed laser treatment of the
AuNPs-liposome mixtures was carried out in triplicate. Following laser treat-
ment, fluorescence microscopy images were taken at 3 locations within the
sample and the average calcein fluorescence in the images was calculated us-
ing ImageJ (National Institutes of Health). To verify if the calcein release was
significant or not, the calcein fluorescence of 3 samples before and after treat-
ment was compared using a paired t-test (SPSS20, IBM, Armonk, NY, USA).
The generation of PNBs was visually confirmed using dark field microscopy.
5.3 Results
5.3.1 Enzymatic triggered release
Release by phospholipases present in the growth medium
To evaluate if biofilm-secreted phospholipases can destabilize liposomes with
subsequent release of the liposomal content, the DPPC:Chol:DSPE-PEG 2000
liposomes containing quenched calcein were added to growth medium re-
moved from a 4h old B. cenocepacia biofilm. The apparent calcein release was
14.3 % relative to the positive control. However, this was not significantly
different from the 13.7 % apparent release from the negative control.
Degradation of liposomes by commercial phospholipase C
As the phospholipase concentration might be too low in the culture medium,
we subsequently checked if liposomes can be destabilized when suspended
in a solution of commercial phospholipase C (PL-C) as a proof-of-concept. As
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can be seen in Figure 5.2, a gradual calcein release was observed in function of
the incubation time of the liposomes with the enzyme. The release obtained
by the enzymatic action after 1 hour was approximately 30 %. As the purpose
was only to verify if the liposomes can indeed show leakage by the action of
a phospholipase enzyme, the experiment was not further optimized at this
stage.
Figure 5.2: Calcein release by PL-C destabilization of the liposomes in function of time
(n = 1).
5.3.2 Triggered release by laser induced plasmonic nanobub-
bles
Due to the limited success in using phospholipases as internal trigger for drug
release, it was decided to switch to an external trigger approach instead. In a
first experiment, the encapsulation of 9 nm AuNPs into DPPC:Chol:DSPE-
PEG 2000 liposomes was attempted. The AuNP containing liposomes were 87
nm in size with a slightly negative ζ-potential. (Table 5.1) When measuring
the absorbance spectrum of the AuNP functionalized liposomes, the presence
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Table 5.1: Size and zeta potential of the AuNPs and AuNP-liposome combinations
used in the optimization process.
Particle Size Zeta potential
(nm) (mV)
DPPC:Chol:DSPE-PEG 2000 - 8 nm Au (1/10) 86.9 (±0.8) -5.4 (±0.5)
8 nm Au (HEPES) 180.1 (±42.6) 0.8 (±5.8)
8 nm Au (water) (bimodal distribution) 14.9 (±0.1)
15 (±1.7)
147.9 (±10.5)
DOPC:DPPG 249.9 (±2.3) -63.5 (±1.5)
70 nm Au (HEPES) 105.8 (±9.2) 9.1 (±0.5)
70 nm Au (water) 72.5 (±0.9) 35.9 (±0.1)
70 nm Au - DOPC:DPPG (8:1000) 191.2 (±7.3) -63.2 (±2.1)
70 nm Au - DOPC:DPPG (94:1000) 183.8 (±2.7) -26.6 (±0.8)
of AuNPs could not be confirmed as the absorption peak caused bu localized
surface plasmon resonance of the AuNPs was absent at 528 nm (Figure 5.3).
DLS measurements of AuNPs alone revealed that the they had agglomerated
to 180 nm in diameter. (Table 5.1) Thus, the lack of inclusion of AuNPs into the
liposomes could likely be attributed to the large size of these AuNP agglom-
erates. Note that the absorption peak around 500 nm of the AuNPs-liposome
sample in Figure 5.3 is caused by calcein absorption.
In a next step, electrostatic binding of AuNPs to liposomes was evaluated.
DOPC:DPPG liposomes containing quenched calcein were fabricated and pu-
rified first. The concentration of the purified liposomes was determined to
be 2.66 x 1012 particles/ml by NanoSight. These liposomes were 250 nm
in diameter and highly negatively charged. (Table 5.1) The liposomes were
mixed with cationic AuNPs (30 mV) of 70 nm at different AuNP to liposome
ratios. When making a dilution at a ratio of 4:1000 (AuNPs to liposomes),
no change in the zeta potential was observed. When increasing the ratio to
94:1000 (AuNPs:liposomes), the zeta potential showed a bimodal distribution
indicating that at least a fraction of the liposomes was coated with AuNPs. In-
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Figure 5.3: Absorption spectra of AuNPs containing DPPC:Chol:DSPE-PEG 2000 lipo-
somes and free AuNPs. The disappearance of the peak around 300 nm suggests that
the concentration of AuNPs in the liposomes is very low.
creasing the AuNP:liposome ratio further to 376:1000 and 752:1000 resulted in
unstable suspensions as the formation of aggregates was obvious within a few
minutes. DLS indeed revealed a marked increase in size with a zeta potential
approaching neutral values. (Table 5.1, Figure 5.4)
To study liposomal release upon pulsed laser irradiation via the genera-
tion PNBs, AuNP functionalized liposomes were chosen at ratios of 8:1000
and 94:1000. The absorption spectra confirmed an SPR peak around 560 nm
originating from the absorbed AuNPs. (Figure 5.5) The peak around 500 nm
in the spectrum of the liposomes was again caused by absorption of the light
by calcein.
Each area of the sample was irradiated with a single 7 ns pulse of 1.95 x
10−2 (± 4.62 x 10−3) µJ/µm2. The formation of VNBs was visually confirmed
using dark field microscopy, as reported before. [29] Calcein release was mea-
sured before and after laser treatment by fluorimetry. The results are sum-
marized in Figure 5.6. As a positive control, the liposomes were completely
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Figure 5.4: The size of the liposomes increases and their zeta potential shifts towards 0
upon increasing the amount of AuNPs added to the liposomes.
degraded using Triton X-100.
The fluorescence of the positive control was used to normalize the fluo-
rescence of the samples before and after treatment. For the sample containing
94:1000 AuNPs to liposomes, a significant calcein release of 8 % with respect to
the sample before laser treatment was found (0.05 significance level). For the
sample containing 8:1000 AuNPs to liposomes, this release was much lower,
only 0.44%, and not significantly different from the sample before laser treat-
ment. No calcein release was observed when applying the laser light to lipo-
somes without AuNPs.
5.4 Discussion
Several bacterial species that are able to form pulmonary biofilms in CF pa-
tients are known to produce lipases or phospholipases. [30–35] Therefore,
these enzymes could potentially be used as an internal trigger to release an-
timicrobial agents from liposomes at the infection site as the (phospho)lipases
accumulate in the biofilm and in the mucus surrounding the biofilm. A lipo-
somal formulation that uses rhamnolipids, a surfactant like virulence factor of
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Figure 5.5: The absorption spectra of the DOPC:DPPG liposomes containing 8:1000 (A)
or 94:1000 (B) of positively charged AuNPs to liposomes.
P. aeruginosa , as a trigger for release has already been tested and found supe-
rior to treatment with the free antibiotic. [4, 36] However, the rhamnolipids
are to date only found to be produced by P. aeruginosa and not the other bac-
terial species infecting CF patients. As P. aeruginosa , Staphylococcus aureus and
Burkholderia cepacia complex bacteria were all shown produce lipases and/or
phospholipases, using this virulence factor for triggered release would mean
that the formulation is less selective for P. aeruginosa .
To assess whether release from the liposomes can be induced by secreted
(phospho)lipases, growth medium removed from a B. cenocepacia biofilm was
added to the liposomes and the leakage of quenched calcein was evaluated.
Unfortunately, no difference between the negative control and the sample was
observed. The small amount of release that was observed was most likely
caused by the Mueller-Hinton broth itself. Mueller-Hinton broth contains the
acid hydrosylate of casein, beef extract and starch. It is therefore difficult to
say which component caused liposome destabilization. The negative outcome
of this experiment may be due to the absence or low concentration of (phos-
pho)lipases in the collected biofilm medium since release could be obtained
using a commercial phospholipase-C (Figure 5.2).
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Figure 5.6: The fluorescence intensity before and after laser treatment normalized to
the positive control. For the sample containing 8:1000 AuNPs to liposomes, no sig-
nificant difference could be shown between the fluorescence before and after laser
treatment while this was the case for the sample containing 94:1000 AuNPs versus
liposomes (P < 0.05).
In Chapter 3, it was confirmed that PEGylation was highly beneficial in
terms of transport of the nanoparticles through cystic fibrosis sputum and
biofilms. PEGylation is also a strategy which is often employed to increase
the stability of pharmaceuticals by protecting them from enzymatic degrada-
tion. [37] Furthermore, a dense PEG coating was proven to be necessary to
enhance the transport of nanoparticles in CF mucus. [38, 39] Therefore, the
use of PEGylated liposomes in the context of treating pulmonary infections
in CF patients is likely not compatible with using an enzymatic trigger since
the PEG coating can prevent the enzyme from approaching the surface of the
212
5.4. Discussion
liposome closely enough to exert its enzymatic effect. Furthermore, this type
of triggered release relies on the presence of certain virulence factors which
are likely not or not always being produced by the bacterial strains infecting
CF patients. Due to the negative outcome of the experiment mentioned above
in combination with these consideration, it was decided not to continue with
this approach and rather turn our attention to the use of an external trigger.
As a proof-of-concept we chose to make use of a light trigger. Light-
triggered release from liposomes is an area of current interest. The generation
of plasmonic nanobubbles (PNBs) around plasmonic metal nanoparticles by
the absorption of short intense laser pulses is an area of special interest, as it is
a purely mechanical effect. The heating of the nanoparticles only serves as an
intermediate form of energy which is entirely converted to mechanical energy
(i.e. expansion of the plasmonic nanobubble). As such, there is no heat dif-
fusion into the surrounding tissue which can be damaging to healthy tissue.
[24, 25] Therefore, we specifically wanted to make use of the disruptive force
of PNBs that can be induced around AuNPs upon pulsed laser irradiation.
In a first experiment, it was attempted to encapsulate 8 nm AuNPs into
DPPC:Chol:DSPE-PEG 2000 liposomes. These liposomes are the PEGylated
variant of the liposomes that are used in the Arikayce® formulation, which is
now being tested in clinical trials for the treatment of pulmonary P. aeruginosa
biofilm infections in cystic fibrosis patients. The PEGylated lipid was added
since PEGylation has beneficial effects on the transport of nanoparticles in cys-
tic fibrosis lung mucus and in biofilms (cfr. Chapter 3). However, likely due
to strong AuNP agglomeration, incorporation of these AuNPs in the lumen of
the liposomes was unsuccessful.
In a next experiment, electrostatic binding was evaluated of 70 nm cationic
AuNPs to anionic calcein loaded DOPC:DPPG liposomes. Provided that the
ratio of AuNPs to liposomes was below approximately 1:100, a stable colloidal
suspension was obtained. At higher AuNP:liposome ratios, the zeta potential
of the formed liposome-AuNP aggregates was shifted towards neutral val-
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ues, resulting in aggregate formation. Samples with number ratios 8:1000 and
94:1000 (AuNPs:liposomes) were subsequently treated with pulsed laser light.
For the 8:1000 AuNP:liposome mixture, the calcein release from the liposomes
was very low. (Figure 5.6) A higher release was achieved by increasing the
AuNP concentration to 94:1000. Assuming that there is maximum 1 AuNP per
liposome, both values are close to what can be expected based on the number
ratios of AuNPs versus liposomes. It shows that a single AuNP could already
be sufficient to disrupt a liposome upon VNB formation. Furthermore, no
calcein release was observed when irradiating the liposomes with the pulsed
laser in the absence of AuNPs, confirming that the PNB generation is solely
responsible for the triggered release from the liposomes. Therefore, binding
of the AuNPs to the liposomes and the generation of PNBs seems to be a
promising route to induce triggered release from liposomes. Further research
can therefore be directed to more efficient functionalization of liposomes with
AuNPs compromising the sample’s colloidal stability. For example, a biotiny-
lated lipid can be incorporated into the liposome to couple streptavidin-coated
AuNPs, or gold can be even deposited directly on the liposome itself. [40–44]
5.5 Conclusions
In this chapter, the triggered release of quenched calcein from liposomes us-
ing an enzymatic or physical stimulus was investigated. Phospholipase C was
found to induce release. However, no enzymatically induced release was seen
for liposomes incubated with the supernatant of a B. cenocepacia biofilm. To
be able to induce release independently of the presence of a certain virulence
factor at the infection site, an external physical stimulus can be used. The
use of plasmonic nanobubbles (PNBs) induction using pulsed laser irradia-
tion was investigated. A major advantage of this technique is the absence of
heat transfer to the surrounding medium, which limits toxic side effects on
healthy tissue. It can be concluded that calcein release could be induced via
this mechanism and that the amount of calcein released correlated with the
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concentration of the AuNPs present in the sample. Further work should be
directed towards the optimization of the AuNP-liposome system to improve
the triggered release capabilities.
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General discussion and future perspectives
Although our understanding of chronic biofilm infections and their role in
the acceleration of the disease progression in cystic fibrosis (CF) has increased
considerably, efficient eradication of these infections can still not be achieved
to date. Reasons for this include degradation of the antimicrobial agent before
it reaches its target location, binding of the antimicrobial agent to non-target
materials and the increased antimicrobial tolerance of biofilm bacteria. [1–4]
However, researchers were able to show that by encapsulating the antimicro-
bial agent into nanoparticles, degradation and aspecific binding of the antimi-
crobial agent can be avoided, leading to increased killing of biofilm bacteria.
[3, 5, 6] Also, by fusion of the nanocarrier with the bacteria or by sustained
release of the antibiotic from nanocarriers that adsorb onto the biofilm, the in-
creased biofilm tolerance can be overcome. [7, 8] As elaborated in Chapter 2,
the use of nanomedicines specifically engineered for this purpose is a viable
approach for successful biofilm eradication. This thesis presents fundamental
information on the transport of nanomedicines in biofilms that are known to
accelerate the decline in pulmonary function in CF patients. Based on the re-
sults obtained in this PhD project, a set of guidelines for future nanomedicine
design can be provided.
Firstly, a recommendation regarding the nanoparticle size can be provided.
It was experimentally determined that the nanocarrier should be smaller than
0.1 - 0.2 µm in diameter to ensure maximal penetration into the dense bac-
terial clusters of the evaluated Pseudomonas aeruginosa and Burkholderia multi-
vorans biofilms. In a CF context, the mesh size of the lung mucus also needs
to be taken into account as the nanoparticles would need to transverse the
mucus in order to reach the infection site. The CF mucus mesh size was in-
vestigated thoroughly by Justin Hanes and coworkers and found to be on av-
erage 0.14 µm. [9] When combining both findings, it is recommended that
nanoparticles of around 0.1 µm are used as drug delivery nanocarriers. Using
smaller nanoparticles is less interesting since larger nanoparticles can trans-
port a larger amount of antimicrobial agents. [10] Additionally, when lipo-
somes are used as nanocarrier, the smaller the liposomes the more more prone
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they are to premature drug leakage as the increased curvature leads to more
packaging defects in the lipid bilayer. [11, 12] Furthermore, as the mesh size
of CF mucus can show heterogeneity, the nanoparticles can potentially expe-
rience size exclusion effects so that larger nanoparticles can be transported
deeper into the mucus in a given amount of time compared to the smaller
nanoparticles, which are able to enter the smaller pores of the mucus as well.
The findings of Justin Hanes and coworkers that larger nanoparticles pene-
trate more rapedly into CF and human cervicovaginal mucus than smaller
particles could be a consequence of this effect. [9, 13] However, it should be
noted that in the experiments with human cystic fibrosis sputum as described
in Chapter 3, a higher mobility of the 0.2 µm versus the 0.1 µm PEGylated
polystyrene nanoparticles was not observed. Reasons for this discrepancy
could arise form the different experimental approach. Hanes and colleagues
used a diamine-PEG to functionalize the polystyrene particles while methoxy-
PEG-amine was used in this thesis. Also Hanes and coworkers pooled mucus
samples from different patients, diluted the samples and equilibrated the sam-
ples for 2 hours at 37 °C. The samples in this thesis were not pooled to allow
investigation of patient variation, not diluted to ensure a measurement repre-
sentative for the in vivo situation and equilibrated only a short time at 37 °C to
limit degradation of the sputum samples. Identifying which factor contributes
the most to the difference in observations would require further experimental
investigation.
A second recommendation is to coat the nanocarrier with polyethyleneg-
lycol (PEG). The beneficial effect of PEGylation on drug stability, solubility,
toxicity and clearance is widely known. [14–16] Consequently, PEGylation
is also applied to improve the stability and to reduce the clearance of drug
delivery nanocarriers. [17] As can be concluded from Chapter 3, PEGylation
prevents interaction and binding of nanoparticles to mucus or biofilm con-
stituents as well, increasing the nanoparticle transport rates. When PEGy-
lated, the nanocarriers are able to cross the mucus barrier and to penetrate
deep into the bacterial clusters of the biofilm, as would be required to de-
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liver antimicrobial agents in close proximity to the bacteria. Therefore drug
losses due to enzymatic inactivation in the mucus and biofilm and via bind-
ing of the drug to mucus or biofilm components can be limited in comparison
to when the antibiotic is administered in its free form. [3, 6] However, the
major disadvantage of using PEGylated nanoparticles is that these will not ac-
cumulate in the biofilm but will continuously diffuse in and out. In the case
of accumulation in the biofilm, the nanocarriers could function as a depot for
sustained release of the antimicrobial agent, which was proven to increase the
antimicrobial activity towards biofilm bacteria. [18, 19] Therefore, PEGyla-
tion should be ideally combined with a strategy that ensures accumulation
of the nanocarriers inside the biofilm, preferentially in the dense cell clus-
ters. For liposomal drug delivery to biofilms, both passive targeting based on
electrostatic, hydrophobic or hydrogen bonding interactions and active target-
ing using antibodies or selective targeting ligands such as concanavalin-A or
wheat germ agglutinin have been thoroughly discussed in Chapter 2. How-
ever, there is only one paper combining PEGylated liposomes with targeting
via wheat germ agglutinin. [20] In this paper, the targeting to bacteria in sus-
pension was shown to result in complete eradication of the bacteria whereas
untargeted liposomes did not. However, these experiments were run using
planktonic bacteria. Although the experiment shows that the liposomes could
be targeted towards the bacteria, the benefit of combining PEG with a target-
ing strategy remains untested in biofilms. In cancer research however, the
combination of PEG with active targeting, e.g. by using specific antibodies,
was already shown to be highly beneficial. [21, 22] Therefore, it would be of
interest to test whether this approach would lead to improved treatment of
biofilm infections as well.
Thirdly, advice regarding the release of the antimicrobial agent from the
nanocarrier can be provided. Ideally, the nanocarrier shows a high stability
and low drug leakage during storage and while diffusing to the infection site.
In case of liposomes, this can be achieved by tuning the liposomal formula-
tion, e.g. by adding cholesterol, to limit drug leakage. [23] PEGylation has the
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additional benefit to increase the nanoparticle stability by preventing aggre-
gation. [24] However, if for example the composition of liposomes is tuned to
achieve maximal stability, the liposomal content will not readily be released.
Furthermore, the location at which the release occurs is of importance, as re-
lease ideally takes place at the infection site. To achieve efficient release and to
have more control over the location where the release occurs, triggered release
mechanisms can be used. Two major types of triggers can be used. The first
is a local biochemical trigger. A good example hereof is the triggered release
from lipid based nanoparticles by the rhamnolipid virulence factor of P. aeru-
ginosa . [25, 26] This surfactant like virulence factor is present in high numbers
inside and in the vicinity of the biofilm. Therefore, lipid based nanoparticles
will preferentially release their content inside and in close proximity of the
biofilm. Another example of a virulence factor that could trigger release from
liposomes is phospholipase. [27] However, a major downside relying on a
biochemical trigger is that not all bacterial species produce the relevant viru-
lence factors. And even if they do, the production of the virulence factors may
fluctuate over time, or the concentration may be too low. [28, 29] Addition-
ally, as virulence factors can cause increased inflammation and tissue dam-
age, antimicrobial therapy should rather be aimed at limiting virulence factor
production rather than using these virulence factors for triggered release pur-
poses. [30, 31] For these reasons, externally applied triggers for drug release
from nanoparticles provides an interesting, alternative approach that may be
more generally applicable. Ultrasound, heat and light are three physical trig-
gers that are most often used for this purpose. [32] By designing responsive
nanoparticles, applying these stimuli can disrupt the nanocarrier or induce
leakage of its content. An increasingly popular way of triggering release from
liposomes is the use of plasmonic gold nanoparticles. Nobel metal nanopar-
ticles can show surface plasmon resonance, an effect in which the conduct-
ing electrons oscillate in response to the electromagnetic wave of visible light
causing these particles to scatter and absorb certain wavelengths. [33] When
continuously irradiated using low intensity laser light, the particles heat up
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and alter the fluidity of the lipid bilayer, inducing leakage. [34, 35] With this
approach, there is however heat transfer to the surrounding medium, which
can result in thermal damage to tissues. This problem can be circumvented
by using short, high intensity laser pulses instead. This causes the nanopar-
ticles to heat up rapidly to high temperatures so that the surrounding wa-
ter immediately evaporates. [36] The formed vapor bubble, named a plas-
monic vapor nanobubble, limits heat transfer and therefore also the toxic ther-
mal side effects. Two systems combining liposomes with gold nanoparticles
(AuNPs) were evaluated for plasmonic vapor nanobubble triggered release.
The first system, encapsulating AuNPs smaller than 10 nm could not be op-
timized in the time frame of this thesis. The second system, in which 70 nm
cationic AuNPs are attached electrostatically to the outside of anionic lipo-
somes yielded a triggered release which was in proportion to the number of
AuNPs versus liposomes present. Increasing the amount of AuNP’s versus
liposomes yielded unstable formulations. However, unpublished findings by
our lab suggest that an excess of AuNPs could again yield stable formula-
tions. Therefore, it is worth testing if this would lead to destabilization of all
the liposomes. It should also be remarked that in complex biological matrices,
competition by other components could displace the electrostatically bound
AuNPs from the liposomes, making this type of formulation less robust to use
in vivo. Consequentely, further optimization of the system incorporating the
AuNPs inside the liposomes is justified. A final important factor to consider is
the wavelength used for irradiation. Near-infrared light (650 - 900 nm) is able
to penetrate deeper into tissues than visible light and the combination of gold
nanoparticles with near-infrared light is widely investigated for photothermal
therapy of cancer. [37–39] For the liposomes with the 70 nm AuNPs attached,
the wavelength at which light absorption occurs is around 560 nm. As the
absorption wavelength depends on the size and aspect ratio of the AuNPs,
using larger nanospheres in the size range of 155 nm or larger or rod shaped
nanoparticles of for example 25 by 60 nm will absorb wavelengths beyond
650 nm. As these nanoparticles are considerably large in size when compared
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to the size limit for efficient penetration into biofilms and CF mucus, this ap-
proach for triggered release is likely less suited to use in a CF setting. Addi-
tionally, the light would need to be delivered to the target site as well, which is
not possible in CF in a non-invasive way. Therefore, this approach is more vi-
able to use in settings where the biofilm is more easily accessible for the light,
such as biofilm infections in wounds.
Besides the suggested guidelines, the different fluorescence microscopy
techniques presented in this thesis can be used to expedite the rational devel-
opment of future generations of stimuli-responsive drug delivery nanocarri-
ers. Single particle tracking (SPT) provides detailed insight into nanoparticle
dynamics in complex biological media such as biofilms and CF mucus. By
filming diffusing nanoparticles and automated image analysis, information
on the diffusion coefficient and the mode of motion, free or hindered, can be
retrieved for each individual nanoparticle in a straight forward way. This al-
lows the rapid collection of large datasets suited for statistical analysis and to
compare the performance of different nanoparticle formulations. A limitation
of this technique is that it requires fluorescent nanoparticles. The nanopar-
ticles need to be sufficiently bright in order to be detected and it cannot be
excluded that the fluorescent label might influence the physicochemical prop-
erties of the nanoformulation. Furthermore, it requires a microscope setup
equipped with a sensitive camera, which can come with a considerable price
tag. So far, no commercial SPT systems are available that provide trajectory
based information on the diffusion coefficient or the mode of motion of the
particles. With digital cameras becoming increasingly sensitive, fast confocal
systems such as spinning disk or swept field microscopy would be interesting
to try out for particle tracking purposes in the future. Due to their superior
contrast and ability to acquire 3D stacks, they could provide even more de-
tailed information on how nanoparticles behave in complex biological media
such as biofilms or mucus.
A second method that was presented used a classic laser scanning con-
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focal microscope to analyze the percentage of nanoparticles which penetrate
into dense biofilm clusters. The open source program ImageJ was used for
image analysis and the analysis method could at least in part be automated,
reducing the workload. As the confocal microscope is becoming more and
more a standard tool in life sciences laboratories, this method would be easily
available to drug delivery scientists and microbiologists alike. Again, fluores-
cent nanoparticles are needed, thus the same disadvantages of the fluorescent
labeling as mentioned for SPT are applicable here. Furthermore, it is advis-
able to use an inverted microscope to allow easy observation into hydrated
biofilms.
Finally, it should be noted that the results in this thesis were obtained on
biofilms grown in vitro. The structure of in vivo biofilms might differ signif-
icantly as the availability of nutrients and oxygen and the shear forces the
biofilms are subjected to will be different in the lungs of CF patients. Imag-
ing biofilms in explanted CF lungs showed massive colonies of P. aeruginosa
surrounded by an alginate matrix while the in vitro P. aeruginosa biofilms eval-
uated in this thesis often showed a much looser structure. [40] However, it
is difficult to directly compare the observations on the P. aeruginosa structure
in this thesis to the observations of the P. aeruginosa biofilms in the explanted
lungs as these will likely belong to a different strain. A next step would be
to investigate the behavior of nanoparticles in biofilms in a setting which is
more representative for the in vivo situation. The further development of good
in vitro models combining human airway epithelial cells affected by CF with
biofilms as well as new, cheaper animal models that mimic the CF lung dis-
ease and the associated chronic pulmonary infections should facilitate these
studies.
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Despite the advances in the medical field, clinicians are still being con-
fronted with low success rates when treating biofilm related infections. Bio-
films are formed when bacteria adhere to a surface and organize into bacterial
colonies surrounded by a self-produced extracellular, gel-like matrix. Adopt-
ing this biofilm mode of growth enables the bacteria to evade the immune
system and to increase their tolerance to antimicrobial treatment. As a result,
infections involving the formation of biofilms are usually of a chronic nature
and nearly impossible to cure using antimicrobial therapy. The chronic pul-
monary infections seen in cystic fibrosis (CF) patients illustrate the detrimental
effect of biofilm infections as the resulting inflammation speeds up the disease
progression and limits their average life expectancy to 37 years. Therefore,
successfully treating these infections would noticeably improve the morbid-
ity and mortality among CF patients. An in-depth introduction to the biofilm
mode of growth, CF and the link between both is provided in Chapter 1.
Increased sensitivity of biofilms towards nanoparticle encapsulated an-
tibiotics has been repeatedly reported. Especially liposomes and polymer
nanoparticles are highly investigated for this purpose due to their biocom-
patibility and versatility. A comprehensive review of the literature regarding
the use of these nanoparticles for biofilm eradication is given in Chapter 2.
Possible mechanisms behind the increased activity of the nanomedicine for-
mulations were protection of the antibiotic against inactivation by degrading
enzymes or against binding to non-target components, increased transport of
the nanoformulation into the biofilm, increased contact time between the bac-
teria and the antibiotic and the fusion of fusogenic liposomes with the bacteria.
Although several liposomal formulations for the treatment of pulmonary in-
fections in CF patients were or still are being evaluated in clinical trials, none
of these are available on the market yet. This limited success is in part due
to a lack of understanding of the behavior of nanomedicines in CF mucus
and bacterial biofilms. Yet, when dealing with such a complex system, this
fundamental information is the key to the rational development of functional
nanomedicine formulations.
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Advanced fluorescence microscopy methods are particularly suited to stu-
dy nanoparticle dynamics in complex biological media. One such technique
is single particle tracking (SPT) microscopy. As the name implies, in SPT the
diffusional motion of fluorescently labeled nanoparticles is imaged with a sen-
sitive camera. Using dedicated image analysis algorithms, (an estimate of) the
diffusion coefficient can be calculated for each visible particle. In Chapter
3, SPT was for the first time applied to biofilms in order to investigate the
transport of model fluorescent polystyrene nanoparticles in Burkholderia mul-
tivorans and Pseudomonas aeruginosa biofilms. Those are two bacterial species
which cause increased morbidity and mortality amoung CF patients. Nano-
spheres of 0.1 and 0.2 µm in diameter were modified either with a positively
charged amine, a negatively charged carboxylate group or with polyethylene-
glycol (PEG) were added to the biofilms and filmed. The positively charged
particles adhered mainly to the biofilm matrix polymers while the negatively
charged particles attached to the bacteria themselves. The sticking of the neg-
atively charged particles was more pronounced in the B. multivorans biofilm
compared to the P. aeruginosa biofilm, where a fraction of freely diffusing par-
ticles could still be observed. By applying a PEG coating around the nanopar-
ticles, interactions with biofilm constituents could be prevented. SPT revealed
that PEGylated nanospheres could diffuse as fast in biofilms as in pure wa-
ter. Next, the transport of the functionalized nanoparticles was evaluated in
fresh human CF sputum since the nanoparticles would encounter this mucus
before they reach the infection site. Again, the charged nanoparticles were
found to bind to mucus components while the PEGylated particles diffused
freely though the mucus. Due to the higher viscosity of the mucus, however,
the PEGylated particles were slowed down approximately 6 times compared
to in water. In conclusion, the PEGylated nanoparticles are very well capable
of diffusing through CF mucus and biofilms. In future research it would be
interesting to look into the possibility of targeting PEGylated nanoparticles to
the bacteria. This would lead to accumulation of the nanoparticles close to the
bacteria, which would be desirable as this allows the delivery of a high dose
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of antimicrobial agents in close proximity to the bacteria.
While the previous study provided useful information on the most suitable
surface functionalization of nanoparticles, in a next step, the specific influence
of the nanoparticle size on its migration into dense bacterial clusters of the
biofilm was investigated. On the one hand, larger nanoparticles can encapsu-
late more antimicrobial agents and could therefore deliver the highest possible
dose. On the other hand, when nanoparticles are too large to enter the dense
bacterial clusters, the antibiotic cannot be delivered to all the bacteria in an
optimal way. In Chapter 4, a systematic study was performed on the ability
of PEGylated nanoparticles of different sizes (0.04 - 0.5 µm) to penetrate into
dense bacterial clusters of B. multivorans and P. aeruginosa biofilms. Using con-
focal microscopy and image analysis, the fraction of particles that penetrated
inside the clusters could be determined. For the B. multivorans biofilm, parti-
cles below 0.13 µm in diameter could penetrate equally well into the clusters.
For the P. aeruginosa biofilm, the threshold for maximum particle penetration
was slightly lower, namely at 0.10 µm. This small difference is likely due to
species-dependent factors such as the mesh spacing of the biofilm matrix and
the width of the channels in between the bacteria. Furthermore, in earlier
studies by the Justin Hanes’ group, it was shown that particles of that size
are mobile in CF sputum. As liposomes of around 0.1 µm can easily be pre-
pared and can be PEGylated as well, liposomes are good candidates for drug
delivery to pulmonary biofilms in CF patients.
When the nanocarriers finally reach their target location, the antimicrobial
cargo needs to be released in order to exert an antimicrobial effect. However,
the capability of a liposome to release its content is directly opposite to the
need for a formulation which is stable enough to prevent excessive drug leak-
age during storage and the migration to its target location. In order to com-
bine these seemingly incompatible properties, triggered release mechanisms
can be used. Two methods to achieve triggered release from liposomes were
explored in Chapter 5. First, release by a so-called internal trigger present at
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the infection site was studied. In this case, the use of the bacterial virulence
factor phospholipase C was investigated. Phospholipase C was indeed shown
to induce calcein release from the liposomes. However, as not all biofilms pro-
duce the same virulence factors (in the same amount), its general use might
be limited. A more reliable way of triggering release is therefore the use of
a locally applied external stimulus such as laser light. To endow liposomes
with light-responsive properties, the functionalisation with plasmonic gold
nanoparticles (AuNPs) was attempted. It was of particular interest to make
use of a relatively new photothermal effect, namely the induction of plas-
monic nanobubbles (PNBs), as this is gaining considerable interest for life
sciences applications. PNBs are formed when AuNPs heat up through irra-
diation with short intense laser pulses to such a high temperature that the
surrounding water immediately evaporates. When the thermal energy is con-
sumed, the formed PNBs violently collapse, creating shock waves. The me-
chanical disruptive force of such PNBs could be used to destabilize liposomes
and induce release of their cargo. A mayor advantage of PNBs is that there is
virtually no heat transfer to the surrounding medium, which limits toxicity to-
wards healthy tissue. Two AuNP-liposome systems were tested, the first one
having AuNPs encapsulated inside the liposomes and the other consisting of
cationic AuNPs electrostatically attached to the outside of anionic liposomes.
The release of quenched calcein was compared before and after pulsed laser
irradiation using fluorescence intensity measurements. The first system did
not result in the generation of PNBs as the gold nanoparticles formed aggre-
gates too big to incorporate into the liposomes. With the second system, PNB
formation was successfully achieved and a significant release of calcein was
observed. Unfortunately, electrostatic coating only allowed to functionalize
up to about 10% of the liposomes without colloidal destabilization. Future
research should therefore focus on improving the efficiency of AuNP func-
tionalization of the liposomes.
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Ondanks de vooruitgang die geboekt wordt binnen de medische weten-
schappen worden artsen nog steeds geconfronteerd met een laag slaagpercen-
tage voor het behandelen van biofilm gerelateerde infecties. Biofilms wor-
den gevormd wanneer bacterie¨n vasthechten op een oppervlak en zich orga-
niseren in bacterie¨le kolonies die omgeven worden door een extracellulaire,
gel-achtige matrix geproduceerd door de bacterie¨n zelf. Door deze biofilm
modus aan te nemen worden de bacterie¨n in staat gesteld het immuunsys-
teem te omzeilen en hun tolerantie tegenover antmicrobie¨le stoffen te verho-
gen. Daardoor zijn biofilminfecties vaak chronisch van aard en reageren deze
quasi niet op antibiotica behandeling. De chronische longinfecties die waar-
genomen worden bij cystische fibrose (CF) (mucoviscidose) patie¨nten illustre-
ren de destructieve effecten van biofilminfecties aangezien deze de progressie
van de ziekte versnellen en de levensverwachting van deze patie¨nten beper-
ken tot gemiddeld 37 jaar. Een succesvolle behandeling van deze infecties zou
daarom een grote verbetering betekenen voor de levenskwaliteit en levens-
verwachting van CF-patie¨nten. Een grondige introductie tot biofilms, CF en
de link tussen beiden wordt gegeven in Hoofdstuk 1.
Het is meermaals gerapporteerd dat biofilms een verhoogde gevoeligheid
vertonen ten opzichte van antibiotica verpakt in nanopartikels. Het zijn voor-
namelijk liposomen en polymeer nanopartikels die momenteel uitgebreid on-
derzocht worden voor dit doeleinde omwille van hun biocompatibiliteit en
veelzijdigheid. Een overzicht van de beschikbare literatuur omtrent het ge-
bruik van deze nanopartikels voor de behandeling van biofilminfecties wordt
gegeven in Hoofdstuk 2. De achterliggende mechanismen betreffende de ver-
hoogde activiteit van deze nanomedicijnen zijn: de bescherming van het an-
tibioticum tegen inactivatie door enzymen en tegen het binden aan andere
componenten dan het doelwit van het antibioticum, het verhoogt transport
van de nanoformulatie in de biofilm, de langere contacttijd tussen de bac-
terie¨n en het antibioticum en tenslotte de fusie van fusogene liposomen met
de bacterie¨n. Hoewel enkele liposomale formulaties voor de behandeling van
longinfecties in CF patie¨nten reeds getest werden, en momenteel nog getest
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worden, in klinische proeven, zijn deze nog steeds niet commercieel verkrijg-
baar. Dit is deels te wijten aan een gebrek aan kennis met betrekking tot het
gedrag van de nanomedicijnen in CF-mucus en de bacterie¨le biofilms. Door
de complexiteit van de situatie is net deze kennis cruciaal voor het rationeel
ontwikkelen van een werkend nanomedicijn.
Geavanceerde fluorescentiemicroscopietechnieken zijn bijzonder geschikt
voor het bestuderen van de dynamica van nanomedicijnen in complexe, bio-
logische media. E´e´n van deze technieken is single particle tracking (SPT) mi-
croscopie. Zoals de naam doet vermoeden wordt bij SPT de diffusionele be-
weging van fluorescent gelabelde nanopartikels gevolgd door middel van een
gevoelige camera. Via beeldanalyse kan vervolgens de diffusiecoefficie¨nt van
elk afzonderlijk partikel berekend worden. In Hoofdstuk 3 werd SPT voor
het eerst toegepast in biofilms voor onderzoek naar het transport van fluo-
rescente polystyreen nanopartikels in Burkholderia multivorans en Pseudomonas
aeruginosa biofilms. Deze twee soorten bacterie¨n zijn gekend voor het ver-
hogen van de morbiditeit en mortaliteit bij CF-patie¨nten. Nanopartikels met
een diameter van 0.1 en 0.2 µm werden gemodificeerd met een positief gela-
den amine, een negatief geladen carboxy-groep of polyethyleenglycol (PEG)
en werden toegevoegd aan de biofilms en vervolgens gefilmd. De positief
geladen partikels bonden hoofdzakelijk aan polymeren in de biofilm matrix,
terwijl de negatief geladen partikels aan de bacterie¨n zelf bonden. Het binden
van de negatief geladen partikels aan de bacterie¨n was meer uitgesproken in
de B. multivorans biofilm dan in de P. aeruginosa biofilm aangezien in deze laat-
ste nog een fractie vrij diffunderende partikels werd waargenomen. Door de
partikels te coaten met PEG kon de interactie met biofilmcomponenten ver-
meden worden. SPT toonde aan dat gePEGyleerde partikels even snel in de
biofilm als in zuiver water diffundeerden. Vervolgens werd het transport van
de gefunctionaliseerde partikels gee¨valueerd in vers humaan CF-sputum aan-
gezien de nanopartikels met dit mucus in contact zullen komen alvorens ze de
plaats van infectie kunnen bereiken. Opnieuw werd er waargenomen dat de
geladen partikels binden aan componenten in het mucus, terwijl de gePEGy-
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leerde partikels vrij diffundeerden. Door de hogere viscositeit van het mucus
is de diffusiecoefficie¨nt van de gePEGyleerde partikels ongeveer 6 keer lager
dan in zuiver water. Er kan dus geconcludeerd worden dat de gePEGyleerde
nanopartikels in staat zijn om zowel door biofilms als door CF-mucus te dif-
funderen. Het zou interessant zijn om in toekomstig onderzoek te kijken naar
de mogelijkheid om de gePEGyleerde partikels te targetten naar de bacterie¨n.
Dit zal leiden tot een accumulatie van nanopartikels in de nabijheid van de
bacterie¨n, wat een gewenst effect is aangezien dit de vrijzetting van een hoge
dosis aan antimicrobie¨le stoffen in de directe omgeving van de bacterie¨n kan
bewerkstelligen.
Terwijl de voorgaande studie informatie verschaft over de optimale opper-
vlaktefunctionalisatie van de nanopartikels, wordt in een volgende stap de
rol van de grootte van de nanopartikels op hun migratie in dense bacterie¨le
clusters van de biofilm onderzocht. Het gebruiken van grotere nanopartikels
betekent dat er meer antimicrobie¨le stoffen in de partikels ingekapseld kun-
nen worden en er dus een hogere dosis afgeleverd kan worden. Bovendien
kunnen de antimicrobie¨le stoffen niet optimaal aan de bacterie¨n worden af-
geleverd als het nanopartikel te groot is om in de dense bacterie¨n clusters te
kunnen doordringen. In Hoofdstuk 4 werd daarom een systematische stu-
die uitgevoerd naar het vermogen van gePEGyleerde nanopartikels van ver-
schillende groottes (0.04 - 0.5 µm) om in dense clusters van B. multivorans en
P. aeruginosa biofilms door te dringen. Door middel van confocale microsco-
pie en aansluitende beeldanalyse werd de fractie aan partikels die in staat
was om door te dringen in deze clusters bepaald. Voor de B. multivorans bi-
ofilm vertoonden partikels kleiner dan 0.13 µm een even goede penetratie in
de clusters. Voor de P. aeruginosa biofilm lag deze waarde iets lager, nl. op
0.10 µm. Dit kleine verschil is vermoedelijk te wijten aan bacteriesoort gebon-
den verschillen zoals de poriegrootte van de biofilm matrix en de grootte van
de kanalen tussen de bacterie¨n. Bovendien werd in eerdere studies door de
onderzoeksgroep van Justin Hanes reeds aangetoond dat partikels van deze
grootte mobiel zijn in CF-mucus. Aangezien liposomen rond 0.10 µm een-
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voudig aangemaakt en gePEGyleerd kunnen worden, zijn liposomen goede
kandidaten voor het toedienen van geneesmiddelen tegen pulmonaire infec-
ties bij CF-patie¨nten.
Wanneer de nanopartikels eindelijk hun doelwit bereiken, moet de antimi-
crobie¨le lading worden vrijgezet om een antibacterieel effect te kunnen uitoe-
fenen. Het vermogen van een liposoom om zijn lading te kunnen vrijzetten
staat echter lijnrecht tegenover het feit dat de formulatie stabiel genoeg moet
zijn om lekkage tijdens de opslag en de migratie naar zijn doelwitlocatie te be-
perken. Om deze schijnbaar niet-compatibele eigenschappen te kunnen com-
bineren, kan een getriggerde vrijzetting ingezet worden. Twee manieren om
dit te bewerkstelligen werden onderzocht in Hoofdstuk 5. Eerst werd de vrij-
zetting door middel van een interne trigger onderzocht. In dit geval was het
fosfolipase C, een virulentiefactor die door de bacterie¨n geproduceerd wordt
en dus aanwezig is op de plaats van infectie. Fosfolipase C was in staat om
calceı¨ne vrij te stellen uit de liposomen. Echter, niet alle biofilms produceren
fosfolipase C (aan dezelfde hoeveelheid) waardoor het gebruik van deze trig-
ger een beperkte toepasbaarheid heeft. Een meer betrouwbare manier om de
vrijzetting te triggeren is het gebruik van een externe stimulus, zoals laserlicht.
Om de liposomen responsief te maken aan licht, werd er getracht om deze te
functionaliseren met plasmonische goudnanopartikels (AuNP’s). Meer spe-
cifiek werd er gebruik gemaakt van een relatief nieuw ontdekt fotothermaal
effect dat resulteert in de vorming van plasmonische nanobubbles (PNB’s).
Dit effect komt meer en meer in de belangstelling voor toepassingen binnen
de levenswetenschappen. PNB’s worden gevormd door AuNP’s te verhit-
ten door instraling met korte, intense laserlicht pulsen. Door dit instralen zal
het omringende water van de AuNP’s onmiddellijk verdampen. Wanneer de
thermale energie verkregen door de laserpuls is opgebruikt voor het verdam-
pen van het water, zullen de PNB’s imploderen. Dit proces gaat gepaard met
het vormen van een schokgolf doorheen het medium. Deze beschadigende,
mechanische kracht van de PNB’s kan vervolgens gebruikt worden om de li-
posomen te destabiliseren en zo een vrijstelling van hun lading te induceren.
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Een groot voordeel van deze PNB’s is dat er vrijwel geen transfer van warmte
is naar het omgevende medium, wat thermische beschadiging van gezond
weefsel beperkt. Twee AuNP-liposoom combinaties werden getest. Bij de eer-
ste combinatie werden de AuNP’s ingekapseld in de liposomen, terwijl bij de
tweede combinatie de kationische AuNP’s elektrostatisch aan de buitenkant
van anionische liposomen werden gebonden. De vrijstelling van gequenched
calceı¨ne werd vergeleken voor en na bestraling met een gepulseerde laser door
middel van fluorescentiemetingen. Het eerste systeem resulteerde niet in de
generatie van PNB’s aangezien de AuNP’s aggregaten vormden die te groot
waren om in de liposomen te kunnen incorporeren. Met het tweede systeem
was de generatie van PNB’s wel succesvol en werd er een significante vrijzet-
ting van calceı¨ne geobserveerd. Helaas liet dit elektrostatisch coaten slechts
toe om 10 % van de liposomen te functionaliseren zonder de colloı¨dale sta-
biliteit te compromitteren. Toekomstig onderzoek moet daarom focussen op
het verbeteren van de efficie¨ntie van het met AuNP functionaliseren van de
liposomen.
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The ImageJ macro used to reduce the work load during image analysis was
the following:
//run(”Brightness/Contrast...”);
run(”Enhance Contrast”, ”saturated=0.35”);
run(”Median...”, ”radius=2”);
curtit = getTitle();
run(”Duplicate...”, ”title=newimage.nd2”);
selectImage(”newimage.nd2”)
setThreshold(150,4095);
run(”Make Binary”);
run(”Fill Holes”);
run(”Analyze Particles...”, ”size=2-Infinity circularity=0.00-1.00
show=Nothing add”);
roiManager(”Show All with labels”);
roiManager(”Show All”);
setOption(”ExpandableArrays”, true)
roiManager(”Select”, newArray(0));
run(”Select All”);
roiManager(”Combine”);
run(”Make Inverse”);
roiManager(”Add”);
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This macro needs to be run on the image containing the signal of the bac-
teria. It is therefore advised to use ’Split Channels’ upon opening the image.
The first two lines of the macro adjust the brightness and contrast of the image.
Next, a median filter of 2 was used to reduce noise and smoothen the edges.
The following three lines duplicate the image. One image can be used to visu-
ally verify the obtained mask and regions of interest (ROI) with the borders of
the cluster and the other is used for further processing into a binary mask af-
ter applying a threshold. It must be noted that the threshold should be chosen
by the user. The large variations in fluorescence intensities of the clusters pre-
vented the usage of a fixed threshold and using an auto-threshold protocol did
not result in a reliable and accurate detection of the cluster edges. The thresh-
old values can be filled manually in between the brackets of the ’setThreshold’
command in the macro. It is advised to first try to threshold a number of im-
ages by hand to get a feeling for the range in which the thresholds vary and
to save several copies of this macro that employ the most common threshold
values. Next, ’Fill Holes’ is used to fill up the holes inside the cluster since
these need to be included in the mask as they are a part of the cluster area. Via
’Analyze Particles’, regions of binary mask with an area higher than a chosen
value (2 in this case) are converted into a ROI. The final steps add all the de-
tected ROI’s, which are the cluster-regions of the biofilms, to the ROI manager
of ImageJ. The inverse ROI, which represents the bulk area surrounding the
biofilm, is calculated and included in the ROI manager as well.
Measuring the average fluorescence intensities in the cluster and bulk area
were done manually. Via ’Set Measurement’ in the ’Analyze’ menu, the mea-
surement parameters can be chosen. The mean gray value, which is the gray
value of each pixel divided by the number of pixels in the ROI or the image,
reflects the average fluorescence intensity. First, the image containing the sig-
nal of the nanoparticles is selected. For the cluster area, all the ROI’s of the
cluster regions need to be combined via the ”OR (Combine)” option of the
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ROI manager and by using the ”Measure” tool, the average fluorescence in-
tensity in the cluster area can be determined. For measuring the fluorescence
intensity in the bulk area, the last ROI in the ROI manager panel is used. This
is the inverse ROI calculated by the macro and by running ’Measure’ again,
the average fluorescence intensity in the bulk area can be determined.
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